University of Tennessee Health Science Center

UTHSC Digital Commons
Theses and Dissertations (ETD)

College of Graduate Health Sciences

12-2010

Mitochondrial Regulation of Arterial Contractility
Damodaran Narayanan
University of Tennessee Health Science Center

Follow this and additional works at: https://dc.uthsc.edu/dissertations
Part of the Cardiovascular System Commons

Recommended Citation
Narayanan, Damodaran , "Mitochondrial Regulation of Arterial Contractility" (2010). Theses and
Dissertations (ETD). Paper 177. http://dx.doi.org/10.21007/etd.cghs.2010.0223.

This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC
Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized
administrator of UTHSC Digital Commons. For more information, please contact jwelch30@uthsc.edu.

Mitochondrial Regulation of Arterial Contractility
Abstract
Rationale: Physiological functions of mitochondria in contractile arterial smooth muscle cells are poorly
understood. Mitochondria can uptake calcium (Ca2+), but intracellular Ca2+ signals that regulate
mitochondrial Ca2+ concentration ([Ca2+]mito) and physiological functions of changes in [Ca2+]mito in
arterial smooth muscle cells are unclear.
Objective: Identify Ca2+ signals that regulate [Ca2+]mito, examine the significance of changes in [Ca2+]mito,
and test the hypothesis that [Ca2+]mito controls functional ion channel transcription in smooth muscle
cells of resistance–size cerebral arteries.
Methods and Results: Endothelin–1 (ET–1) activated Ca2+ waves and elevated global Ca2+ concentration
([Ca2+]i) via inositol 1,4,5–triphosphate receptor (IP3R) activation. IP3R–mediated sarcoplasmic reticulum
(SR) Ca2+ release increased [Ca2+]mito and induced mitochondrial depolarization, which stimulated
mitochondrial reactive oxygen species (mitoROS) generation that elevated cytosolic ROS. In contrast, a
global [Ca2+]i elevation did not alter [Ca2+]mito, mitochondrial potential, or mitoROS generation. ET–1
stimulated nuclear translocation of nuclear factor kappa B (NF–κB) p50 subunit and ET–1–induced
IP3R–mediated mitoROS elevated NF–κB–dependent transcriptional activity. ET–1 elevated
voltage–dependent Ca2+ (CaV1.2) channel expression, leading to an increase in both pressure (myogenic
tone)– and depolarization–induced vasoconstriction. Baseline CaV1.2 expression and the ET–1–induced
elevation in CaV1.2 expression were both reduced by IP3R inhibition, mitochondrial electron transport
chain block, antioxidant treatment, and NF–κB subunit knockdown, leading to vasodilation.
Conclusions: IP3R–mediated SR Ca2+ release elevates [Ca2+]mito, which induces mitoROS generation.
MitoROS activate NF–κB, which stimulates CaV1.2 channel transcription. Thus, mitochondria sense
IP3R–mediated SR Ca2+ release to control NF–κB–dependent CaV1.2 channel expression in arterial
smooth muscle cells, thereby modulating arterial contractility.
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ABSTRACT
Rationale: Physiological functions of mitochondria in contractile arterial smooth muscle
cells are poorly understood. Mitochondria can uptake calcium (Ca2+), but intracellular
Ca2+ signals that regulate mitochondrial Ca2+ concentration ([Ca2+]mito) and physiological
functions of changes in [Ca2+]mito in arterial smooth muscle cells are unclear.
Objective: Identify Ca2+ signals that regulate [Ca2+]mito, examine the significance of
changes in [Ca2+]mito, and test the hypothesis that [Ca2+]mito controls functional ion
channel transcription in smooth muscle cells of resistance-size cerebral arteries.
Methods and Results: Endothelin-1 (ET-1) activated Ca2+ waves and elevated global
Ca2+ concentration ([Ca2+]i) via inositol 1,4,5-triphosphate receptor (IP3R) activation.
IP3R-mediated sarcoplasmic reticulum (SR) Ca2+ release increased [Ca2+]mito and induced
mitochondrial depolarization, which stimulated mitochondrial reactive oxygen species
(mitoROS) generation that elevated cytosolic ROS. In contrast, a global [Ca2+]i elevation
did not alter [Ca2+]mito, mitochondrial potential, or mitoROS generation. ET-1 stimulated
nuclear translocation of nuclear factor kappa B (NF-κB) p50 subunit and ET-1-induced
IP3R-mediated mitoROS elevated NF-κB-dependent transcriptional activity. ET-1
elevated voltage-dependent Ca2+ (CaV1.2) channel expression, leading to an increase in
both pressure (myogenic tone)- and depolarization-induced vasoconstriction. Baseline
CaV1.2 expression and the ET-1-induced elevation in CaV1.2 expression were both
reduced by IP3R inhibition, mitochondrial electron transport chain block, antioxidant
treatment, and NF-κB subunit knockdown, leading to vasodilation.
Conclusions: IP3R-mediated SR Ca2+ release elevates [Ca2+]mito, which induces
mitoROS generation. MitoROS activate NF-κB, which stimulates CaV1.2 channel
transcription. Thus, mitochondria sense IP3R-mediated SR Ca2+ release to control NFκB-dependent CaV1.2 channel expression in arterial smooth muscle cells, thereby
modulating arterial contractility.
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CHAPTER 1. INTRODUCTION*
1.1.

Ca2+ Signaling in Vascular Smooth Muscle Cells

Calcium (Ca2+) is a highly versatile signal transduction element in almost every
cell type, controlling a wide variety of functions (Berridge, 2001; Bootman et al., 2001;
Berridge, 2004). Ca2+ translates an array of extracellular stimuli, including hormones,
neurotransmitters, and growth factors into distinct intracellular functions, varying from
contraction to secretion, and from survival to differentiation. Under resting conditions,
cytosolic Ca2+ concentration ([Ca2+]i) is maintained at ~100 nM, whereas the extracellular
medium and intracellular stores contain more than 1 mM (Rizzuto & Pozzan, 2006). The
difference in concentrations permits stimulation of rapid Ca2+ signals, to regulate various
cellular responses. Under resting conditions, [Ca2+]i is influenced by the regulation of
several processes, which either introduce Ca2+ into or remove Ca2+ from the entire
cytosol or a localized region of the cytosol (Bootman et al., 2001). Stimuli that elevate
[Ca2+]i cause Ca2+ influx from extracellular space and/or Ca2+ release from internal
sources. Most of this Ca2+ is bound to buffers, whereas a small proportion of the Ca2+
binds to effector elements, leading to stimulation of numerous Ca2+-dependent processes
(Berridge et al., 1998). Removal of Ca2+ from the cytosol occurs via various plasma
membrane exchangers, which extrude Ca2+ into the extracellular space, or intracellular
pumps, which recycle Ca2+ back into organelles (Berridge et al., 1998). Interplay
between these opposing processes is responsible for the maintenance of [Ca2+]i and
modulation of Ca2+-dependent functions (Bootman et al., 2001).
To influence different cellular functions, Ca2+ signals are flexibly and precisely
regulated with regard to space, time, and amplitude (Berridge et al., 1998). Spatial
distribution of Ca2+ signals occur due to differences in Ca2+sources, including Ca2+ entry
from extracellular medium through plasma membrane ion channels, and Ca2+ release
from internal stores (Berridge et al., 2003). Diffusion of Ca2+ from one cellular
compartment to another, and localization of a Ca2+ signal to a specific cellular region also
contribute to spatial heterogeneity. Temporal organization of Ca2+ signals occurs by
modulation of the frequency of Ca2+ signals, leading to variations in intensity and nature
of cellular process (Berridge et al., 2003). Changes in amplitude or concentration of Ca2+
also serve to differentially influence specific functions. The spatiotemporal organization
of Ca2+ signals influences the diversity of Ca2+ signals, controls recruitment of different
intracellular components, and regulation of specific cellular functions (Berridge, 2001;
Bootman et al., 2001; Berridge, 2004).

* Portions of this chapter adapted with permission. Narayanan D, Xi Q, Pfeffer LM, &
Jaggar JH (2010). Mitochondria control functional CaV1.2 expression in smooth muscle
cells of cerebral arteries. Circ Res 107, 631-641.
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1.2.

Ca2+ Transport Mechanisms across Plasma Membrane

Ca2+ entry from the extracellular medium occurs through plasma membrane ion
channels in response to a wide variety of stimuli, including membrane depolarization,
stretch, noxious stimuli, extracellular agonists, intracellular messengers, and the depletion
of intracellular stores (Berridge et al., 2003). Under physiological conditions, the
membrane potential of smooth muscle cells from resistance-size arteries is ~45 mV (Knot
& Nelson, 1998). The negative membrane potential, coupled with a high extracellular
Ca2+ concentration creates a considerable electrochemical gradient across the plasma
membrane, which drives Ca2+ entry through ion channels on the plasma membrane.
Based on the mechanism of activation, several different types of Ca2+ influx channels
have been found in vascular smooth muscle cells – voltage-dependent Ca2+ channels
(VDCCs), receptor-operated Ca2+ channels (ROCCs), and store-operated Ca2+ channels
(SOCCs) (Bootman et al., 2001). Two Ca2+ efflux mechanisms that exist are the plasma
membrane Ca2+-adenosine 5’-triphosphatase (ATPase) (PMCA) and sodium (Na+)/Ca2+
exchanger (NCX).
1.2.1.

Voltage-dependent Ca2+ channels

VDCCs open in response to membrane depolarization, permitting rapid Ca2+ entry
to regulate numerous physiological functions, including excitation–contraction coupling,
excitation-secretion coupling, neurotransmitter release, gene expression, and hormone
secretion (Halling et al., 2005; Liao et al., 2005). VDCCs are hetero-oligomeric protein
complexes, composed of an α1 subunit in association with auxiliary β, α2δ, and γ subunits
(Liao et al., 2005). The 190-250 kilodalton (kDa) α1 subunit is the autonomous poreforming subunit, comprising four membrane-spanning domains, with each domain
consisting of six transmembrane segments (S1–S6) (Liao et al., 2005). The S4 segment
contains three to five positively charged amino acids and serves as the voltage sensor of
the channel (Liao et al., 2005). The α1 subunit also contains binding sites for
dihydropyridines. An intracellular β subunit, a transmembrane, disulfide-linked α2δ
subunit, and a γ subunit interact with the α1 subunit to regulate its expression and
characteristics, such as activity and membrane trafficking of the channel (Liao et al.,
2005). Based on the homology of their sequences, VDCCs are classified into three
families - CaV1 (L-type), CaV2 (P/Q-, N-, and R-type), and CaV3 (T-type) (Catterall,
2000; Ertel et al., 2000). VDCC α1 subunits are encoded by ten genes. Based on the α1
subunit, there are four types of CaV1 channels. CaV1.1 (α1S) expressed in skeletal muscle
cells, CaV1.2 (α1C) expressed in heart, vascular, and visceral smooth muscle cells, CaV1.3
(α1D) expressed in brain, and CaV1.4 (α1F) expressed in the retina (Ertel et al., 2000).
CaV1.2 channel is the major VDCC isoform and the primary Ca2+ entry pathway
expressed in vascular smooth muscle cells (Gollasch & Nelson, 1997). Molecular
diversity of CaV1.2 channels is achieved by alternative gene splicing and transcriptional
regulation by different promoters in the 5’ flanking regions of α1C gene. This has given
rise to exon 1a, exon 1b, and exon 1c in the N-terminus of α1C subunit of CaV1.2 in
vascular smooth muscle cells (Cheng et al., 2007). The α1C subunit of CaV1.2 is
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synthesized as a ~240 kDa protein which is proteolytically cleaved in its C-terminal
domain by enzymes, including calpain to yield ~190 and 50 kDa products (Gerhardstein
et al., 2000). The 50 kDa C-terminal product reassociates with the 190 kDa channel to
form the fully functional CaV1.2 channel.
Activation of CaV1.2 channels by membrane depolarization, leads to Ca2+ influx,
[Ca2+]i elevation, and vasoconstriction (Berridge, 2001; Cheng et al., 2007). Ca2+ influx
also stimulates Ca2+ release from intracellular stores. In small, resistance-sized arteries
and arterioles, CaV1.2 channels are essential for myogenic tone development and blood
pressure regulation (Cheng et al., 2007). Hypertension is associated with an elevation in
arterial smooth muscle cell CaV1.2 expression, which leads to increased Ca2+ influx,
[Ca2+]i elevation, and vasoconstriction (Wang et al., 2006). L-type Ca2+ channel blockers
are widely used to treat hypertension because of their ability to reduce arterial smooth
muscle cell contractility (Triggle, 2006).
Vascular smooth muscle cells also express CaV1.3, CaV2.1, CaV3.1, and CaV3.2
channels. Ca2+ influx through these channels make a minor contribution to [Ca2+]i in
vascular smooth muscle cells.
1.2.2.

Store-operated Ca2+ channels

SOCCs are plasma membrane, non-selective, cation channels that are activated in
response to depletion of intracellular Ca2+ stores (Bootman et al., 2001). Although, the
precise mechanisms are presently unclear, there exist two major theories which attempt to
elucidate the activation mechanism of SOCCs. According to these schemes, SOCCs are
activated by either a conformational coupling between Ca2+ channels on the SR and those
on the plasma membrane, or SR Ca2+ depletion stimulates a second messenger, which
activates plasma membrane Ca2+ channels (Bootman et al., 2001).
The molecular identities of SOCCs are presently unclear. Many of the SOCCs are
speculated to belong to the large transient receptor potential (TRP) channel family, which
were first identified in Drosophila (Beech et al., 2004). The mammalian TRP channel
superfamily that is subdivided into 7 families, is encoded by at least 28 different genes
(Beech et al., 2004). Vascular smooth muscle cells express at least members of three
TRP families, including TRPC (1, 3, 4, 5, 6, and 7), TRPM (2, 4, 7, and 8), and TRPV (2
and 4) (Earley & Brayden, 2010). TRP channels, which are permeable to Ca2+, Na+,
potassium (K+), and magnesium (Mg2+), regulate multiple functions in arterial smooth
muscle cells, including membrane potential, [Ca2+]i, contractility, and proliferation
(Beech et al., 2004; Adebiyi et al., 2010). Recent studies have identified two other
proteins, including Orai1 and stromal interaction molecule (STIM)1 which regulate storeoperated Ca2+ entry in smooth muscle cells (Guibert et al., 2008). Orai1 is a plasma
membrane protein which has been suggested to be the pore subunit of store-operated
current (Guibert et al., 2008). STIM1 is primarily an endoplasmic reticulum (ER)
membrane protein but it is also present in the plasma membrane (Guibert et al., 2008).
Few studies have suggested that SOCCs comprise an assembly of proteins, including
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TRPC, STIM1 and Orai1 present in the plasma membrane (Guibert et al., 2008).
In smooth muscle cells, the regulation, ion selectivity, and conductance of storeoperated cation currents differ in anatomically diverse blood vessels (Xi et al., 2008). In
rat cerebral artery smooth muscle cells, the preparation used in this study, there is very
little evidence for SOCCs. Ca2+ depletion of sarcoplasmic reticulum (SR) by
thapsigargin, an SR Ca2+ ATPase inhibitor (Lytton et al., 1991) resulted in
vasoconstriction at 60 mm Hg but not at 20 mm Hg of intravascular pressure, indicating
that SR Ca2+ depletion-induced current is pressure-dependent (Xi et al., 2008). SR Ca2+
depletion has been suggested to constrict cerebral arteries by inhibiting Ca2+ sparks and
large conductance Ca2+-activated K+ (KCa) channels, which are activated by an elevation
in intravascular pressure (Xi et al., 2008).
1.2.3.

Receptor-operated Ca2+ channels

ROCCs comprise a range of structurally and functionally diverse channels that
exist in many cells, including vascular smooth muscle cells (Bootman et al., 2001). They
are Ca2+-permeable, non-selective, cation channels activated by the binding of an agonist
to the extracellular domain (Bootman et al., 2001). In vascular smooth muscle cells, a
wide variety of agonists, including adenosine 5’-triphosphate (ATP), serotonin,
norepinephrine (NE), acetylcholine, endothelin-1 (ET-1), vasopressin, glutamate, and
angiotensin II (Ang II) activate ROCCs, and induce Ca2+ entry (Large, 2002). Apart
from the P2X1 receptor, an ATP-gated cation channel, other receptor-operated currents
are likely to be mediated via G-protein-coupled receptors, and some through tyrosine
kinases (Large, 2002). In guinea pig aorta, NE-induced Ca2+ influx was only partially
blocked by Ca2+ channel blockers (Gouw et al., 1990). In rat cultured aortic smooth
muscle cells, ATP, Ang II, and vasopressin cause 45Ca2+ influx that is independent of
membrane depolarization and unaffected by Ca2+ channel antagonists, but reduced by
phospholipase C (PLC) inhibitors (Ruegg et al., 1989).
Several TRP channels, including TRPC4, TRPC5, and heteromultimeric complex
of TRPC6 and TRPC7 can be activated by various stimuli, such as vasopressin (Plant &
Schaefer, 2003; Earley, 2006; Maruyama et al., 2006) suggesting that TRP channels
could also act as ROCCs.
1.2.4.

Other Ca2+ entry channels

Apart from VDCCs, SOCCs, and ROCCs, Ca2+ influx could occur through other
pathways. One example is the stretch-activated cation channels which allow Ca2+ entry
and regulate cell contractility (Bootman et al., 2001; Hill et al., 2001). In isolated
vascular smooth muscle cells, longitudinal stretch activates a non-selective, inward cation
conductance (Hill et al., 2001). Therefore, it is accepted that stretch activation
contributes to membrane depolarization, leading to activation of VDCCs (Hill et al.,
2001). Mechanical disturbance of cell membranes also releases factors that modulate the
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activity of stretch-activated channels (Hill et al., 2001). Second messengers, including
fatty acids, arachidonic acid metabolites, diacylglycerol (DAG), and cyclic nucleotides
have been suggested to activate channels by regulating ion channel gating (Hill et al.,
2001).
1.2.5.

Plasma membrane Ca2+-ATPases

PMCA extrude Ca2+ from cytosol to the extracellular compartment using energy
derived from ATP hydrolysis to pump Ca2+ against the steep electrochemical gradient
(Berridge, 2001). The C-terminus contains a calmodulin (CaM)-binding domain, which
acts as an autoinhibitory domain and maintains the pump in an inactive state (Sanders,
2001). Binding of CaM removes the inhibition and stimulates pump activity (Sanders,
2001). Phosphorylation by protein kinases, including protein kinase A (PKA) and G
(PKG) also reduces autoinhibition and facilitates Ca2+ transport (Sanders, 2001).
Four isoforms of PMCAs (1-4) are widely expressed (Bootman et al., 2001).
Vascular smooth muscle cells express PMCA1 and PMCA4 (Abramowitz et al., 2000).
PMCA4b inhibits neuronal nitric oxide synthase (nNOS), by binding of its C-terminus to
the PDZ domain of nNOS (Schuh et al., 2001). Transgenic mice overexpressing
PMCA4b in vascular smooth muscle cells are associated with elevated peripheral blood
pressure due to inhibition of nNOS activity (Gros et al., 2003). Mesenteric arteries from
these transgenic mice display more prominent myogenic response and elevated responses
to vasoconstrictors, including phenylephrine and prostaglandin F2α (Gros et al., 2003).
PMCAs localize in caveolae of visceral smooth muscle cells, endothelial cells, and rat
cardiomyocytes, but whether similar localization occurs in vascular smooth muscle cells
is unclear.
1.2.6.

Plasma membrane Na+/Ca2+ exchanger

NCX is an integral plasma membrane protein which counter-transports Ca2+ in
exchange for Na+, utilizing the Na+ gradient across the plasma membrane, generated by
the Na+/K+-ATPase (NKA), as an energy source (Bootman et al., 2001). The mammalian
NCX family comprises three isoforms NCX (1-3) with numerous splice variants.
Vascular smooth muscle cells predominantly expresses NCX1.3 and NCX1.7 (Quednau
et al., 1997). NCXs function either to pump one molecule of Ca2+ out (forward mode) of
cells, or into cells (reverse mode) in exchange for three molecules of Na+. NCX activity
is regulated by membrane potential, ATP, and transmembrane gradients of Na+ and Ca2+
(Iwamoto et al., 2005). In vascular smooth muscle cells, NCXs are colocalized with
NKA on the plasma membrane near the SR, suggesting that NCX/NKA can functionally
operate with SERCA (Ishida & Paul, 2005). Under physiological conditions, high
extracellular Na+ concentration stimulates NCX to pump Ca2+ out of cells.
Cardiovascular diseases, including hypertension are associated with improper functioning
of NCX. High salt diet inhibits NKA, leading to elevated submembrane Na+ levels,
resulting in NCX functioning in the reverse mode. Ca2+ influx through NCX increases
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[Ca2+]i and may contribute to salt-sensitive hypertension (Iwamoto et al., 2005). Aortic
smooth muscle cells from spontaneously hypertensive rats are associated with elevated
NCX1 expression and enhanced Ang II-induced Ca2+ efflux via NCX (Ishida & Paul,
2005).
1.3.

Intracellular Ca2+ Stores

Cytosol of smooth muscle cell is packed with myofilaments and intermediate
filaments, occupying up to 90% of the cell volume with the intracellular organelles
sharing the remaining space (Wray & Burdyga, 2010). Intracellular stores contain a high
Ca2+ concentration, and release Ca2+ into the cytosol upon stimulation and opening of
Ca2+ channels on their membrane. SR, a rich reticular network, which occupies ~5% of
cell volume, is the major intracellular Ca2+ source (Wray & Burdyga, 2010). Apart from
the SR, mitochondria can store and release Ca2+.
1.3.1.

Sarcoplasmic reticulum

In vascular smooth muscle cells, Ca2+ release from the SR occurs through inositol
1,4,5-triphosphate (IP3) receptors (IP3R) and ryanodine-sensitive Ca2+ release (RyR)
channels. Ca2+ release from these channels are regulated by a collection of messengers,
including Ca2+, IP3, cyclic ADP ribose (cADPR), nicotinic acid adenine dinucleotide
phosphate (NAADP), and sphingosine-1-phosphate (S1P), that operate on both the
luminal and cytosolic surfaces of the channel (Berridge et al., 2003).
Sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), which is located on the SR
membrane pumps Ca2+ from the cytosol into the SR (Inesi, 1987).
1.3.1.1. Ryanodine-sensitive Ca2+ release channels
RyR channels specifically bind the plant alkaloid ryanodine, which is the reason
for its name (Jaggar et al., 2000). Three molecularly distinct RyR isoforms (1-3),
encoded by distinct genes, are present in a variety of tissues (Jaggar et al., 2000). RyR1
is expressed primarily in skeletal muscle, whereas RyR2 and RyR3 are found in cardiac
muscle and brain, respectively (Jaggar et al., 2000). All three RyR isoforms are
expressed in smooth muscles of pulmonary and systemic vessels, with variations in the
type and the relative proportion of each being tissue- and species-dependent (Wray &
Burdyga, 2010). In rat cerebral artery smooth muscle cells, RyR2 is the predominant
isoform (Vaithianathan et al., 2010).
Each of these isoforms exists as a homotetramer with the subunits surrounding a
central Ca2+ pore (Jaggar et al., 2000; Wray & Burdyga, 2010). The subunits are
associated with FK-506-binding protein (FKBP), a regulatory protein. The pore-forming,
membrane-spanning regions are localized to the C-terminus (Wray & Burdyga, 2010).
The cytosolic N-terminus, which is the modulatory region, contains phosphorylation sites
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and binding sites for Ca2+, adenine nucleotides, CaM, and FKBP. RyRs are
approximately twice as large as IP3R (Wray & Burdyga, 2010). Because of their massive
size, RyR is suitable for sudden and large release of SR Ca2+ (Wray & Burdyga, 2010).
The principal endogenous modulator of RyR activity is Ca2+, which upon binding
can activate or inhibit the channels. Low cytosolic Ca2+ concentrations (nM to µM)
activate RyR, whereas high cytosolic Ca2+ concentrations (µM to mM) inhibit RyRs
(Bootman et al., 2001). Similarly, ryanodine at low concentrations (1-10 µM) locks
RyRs into a long-lived subconductance state, leading to Ca2+ release over a prolonged
period of time and eventually SR Ca2+ depletion. At high concentrations (~100 µM),
ryanodine irreversibly inhibits RyR channel opening. RyR channels have to be activated
for ryanodine to bind to them (Bootman et al., 2001). Millimolar concentrations of
caffeine activate RyRs by increasing the sensitivity of RyRs to Ca2+, resulting in basal
Ca2+ concentrations to become activatory and stimulate further Ca2+ release (Bootman et
al., 2001). Changes in the SR luminal Ca2+ concentration, which is ~1 mM can activate
RyRs (Bootman et al., 2001). Activation of SERCA, which is responsible for
maintaining SR Ca2+ load, activates RyR by increasing luminal Ca2+ concentration
(Bootman et al., 2001). cADPR is an endogenous cellular messenger that causes RyRmediated SR Ca2+ release. The precise mechanism by which cADPR activates RyR is
unclear. It has been suggested that cADPR binds to the inhibitory protein FKBP,
resulting in increasing the open probability of RyR (Bootman et al., 2001). cADPR
could also activate SERCA, leading to an increase in SR Ca2+ load, resulting in RyR
activation (Lukyanenko et al., 2001). RyR channels can also be regulated by several
protein kinases and phosphatases, including PKA, protein kinase C (PKC), PKG, CaM
kinase II, and protein phosphatase 1 (Jaggar et al., 2000; Bootman et al., 2001; Wray &
Burdyga, 2010).
1.3.1.2. Inositol 1,4,5-triphosphate receptors
Binding of ligands, including hormones, and growth factors to plasma membrane
Gq protein-coupled receptors activates PLC, leading to hydrolysis of phosphatidylinositol
4,5-biphosphate (PIP2) to produce IP3 and DAG (Bootman et al., 2001). IP3 binds to
IP3R-gated Ca2+ channels on the SR, leading to Ca2+ release. DAG serves as an
intracellular messenger to activate PKC (Bootman et al., 2001).
Distinct genes encode each of the three IP3R isoforms (1-3) (Wray & Burdyga,
2010). IP3R isoforms, which are structurally and functionally related, differ in their
sensitivities to destruction by intracellular proteases, with IP3R1 and IP3R3 being more
susceptible to breakdown than IP3R2 (Wray & Burdyga, 2010). IP3Rs are extensively
expressed in brain and other tissues including vascular smooth muscles. In vascular
smooth muscles, IP3R density is ~100 times less than that in the brain, and the
stoichiometric ratio of IP3Rs to RyRs is 3-4:1 (Wray & Burdyga, 2010). Smooth muscle
cells express multiple IP3R isoforms (Zhao et al., 2008; Wray & Burdyga, 2010). IP3R1
has been found in rat aorta, basilar, and mesenteric arteries, whereas IP3R2 and IP3R3
have been detected in basilar artery and a cell line derived from rat aorta, respectively
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(Wray & Burdyga, 2010). IP3R1 is the predominant isoform expressed in smooth muscle
cells of resistance-size cerebral arteries (Zhao et al., 2008).
IP3Rs are tetrameric, with a monomeric mass of ~300 kDa, containing ~2700
amino acids (Wray & Burdyga, 2010). IP3Rs can form either homo- or hetero-tetramer,
although reports suggesting IP3R as a heterotetramer complex have been derived from
cell lines (Patterson et al., 2004). The IP3R structure can be divided to two regions. The
C-terminal end of IP3R contains the Ca2+ channel region, which shares sequence
homology with that of the RyR (Patterson et al., 2004). The C-terminal region consists
of six membrane-spanning helices with the C-terminus projecting into the cytosol
(Patterson et al., 2004). The N-terminal region which also extends to the cytosol,
contains the IP3-binding site (Patterson et al., 2004). The modulatory domain, which
contains binding sites for Ca2+, nucleotides, CaM, and protein kinases is located between
the ligand-binding domain and the channel pore (Patterson et al., 2004).
The principal mechanism which results in IP3R-mediated SR Ca2+ release, is the
interaction of IP3 with IP3R (Bootman et al., 2001). IP3 produced at the plasma
membrane is highly mobile and diffuses in the cytosol to bind IP3R on the SR membrane
(Bootman et al., 2001). Binding of IP3 induces a conformational change in IP3R,
resulting in channel opening and release of Ca2+, which is stored at high concentrations in
the SR (Patterson et al., 2004). Although binding of IP3 is essential for IP3R activation,
Ca2+ concentration at their cytosolic side also regulate IP3R activity, thereby permitting
IP3R-mediated Ca2+ release to regulate further Ca2+ release (Patterson et al., 2004).
Binding of IP3 increases the IP3R sensitivity to Ca2+, which has a biphasic action
(Patterson et al., 2004). At low IP3 levels (<100 nM), IP3Rs are stimulated by Ca2+
concentrations between 100 and 300 nM, whereas inhibited by cytosolic Ca2+
concentrations >1 µM (Worley et al., 1987; Bootman et al., 2001). At high IP3 levels
(>100 nM), very high Ca2+ concentration is required to induce inhibition of IP3R
(Berridge, 2001). Ca2+-dependence of IP3R activity is important for the generation of
complex patterns of Ca2+ signals seen. SR luminal Ca2+ can also regulate IP3R activity,
whereby a reduced SR Ca2+ load, leads to a decrease in IP3-induced Ca2+ release
(Patterson et al., 2004). In permeabilized hepatocytes, IP3R is inactivated by IP3, and this
effect is enhanced by cytosolic Ca2+, suggesting that IP3 and Ca2+ inhibit IP3R, resulting
in limiting the IP3R-mediated SR Ca2+ release (Hajnoczky & Thomas, 1994). Certain SR
luminal proteins, including calreticulin and calnexin, which are Ca2+-binding proteins are
also known to interact with IP3R and regulate their activity (Berridge, 2001). IP3R
activity can also be modulated by other signaling pathways, including phosphorylation by
PKA, PKC, PKG, and CaM kinase II (Bootman et al., 2001).
In smooth muscle cells of resistance-size cerebral arteries, IP3R1 activation also
induces physical coupling of the N-terminus of IP3R1 and the C-terminus of plasma
membrane TRPC3 channel, leading to non-selective cation current (ICat) activation. IP3Rdependent ICat activation produces membrane depolarization, CaV1.2 channel activation,
and global [Ca2+]i elevation (Xi et al., 2008; Zhao et al., 2008; Adebiyi et al., 2010).
This is an additional mechanism by which IP3R activation contributes to global [Ca2+]i
elevation in arterial smooth muscle cells.
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1.3.1.3. Sarcoplasmic/endoplasmic reticulum Ca2+ATPases
Three mammalian isoforms of SERCA (1-3) exist and splice variants have been
reported in each of the isoforms (Rizzuto et al., 1993). SERCA2a, 2b, and 3 are the
isoforms expressed in vascular smooth muscle cells, with SERCA2b being the major
isoform (Wu et al., 2001; Ishida & Paul, 2005).
SERCA transports two molecules of Ca2+ into the SR using the energy from the
hydrolysis of one molecule of ATP (Inesi, 1987). Counter-transport of two or three
hydrogen (H+) ions into the cytosol ensures partial charge balancing (Levy et al., 1990).
In smooth muscle cells, the locations of Ca2+ release and re-uptake by the SERCA on the
SR membrane are spatially separated (Floyd & Wray, 2007). Ca2+-binding proteins in
the SR lumen regulate SERCA activity to attain a free Ca2+ concentration of ~500 µM.
In uterine smooth muscle cells, overloading the SR with Ca2+ did not alter, whereas
reducing SR Ca2+ load, inhibited IP3-induced Ca2+ signals, suggesting that the ability of
SR to store Ca2+ is finite (Floyd & Wray, 2007).
Phospholamban (PLN) endogenously inhibits SERCA through direct proteinprotein interactions by lowering its apparent Ca2+ affinity (Wray & Burdyga, 2010). PLN
is phosphorylated by PKA or CaM kinase, leading to removal of the inhibition, resulting
in an increase in SERCA activity (Ishida & Paul, 2005; Wray & Burdyga, 2010).
Sarcolipin, a PLN homolog, which inhibits SERCA by lowering its apparent Ca2+
affinity, is expressed in skeletal and cardiac muscles, but not in smooth muscle cells
(Vangheluwe et al., 2005). SERCA activity is also controlled by regulators such as
insulin-receptor substrate 1/2, the Ca2+-binding protein S100A1, acylphosphatase, and the
antiapoptotic protein Bc1-2 (Wray & Burdyga, 2010).
1.3.2.

Mitochondria

Intracellular Ca2+ signaling is also regulated by mitochondria which accumulate
and retain Ca2+. Electron transport chain (ETC) complexes present on the inner
mitochondrial membrane transfer electrons to molecular oxygen during oxidative
phosphorylation. The electron transfer is coupled with translocation of protons into the
intermembrane space, which creates and sustains the mitochondrial membrane potential
(ψm) which is ~150-200 mV more negative than the cytosol (McCarron et al., 2006).
This difference in potential between the cytosol and mitochondrial matrix, drives Ca2+
transport into the mitochondria (McCarron et al., 2006). Mitochondria act as a local,
spatial buffering system, by regulating Ca2+ signals which arise from the SR or plasma
membrane in many cells, including smooth muscle cells. Mitochondrial Ca2+ uptake
occurs via the voltage-dependent anion channel (VDAC), mitochondrial Ca2+ uniporter
(MCU), and rapid uptake mode (RaM) (Gunter et al., 2000). The mitochondrial
permeability transition pore (mPTP) and the mitochondrial Na+/Ca2+ exchanger (mNCX)
extrude Ca2+ from the mitochondrial matrix to the cytosol (Gunter et al., 2000).
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1.3.2.1. Voltage-dependent anion channel
Ca2+ transit through the outer mitochondrial membrane occurs through VDAC,
the most abundant protein on the outer mitochondrial membrane. Mammals have three
distinct VDAC isoforms (1-3). VDAC is an anion-selective channel, fully opened at low
potential (<20–30 mV), but switches to cation selectivity at higher potentials (“closed”
state) (Colombini, 2004). In the resting condition, VDAC is closed and exhibits higher
permeability to Ca2+, rather than in the opened state (Tan & Colombini, 2007). In HeLa
cells and skeletal myotubes, VDAC overexpression enhanced Ca2+ transport from SR into
the mitochondrial matrix (Rapizzi et al., 2002). VDAC activity is regulated by several
factors, including nicotinamide adenine dinucleotide (NADH), Bcl-2 proteins,
chaperones, and cytoskeletal elements (Rizzuto et al., 2009).
1.3.2.2. Mitochondrial Ca2+ uniporter
MCU is a highly selective ion channel located on the inner mitochondrial
membrane that transports Ca2+ from the cytosol into the mitochondrial matrix (Rizzuto et
al., 2000). MCU has both an activation site as well as a transport site (Gunter & Pfeiffer,
1990). MCU activation stimulates Ca2+ influx into the mitochondrial matrix due to the
negative ψm (Rizzuto et al., 2000). MCU has low sensitivity to Ca2+ and is activated by
Ca2+ concentrations >3 μM (Km ~10 μM) in the inter membrane space (Poburko et al.,
2004). The velocity of Ca2+ uptake is near zero for external [Ca2+]i <200-300 nM
(Poburko et al., 2004). [Ca2+]i regulates MCU activity in a biphasic manner (Montero et
al., 2004; Moreau et al., 2006). Studies in HeLa cells suggested that MCU activation by
Ca2+ is mediated by the activation of Ca2+-dependent CaM and subsequently, CaM kinase
II (Montero et al., 2004). Following activation, cytosolic Ca2+ elevation inactivates the
MCU and limits mitochondrial Ca2+ uptake. This biphasic regulation of MCU activity by
cytosolic Ca2+ occurs with MCU activation and Ca2+ uptake occurring with a time
constant of ~6 seconds, while the Ca2+-dependent MCU inactivation occurs with a time
constant of ~17 seconds. This mechanism permits oscillations in mitochondrial Ca2+
concentrations ([Ca2+]mito), but prevents excessive Ca2+ uptake when [Ca2+]i elevation is
prolonged (Moreau et al., 2006). Different PKC isoforms have been suggested to
participate in the cytosolic Ca2+-mediated regulation of MCU activity (Rizzuto et al.,
2009). Overexpression of uncoupling proteins, including UCP2 and UCP3 in an
endothelial cell line enhanced mitochondrial Ca2+ uptake, and small interfering RNA
(siRNA)-mediated knockdown decreased MCU activity and mitochondrial Ca2+
sequestration, suggesting that uncoupling proteins could be essential components of
MCU (Trenker et al., 2007). MCU activity is inhibited by ruthenium red and its related
compound Ru360, and adenine nucleotides (ATP>ADP>AMP) (Rizzuto et al., 2009).
1.3.2.3. Rapid uptake mode
Ca2+ pulses of physiological concentration (~400 nM) more effectively induce
mitochondrial Ca2+ uptake compared to a steady [Ca2+]i for the same overall time
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(Rizzuto et al., 2000; Rizzuto et al., 2009). RaM is a mechanism by which large amounts
of Ca2+ are transported in short pulses at least 300 times faster than through the MCU
(Rizzuto et al., 2000). The activity, identity, and regulation of RaM remains poorly
understood. It is speculated that RaM transports Ca2+ only for a brief period during the
initial part of the pulse, followed by inactivation induced by binding of Ca2+ to an
external site (Rizzuto et al., 2009). RaM exhibits a high initial Ca2+ uptake velocity, and
its steady-state uptake is inhibited at [Ca2+]i >150-180 nM (Gunter & Gunter, 2001),
suggesting that RaM functions in resting conditions to maintain basal [Ca2+]mito (Poburko
et al., 2004).
1.3.2.4. Mitochondrial permeability transition pore
Mitochondria accumulate Ca2+ in the presence of adenine nucleotides. Depletion
of adenine nucleotides in the presence of oxidants stimulates Ca2+ overload in the
mitochondrial matrix. Ca2+ overload triggers opening of mPTP, a high conductance, nonselective channel located in the inner-outer contact sites of the mitochondrial membranes
(Rizzuto et al., 2000; Rizzuto et al., 2009). Several factors, including high [Ca2+]mito,
mitochondrial depolarization, oxidative stress, adenine nucleotide depletion, and a high
concentration of inorganic phosphate (Pi) stimulate mPTP opening (Duchen, 2000a;
Rizzuto et al., 2009). mPTP opening is stimulated by Ca2+ influx into the mitochondrial
matrix which binds to a site on the mPTP (Rizzuto et al., 2009). In the presence of high
Ca2+ concentrations, cyclophilin D (CypD) binds to the inner mitochondrial membrane
and to adenine nucleotide translocase (ANT), thus inhibiting ATP/adenosine 5’diphosphate (ADP) binding and inducing mPTP opening (Rizzuto et al., 2009). mPTP
opening is inhibited by cyclosporine A, and ions such as Mg2+, strontium (Sr2+), and
manganese (Mn2+) (Rizzuto et al., 2009). The molecular identity of mPTP is unclear
with studies speculating it to be a multi-protein complex comprising VDAC, ANT, and
CypD, while others indicate that inhibiting one or more of these components does not
affect mPTP activity (Duchen, 2000a; Rizzuto et al., 2009). Apoptosis which causes loss
of mitochondrial components is associated with mPTP opening (Chang & Yang, 2000;
Rizzuto et al., 2009). Reversible mPTP openings have been observed both in individual
isolated mitochondria (Huser et al., 1998) and in intact cells (Petronilli et al., 1999).
However, it is unclear whether mPTP can function as a physiological mitochondrial Ca2+
release channel (Bernardi & Petronilli, 1996).
1.3.2.5. Mitochondrial Na+/Ca2+ exchanger
mNCX mediates physiological Ca2+ cycling out of the mitochondrial matrix
(Rizzuto et al., 2000). One molecule of Ca2+ is transported out of the mitochondria for
every three molecules of Na+ transported in (Rizzuto et al., 2000). Difference in Na+
concentration between the cytosol and mitochondria causes Na+ influx into the
mitochondrial matrix. Na+ influx drives Ca2+ efflux out of the mitochondria into the
cytosol. mNCX is inhibited by ions such as Sr2+, barium (Ba2+), Mg2+ or Mn2+,
ruthenium red, and drugs, including antimycin A, amiloride, trifluoperazine, diltiazem,
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verapamil, clonazepam, bepridil and CGP37157 (Rizzuto et al., 2009). mNCX is
inhibited by protonophores which disrupt ψm, indicating that mNCX activity is regulated
by the difference in potential between the cytosol and mitochondria (Rizzuto et al.,
2000). Studies done in cultured vascular smooth muscle cells have found that CGP37157, a selective mNCX inhibitor, increased resting [Ca2+]mito indicating that mNCX
contributes to mitochondrial Ca2+ efflux in smooth muscle cells (Poburko et al., 2004).
1.3.3.

Other intracellular stores

NAADP is formed from β-NADP+ and β-NAD+ by ADP ribosyl cyclases which
also produce cADPR (Berridge, 2001). Unlike cADPR, NAADP does not activate RyR,
but stimulates Ca2+ release from an internal store, which is distinct from the SR because
Ca2+ depletion of SR does not affect NAADP-mediated Ca2+ release (Bootman et al.,
2001). The mechanism(s) behind NAADP-mediated Ca2+ release and the channel
identity remains unclear (Clapham, 1995).
Sphingolipids, including sphingosylphosphorylcholine and S1P stimulate Ca2+
release in several different cell types (Bootman et al., 2001). Sphingolipid-derived
messengers are believed to be responsible for agonist-induced SR Ca2+ signals that are
generated independently of IP3R or RyR (Berridge et al., 2003). The exact mechanism
for S1P-mediated Ca2+ release is unclear. The identity of the S1P receptor is believed to
be the sphingolipid Ca2+-release-mediating protein of ER (SCaMPER), a 20 kDa protein
with a transmembrane domain (Bootman et al., 2001). In rat cerebral artery smooth
muscle cells, plasma membrane S1P receptors activate PLC, leading to IP3R and RyR
activation, resulting in Ca2+ release (Yatomi, 2006).
1.4.

Cytosolic Ca2+ Signals

In arterial smooth muscle cells, four principal Ca2+ signaling modalities have been
described: “Global intracellular Ca2+”, “Ca2+ sparks”, “Ca2+ sparklets”, and “Ca2+
waves”. These Ca2+ signals differ with respect to spatial localization, temporal kinetics,
and amplitude properties (Jaggar et al., 2000; Lee et al., 2002; Wray et al., 2005).
Several factors, including Ca2+ sensitivity and proximity to the source of a Ca2+ signal,
influence whether proteins detect local or global Ca2+ signals (Jaggar, 2007).
1.4.1.

Global intracellular Ca2+

Global [Ca2+]i is the spatially averaged cytosolic [Ca2+]i. In arterial smooth
muscle cells, an elevation in global [Ca2+]i occurs because of Ca2+ influx through plasma
membrane Ca2+ channels and Ca2+ release from the SR through IP3R channels (Jaggar et
al., 2000; Zhao et al., 2008). Either of these events which produce an initial rise in global
[Ca2+]i can be further enhanced by RyR-mediated Ca2+ release via a Ca2+-induced Ca2+
release mechanism (Bolton et al., 2004). In addition to these mechanisms, IP3R
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activation induces Ca2+ influx through plasma membrane TRPC3 channels, resulting in a
further elevation in global [Ca2+]i (Adebiyi et al., 2010). A nanomolar elevation in global
[Ca2+]i regulates cell contractility by modulating Ca2+/CaM-dependent myosin light chain
(MLC) kinase activity (Nelson et al., 1988; Brayden & Nelson, 1992; Endo, 2006). Ca2+
binds CaM and the Ca2+-CaM complex activates MLC kinase which phosphorylates
MLC20. MLC20 is bound to the myosin head near the neck, and prevents it from
interacting with actin. MLC20 phosphorylation by MLC kinase activates the myosin
head, initiating contraction. A reduction in global [Ca2+]i leads to MLC20
dephosphorylation by MLC phosphatase, resulting in vasodilation (Jaggar, 2001; Endo,
2006).
Ca2+ influx through CaV1.2 channels is the major contributor to global [Ca2+]i in
arterial smooth muscle cells. Therefore, membrane potential, a key regulator of CaV1.2
channel activation, influences global [Ca2+]i (Knot & Nelson, 1998). In cerebral artery
smooth muscle cells under physiological conditions, the membrane potential is ~-45 mV,
and global [Ca2+]i is ~193 nM (Knot & Nelson, 1998; Cheranov & Jaggar, 2004; Zhao et
al., 2008). Small changes in membrane potential result in significant changes to Ca2+
influx through CaV1.2 channels, global [Ca2+]i, and arterial diameter. Membrane
depolarization from -45 mV by ∼9 mV elevates global [Ca2+]i by ∼45 nM and constricts
the artery by about 25%. In arterial smooth muscle cells, the entire range of global
[Ca2+]i which is from ~120 to 350 nM, and arterial diameter from fully dilated to
maximally constricted state, is associated with membrane potentials from -65 to -25 mV
(Knot & Nelson, 1998).
1.4.2.

Ca2+ sparks

Ca2+ sparks are localized, intracellular Ca2+ transients that occur due to the
activation of RyR channels on the SR (Cheng et al., 1993; Nelson et al., 1995; Jaggar et
al., 2000). In resting arterial smooth muscle cells, the Ca2+ spark frequency is very low
(~1 Hz in rat cerebral artery), and the spatial spread (full width at half maximal
amplitude) is only ~2-3 µm (Jaggar et al., 2000). A single Ca2+ spark does not alter
global [Ca2+]i significantly in arterial smooth muscle cells (Wellman & Nelson, 2003).
However, Ca2+ sparks can produce a rapid, local elevation in [Ca2+]i and activate Ca2+sensitive proteins. One of the targets for Ca2+ sparks is the plasma membrane KCa
channel (Jaggar et al., 2000). Ca2+ sparks generate a micromolar [Ca2+]i elevation near
the release site, which activates many plasma membrane KCa channels, causing a transient
KCa current (Jaggar et al., 2000; Perez et al., 2001; Zhuge et al., 2002). KCa channel,
which has a low Ca2+ affinity would not be activated by global [Ca2+]i changes (Perez et
al., 2001). Ca2+ spark-activated KCa current induces membrane hyperpolarization, which
reduces CaV1.2 activity, causing global [Ca2+]i reduction and vasodilation (Nelson et al.,
1995; Jaggar et al., 2000). Therefore, in small resistance-size arteries, RyR, KCa, and
CaV1.2 channels form a functional unit that provides a negative feedback mechanism for
the regulation of vascular tone and blood pressure (Jaggar et al., 2000).
RyR channels also form signaling complex with TRPV4 and KCa channels in rat
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cerebral artery smooth muscle cells, and produce membrane hyperpolarization and
vasodilation (Earley et al., 2005). In smooth muscle cells of pulmonary arteries and
portal vein, Ca2+ sparks activate Ca2+-activated chloride (ClCa) channels, leading to
chloride (Cl-) efflux and membrane depolarization (Wang et al., 1992; Hogg et al., 1993).
Rat pulmonary artery smooth muscle cells express both KCa and ClCa channels, giving
rise to mixed K+ and Cl- efflux.
1.4.3.

Ca2+ waves

Ca2+ waves are intracellular Ca2+ transients that propagate across the whole cell
along the longitudinal axis (Jaggar et al., 2000; Jaggar & Nelson, 2000). Ca2+ wave
generation requires: 1) a stimulus that activates Ca2+ channels, initiating Ca2+ release; 2)
regenerative Ca2+ release propagating across the cell; 3) Ca2+ clearance from the cytosol;
4) refilling of intracellular Ca2+ stores; and 5) reactivation of Ca2+ release channels (Lee
et al., 2005).
In resting arterial smooth muscle cells, Ca2+ wave frequency is low (Jaggar &
Nelson, 2000). Vasoconstrictors, including ET-1, NE, phenylephrine, uridine 5’triphosphate (UTP), and vasopressin stimulate Ca2+ waves in smooth muscle cells of rat
tail artery, portal vein, mesenteric and cerebral arteries (Boittin et al., 1999; Jaggar &
Nelson, 2000; Mauban et al., 2001; Lamont & Wier, 2004; Dai et al., 2007). Elevating
the agonist concentration increases the frequency but not the amplitude of Ca2+ waves
(Shimamura et al., 1999; Lee et al., 2002). Intravascular pressure elevation increases
Ca2+ wave frequency via increasing IP3 synthesis and activating RyR channels (Jaggar,
2001). Blocking SERCA abolishes Ca2+ waves, suggesting the requirement of Ca2+
release from intracellular Ca2+ stores (Lee et al., 2002). Ca2+ waves could occur by
activation of both RyR and IP3Rs, with the relative involvement of each varying in
different smooth muscle cells. In rat portal vein smooth muscle cells, an anti-IP3R
antibody blocked NE-induced Ca2+ waves (Boittin et al., 1999). Vasoconstrictor-induced
Ca2+ waves are also abolished by ryanodine (Blatter & Wier, 1992; Lamont & Wier,
2004). In rat pulmonary artery smooth muscle cells, NAADP initiated Ca2+ waves, which
were blocked by ryanodine but not by xestospongin C (XeC), an IP3R inhibitor (Gafni et
al., 1997), suggesting that NAADP-mediated RyR activation results in Ca2+ waves
(Boittin et al., 2002). During a Ca2+ wave, intracellular stores release Ca2+ and need to be
refilled by extracellular Ca2+ influx to maintain the ongoing wave (Lee et al., 2005). In
rat cerebral arteries, diltiazem, a CaV1.2 channel inhibitor blocked Ca2+ influx and
reduced Ca2+ waves (Jaggar, 2001). The oscillatory feature of Ca2+ waves implicates
repetitive [Ca2+]i increase due to Ca2+ release from intracellular stores, and [Ca2+]i
decrease due to both a reduction in Ca2+ release and removal of cytosolic Ca2+ (Aalkjaer
& Nilsson, 2005).
Presently, the physiological function of Ca2+ waves is poorly understood. In rat
mesenteric arteries, adrenergic stimulation using vasoconstrictors, including
phenylephrine and NE elevated asynchronous propagating wave-like Ca2+ transients
which induced vasoconstriction (Miriel et al., 1999; Mauban et al., 2001; Lamont &
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Wier, 2004) and synchronous spatially uniform Ca2+ transients which caused oscillatory
vasomotion (Mauban et al., 2001; Lamont & Wier, 2004). In rat cerebral arteries,
alkalinizing external pH (Heppner et al., 2002) or increasing intravascular pressure from
10 to 60 mm Hg (Jaggar, 2001) elevated Ca2+ wave frequency, but Ca2+ waves do not
appear to significantly contribute to the global [Ca2+]i elevation required for
vasoconstriction (Jaggar, 2001; Heppner et al., 2002). Therefore, it is unclear if Ca2+
waves influence vascular contractility with reports suggesting that activation of a large
Ca2+ wave frequency can induce constriction, while others indicate that Ca2+ waves and
oscillations do not contribute to contractile Ca2+ (Jaggar, 2007). Apart from contractility,
Ca2+ waves have been suggested to regulate gene expression in cultured mouse cerebral
artery segments (Wilkerson et al., 2006). IP3R-mediated Ca2+ waves induced nuclear
translocation of proliferating cell nuclear antigen, a transcriptional regulator resulting in
smooth muscle cell proliferation (Wilkerson et al., 2006).
1.4.4.

Ca2+ sparklets

Ca2+ sparklets are intracellular subsarcolemmal Ca2+ transients generated by Ca2+
influx through one or several tightly clustered VDCCs, causing a local high [Ca2+]i
elevation near the Ca2+ channel (Amberg et al., 2007). In cerebral artery smooth muscle
cells, Ca2+ sparklets occur due to the activation of CaV1.2 channels (Navedo et al., 2005;
Navedo et al., 2006). There are two modes of Ca2+ sparklet activity in arterial smooth
muscle cells. Low activity Ca2+ sparklets occure due to random, brief openings of L-type
Ca2+ channels (Navedo et al., 2006). Persistent Ca2+ sparklets occur due to small clusters
of L-type Ca2+ channels operating in a high activity mode, generating sites of constant
Ca2+ influx (Navedo et al., 2006). Persistent Ca2+ sparklets occur as a result of
AKAP150, a scaffolding protein, which targets PKC alpha (PKCα) to specific regions of
the plasma membrane, leading to Ca2+ channel activation, Ca2+ influx, and global [Ca2+]i
elevation (Navedo et al., 2008). Calcineurin, which is associated with AKAP150,
inhibits PKCα and Ca2+ sparklets (Navedo et al., 2008). Membrane depolarization
increases the occurrence of both modes of Ca2+ sparklets, resulting in an elevation in
local and global [Ca2+]i (Santana & Navedo, 2009). Ca2+ sparklet activity is increased in
arterial smooth muscle cells during hypertension, resulting in activation of the
transcription factor nuclear factor of activated T cell (NFAT) c3 (Nieves-Cintron et al.,
2008). Ca2+ sparklet activity is also elevated via a PKA-dependent pathway in cerebral
artery smooth muscle cells during hyperglycemia (Navedo et al., 2010).
1.5.
1.5.1.

Mitochondria in Vascular Smooth Muscle Cells

Electron transport chain and ATP synthesis

Mitochondrial ETC consists of four proteins called Complexes I (NADHubiquinone oxidoreductase), II (succinate dehydrogenase), III (cytochrome bc1), and IV
(cytochrome c oxidase) (Fernie et al., 2004). Electrons are transferred from the strongly
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reducing products (NADH, succinate) of the citric acid cycle through the ETC complexes
to molecular oxygen (O2) (Fernie et al., 2004). Coenzymes ubiquinone (UQ), which is in
the lipid membrane and cytochrome c, which is in the intermembrane space regulate the
electron transfer between the ETC complexes (Fernie et al., 2004). Complex I transfers
electrons from the Kreb’s cycle product NADH to UQ, which also receives electrons
from complex II (Fernie et al., 2004). UQ transfers electrons from Complexes I and II to
III, and cytochrome c transfers electrons from Complex III to IV (Fernie et al., 2004).
Complex IV uses the electrons to reduce O2 to water. Energy obtained as a result of
electron transfer through the ETC complexes is coupled to pump protons from the
mitochondrial matrix to the intermembrane space by complexes I and IV, and by UQ at
complexes I, II, and III (Fernie et al., 2004). Proton pumping creates an electrochemical
proton gradient across the inner mitochondrial membrane (Fernie et al., 2004). ATP
synthase uses the H+ flow down the gradient back into the matrix to stimulate ATP
production from ADP and Pi (Fernie et al., 2004).
1.5.2.

Mitochondrial membrane potential

The proton gradient that is physiologically generated across the inner
mitochondrial membrane by the respiratory chain activity is responsible for the
maintenance of ψm (Gunter et al., 2000). ψm is ~150-180 mV more negative compared to
the cytosol (Gunter et al., 2000). Kinetics of ATP synthase follows a sigmoidal pattern in
response to increase in ψm, reaching a plateau phase when ψm ~50 mV more negative
compared to the cytosol, suggesting that ATP synthesis is regulated primarily by the
availability of the substrates ADP and Pi and not by ψm in the physiological range
(Brookes, 2005). ψm maintenance is essential for the normal functioning of
mitochondria. Transport of ions and metabolites into and out of the mitochondria is
regulated predominantly by ψm (Brookes, 2005). According to Nernst equation,
equilibrium would be reached only if [Ca2+]mito is 106 times that of [Ca2+]i (Graier et al.,
2007). Uncouplers, including carbonyl cyanide 3-chlorophenylhydrazone (CCCP),
which disrupt the proton gradient across the inner mitochondrial membrane, reduce the
driving force for Ca2+, resulting in strongly diminishing mitochondrial Ca2+ uptake
(Graier et al., 2007).
1.5.3.

Spatial proximity between SR and mitochondria

To reconcile the low mitochondrial affinity for Ca2+ at physiological [Ca2+]i,
mitochondria may be exposed to Ca2+ microdomains, such as intracellular Ca2+ stores,
permitting localized mitochondrial Ca2+ uptake to occur (Rizzuto et al., 2009). In HeLa
cells, imaging green fluorescent protein (GFP) constructs targeted to the SR and
mitochondria has revealed that ~5-20 % of the mitochondrial surface is in close
apposition to the SR (Rizzuto et al., 2009). Conventional thin section transmission
electron microscopy studies indicate that mitochondria are located in close proximity
(~10-25 nm) to the SR in many cell types, including arterial smooth muscle cells
(Rizzuto et al., 1999; Duchen, 2000b; Szado et al., 2003; Rizzuto et al., 2009).
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To achieve effective local Ca2+ signaling between the SR and mitochondria, the
SR Ca release sites and the mitochondrial Ca2+ uptake channels should be present at the
interface area (Hajnoczky et al., 2000). Distribution of the IP3Rs and RyRs is not
homogenous on the SR membrane (Hajnoczky et al., 2000). In cardiac muscle cells,
~90% of the SR Ca2+ release channels are located very close to mitochondria (Sharma et
al., 2000). A high density of IP3R1 and IP3R2 exist on regions of the SR which face the
mitochondria (Takei et al., 1992; Simpson et al., 1997). MCU is exclusively localized in
the regions of contact between the mitochondria and ER (Hajnoczky et al., 2000).
2+

In addition to being in close proximity to each other, SR and mitochondria may be
physically tethered to one another to sustain local communication during continuous
organelle movement and reorganization (Hajnoczky et al., 2000; Csordas & Hajnoczky,
2009). The SR-mitochondria physical coupling is established via several anchoring
proteins, including dynamin-like protein-1 (Pitts et al., 1999), glucose-regulated protein
75 (Szabadkai et al., 2006), sigma-1 receptor (Hayashi & Su, 2007), and mitofusin-2 (De
Brito & Scorrano, 2008). Since both SR and mitochondria bind to microtubules/actin
filaments, cytoskeletal proteins may also offer additional physical support to the SRmitochondria associations (Spat et al., 2008). Therefore, the spatial distribution of SR
and mitochondria, and the physical coupling between them may provide a strong
platform for efficient local communication.
Not all the mitochondria are in close proximity to the SR. Some mitochondria
may be isolated or relatively far from the SR, resulting in them either not or poorly
responding to SR Ca2+ release (Hajnoczky et al., 2000). There may also exist substantial
heterogeneity among different mitochondria in the efficacy of Ca2+ uptake with
differences in MCU activation, driving force, rate, and peak of Ca2+ uptake (Rizzuto et
al., 2004). Therefore, a sub-population of mitochondria may be exposed to [Ca2+]i much
higher than other mitochondria in the same cell (McCarron et al., 2006).
1.5.4.

Interplay between mitochondria and cytosolic Ca2+ signals

Ca2+ transport pathways of the mitochondria consist of high velocity, ψm-driven
uptake mechanisms which are activated by local [Ca2+]i elevations, and slow, easily
saturable, concentration-dependent efflux systems, which are only mildly stimulated by
[Ca2+]mito elevations. Therefore, mitochondria accumulate Ca2+ during rapid, local [Ca2+]i
elevations and slowly release it back into the cytosol (Rizzuto et al., 2000). This permits
the mitochondria to alter spatio-temporal patterns of global and local Ca2+ signaling
(Rizzuto et al., 2000; Xi et al., 2005). The physiological range of arterial smooth muscle
cell global [Ca2+]i is ~100-300 nM. Local Ca2+ signals elevate Ca2+ into the micromolar
concentration range, which is sufficient for mitochondrial Ca2+ uptake because in vitro Kd
for Ca2+ of MCU is ~10-20 µM (Gunter & Pfeiffer, 1990; Perez et al., 2001). SR Ca2+
release due to the activation of IP3R-gated Ca2+-release channels caused a micromolar
increase in the local cytosolic [Ca2+]i and Ca2+ uptake by localized mitochondria (Rizzuto
et al., 1993; Duchen et al., 1998; Hajnoczky et al., 2002). In rat pulmonary artery
smooth muscle cells, cytosolic Ca2+ oscillations due to SR Ca2+ release resulted in
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[Ca2+]mito oscillations (Drummond & Tuft, 1999). In cardiac smooth muscle cells, local
SR Ca2+ release via RyR channels elicited miniature [Ca2+]mito elevations termed “Ca2+
marks”, and transient mitochondrial depolarizations termed “flickers” (Duchen et al.,
1998; Pacher et al., 2002).
Vascular smooth muscle cell mitochondria can in turn feedback to alter the
activity of Ca2+ channels which produce the local Ca2+ signals (Cheranov & Jaggar, 2004;
Poburko et al., 2004; Chalmers et al., 2007). In particular, mitochondria regulate IP3R
and RyR channel activity, and in turn influence the propagation of Ca2+ waves and
generation of Ca2+ sparks, respectively (Lee et al., 2002; Wellman & Nelson, 2003).
Mitochondria can regulate these SR Ca2+ release channels by buffering local [Ca2+]i,
controlling ATP synthesis, via reactive oxygen species (ROS) signaling, and cADPr
metabolism (Poburko et al., 2004; Xi et al., 2005; Chalmers et al., 2007). RyR and IP3R
are sensitive to cADPr and ATP, respectively (Bezprozvanny & Ehrlich, 1995;
Sitsapesan et al., 1995), and both channels have distinct Ca2+-sensitive stimulating and
inhibiting sites. By influencing channel modulators and by buffering [Ca2+]i,
mitochondria can regulate both the Ca2+ sensitivity and the duration of opening of RyR
and IP3R. In various cell types, including vascular smooth muscle cells, mitochondria
affect RyR channel activity and influence the frequency and amplitude of Ca2+ sparks
(Pacher et al., 2002; Xi et al., 2005). In cerebral artery smooth muscle cells,
mitochondrial depolarization-induced ROS elevation activated Ca2+ sparks, leading to
KCa channel stimulation, resulting in vasodilation (Xi et al., 2005). In pulmonary and
mesenteric artery smooth muscle cells, mitochondria increased both Ca2+ spark frequency
and amplitude, resulting in increased ClCa current (Wang et al., 2003). Mitochondrial
regulation of IP3R activity has been reported in colonic and arterial smooth muscle cells
(McCarron & Muir, 1999; Sward et al., 2002). In rat tail artery smooth muscle cells,
mitochondrial inhibitors increased the frequency and decreased the amplitude of IP3Rmediated [Ca2+]i oscillations (Sward et al., 2002). Mitochondria can also regulate SR
Ca2+ refilling by controlling ATP synthesis and modulating Ca2+ efflux via mNCX
(Landolfi et al., 1998; Arnaudeau et al., 2001). In vascular smooth muscle cells,
mitochondria regulate the activity of several plasma membrane ion channels, including
SOCCs, VDCCs, KCa, and ClCa channels (Poburko et al., 2004). Mitochondria influence
plasma membrane channel activity by buffering local subplasmalemmal Ca2+ gradients,
which activate or inhibit channels and also through regulation of SR Ca2+ refilling, which
dictates the activity of SOCCs (Poburko et al., 2004). Therefore, the activity of
mitochondria may regulate and be influenced by Ca2+ signals in smooth muscle cells.
1.5.5.

Role of mitochondria in vascular smooth muscle cells

In vascular smooth muscle cells, the physiological role of mitochondria apart
from their energy-generating function is unclear. Mitochondria provide an efficient
system for buffering cytosolic Ca2+ changes, thereby controlling a variety of
mitochondrial events, including ATP synthesis, mPTP opening, and mitochondrial ROS
(mitoROS) generation. However, the physiological consequences of these [Ca2+]mito
elevation-mediated events are poorly understood.
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Mitochondrial dysfunction is associated with several pathological conditions of
the vasculature, including apoptosis, migration, remodeling, and glycation (Lee et al.,
2008; Birukov, 2009; Wang et al., 2009; Ahn et al., 2010). Few studies have examined
the role of mitochondria in regulating physiological functions of vascular smooth muscle
cells. In cerebral artery smooth muscle cells, mitoROS activate Ca2+ sparks and stimulate
KCa channels, resulting in vasodilation (Xi et al., 2005). Cold-induced constriction of
cutaneous arteries is mediated through mitoROS generation (Bailey et al., 2005). During
hypoxia, mitochondria in pulmonary artery smooth muscle cells act as oxygen sensors
and stimulate redox-sensitive transcription factors (Schumacker, 2003; Sato et al., 2005).
Therefore, there is very minimal information available about the role of mitochondria in
mediating normal physiological processes other than ATP synthesis in vascular smooth
muscle cells.
1.6.

Reactive Oxygen Species in Vascular Smooth Muscle Cells

In physiological or pathological conditions, O2 is converted into highly reactive
oxygen-derived molecules and free radicals, called reactive oxygen species (ROS) that
interact with reducible compounds. There are different species of ROS, including
hydrogen peroxide (H2O2), superoxide anion (O2-·), hydroxyl radical (OH·). nitric oxide
(NO), peroxynitrite (ONOO·), hypochlorous acid (HOCl), and singlet oxygen (1O2)
(Mueller et al., 2005; Gloire et al., 2006). O2-· and H2O2 are the two major species of
ROS produced in cells. O2-· through reaction with NO generates ONOO·. OH· is
produced from H2O2 in a Fenton reaction (Turrens, 2003).
1.6.1.

Cellular sources of ROS

Multiple sources generate ROS, including mitochondrial ETC complexes,
NAD(P)H oxidase, cytochrome P450 (CYP450), xanthine oxidoreductase, NO synthase
(NOS), cyclooxygenases, and lipoxygenases (Irani, 2000; Turrens, 2003; Wong et al.,
2003; Mueller et al., 2005; Clempus & Griendling, 2006). The major sources of ROS in
vascular smooth muscle cells are mitochondrial ETC and NAD(P)H oxidase (Mueller et
al., 2005).
1.6.1.1. Mitochondrial ETC complexes
Mitochondrial ETC is a major source of O2-· and H2O2 in most tissues, including
vascular smooth muscle cells (Mueller et al., 2005; Clempus & Griendling, 2006). Under
normal metabolic conditions, electron leakage occurs during transfer between complexes,
resulting in the incomplete reduction of ~1–5% of total O2 consumed, to produce O2-·
(Mueller et al., 2005). Mitochondrial O2-· production occurs primarily at ETC complexes
I and III (Mueller et al., 2005). The main source of O2-· in mitochondria is the
ubisemiquinone radical intermediate (QH·), which is formed from UQ at complex III
(Brookes et al., 2004). QH· formation occurs under two conditions: 1) an increase in
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QH· concentration when ETC is inhibited distally, and 2) an increased rate of QH·
production when ETC functions faster (Brookes et al., 2004). Therefore, both
stimulation and inhibition of mitochondrial ETC elevate mitochondrial O2-· generation.
Mitochondrial superoxide dismutase converts O2-· to H2O2 (Clempus &
Griendling, 2006). Since O2-· generation is non-enzymatic, the rate of mitoROS
production is directly proportional to the rate of metabolism (Brookes, 2005). MitoROS
generation is regulated primarily by the redox state of the ETC complexes, which is
controlled by the ψm and the proton gradient (Brookes, 2005; Xi et al., 2005). Several
other stimuli, including mitochondrial Ca2+ uptake (Wolin et al., 2005), and mPTP
opening (Wang et al., 2008a) stimulate mitoROS production in cell types, including
vascular smooth muscle cells. MitoROS regulates several physiological and pathological
signaling pathways, including cell cycle, cell proliferation, apoptosis, metalloproteinase
function, protein phosphorylation, dephosphorylation, Ca2+ signaling, vascular
contractility, and transcription factors (Brookes et al., 2004; Xi et al., 2005).
1.6.1.2. NAD(P)H oxidase
NAD(P)H oxidases are multiprotein complexes consisting of the p22phox subunit
bound to the catalytic subunit Nox (known as gp91phox in phagocytes) (Touyz et al.,
2002; Mueller et al., 2005; Paravicini & Touyz, 2006; Parfenova & Leffler, 2008;
Basuroy et al., 2009). In addition to the membrane-bound Nox/p22phox complex, there
are three cytosolic subunits, including Rac1, p47phox and p67phox, which are recruited to
the membrane upon activation (Abo et al., 1991; Ambasta et al., 2004; Basuroy et al.,
2009). The catalytic subunit in vascular smooth muscle cells is either Nox1, Nox2, or
Nox4 (Mueller et al., 2005; Paravicini & Touyz, 2006). Nox1 expression levels, which
are low in vascular smooth muscle cells, can be induced by stimuli such as plateletderived growth factor (PDGF), Ang II, and serum (Lassegue & Clempus, 2003). Nox2 is
expressed in endothelial and adventitial cells of large arteries and in vascular smooth
muscle cells of smaller resistance-size arteries (Wang et al., 1998; Gorlach et al., 2000;
Touyz et al., 2002; Parfenova & Leffler, 2008; Basuroy et al., 2009). Nox4 is
constitutively expressed and active in vascular smooth muscle and endothelial cells (Ago
et al., 2004; Hilenski et al., 2004; Basuroy et al., 2009).
Activation of NAD(P)H oxidase results in the assembly of the cytosolic and
membrane-bound subunits to form an enzyme complex (Lassegue & Clempus, 2003;
Mueller et al., 2005). NAD(P)H oxidase produces O2-· by the transfer of two electrons
from NAD(P)H to O2 (Paravicini & Touyz, 2006). Vasoactive hormones (Ang II),
growth factors (PDGF), and mechanical stimuli (shear stress) activate NAD(P)H oxidase
in vascular smooth muscle cells (Mueller et al., 2005).
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1.6.1.3. Cytochrome P450
Membrane-bound microsomal monooxygenase system is present in the SR of
most tissues, including vascular smooth muscle cells (Zangar et al., 2004). It contains
CYP450 enzymes which oxygenate exogenous and endogenous compounds. NAD(P)HCYP450 reductase transfers two electrons to CYP450 resulting in activation of O2,
leading to monooxygenation of substrates (Zangar et al., 2004). The efficiency with
which electrons are transferred from NAD(P)H to CYP450 for substrate oxygenation is
not tightly regulated, resulting in ROS production (Gorsky et al., 1984; Blanck et al.,
1991). Therefore, continuous generation of O2-· and H2O2 by CYP450, as a result of
NAD(P)H consumption occurs both in the presence and absence of substrates (Kuthan &
Ullrich, 1982; Zangar et al., 2004).
1.6.1.4. Xanthine oxidoreductase
The xanthine oxidoreductase system exists as xanthine dehydrogenase (XDH) and
xanthine oxidase (XO) (Mueller et al., 2005). XDH transfers electrons from
hypoxanthine and xanthine to NAD+ to produce NADH and uric acid (Harrison, 2002).
XO forms O2-· and H2O2 by transferring electron from NADH and uric acid to O2
(Harrison, 2002). Therefore, the relative cellular amounts of XDH and XO determine the
ROS produced (Mueller et al., 2005). Several stimuli, including tumor necrosis factor
alpha (TNF-α), and ONOO· convert XDH to XO, and thereby increase ROS production
in vascular smooth muscle cells (Friedl et al., 1989; Sakuma et al., 1997).
1.6.1.5. Nitric oxide synthases
There are three NOS isoforms, namely endothelial NOS (eNOS) and nNOS,
which are constituvely expressed, and inducible NOS (iNOS) (Kibbe et al., 1999). Under
normal conditions, NOS transfers electrons to L-arginine in the presence of cofactor
tetrahydrobiopterin (BH4) to yield NO (Mueller et al., 2005).
eNOS activity is regulated by [Ca2+]i between ~100 and 500 nM, which permits
CaM binding and its activation (Forstermann et al., 1994). In pathological conditions,
including hypertension, elevated levels of O2-· oxidize BH4 , thereby uncoupling eNOS,
which transfers electron to O2 instead of L-arginine to produce additional O2-· (Mueller et
al., 2005).
In addition to eNOS-derived NO production in endothelial cells, NO generation in
vascular smooth muscle cells occurs via iNOS (Griendling & FitzGerald, 2003). iNOS
generates 100-1000-fold more NO than eNOS and nNOS (Kibbe et al., 1999). iNOS is
expressed in conditions where smooth muscle cells change from a contractile to a
proliferative phenotype in response to cellular stress, inflammatory states, and arterial
injury (Kibbe et al., 1999; Griendling & FitzGerald, 2003).
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1.6.1.6. Cyclooxygenases and lipoxygenases
Cyclooxygenases and lipoxygenases metabolize arachidonic acid. O2-·
production occurs due to the hydroperoxidase activity of the enzymes via side-chain
reactions that are dependent upon the presence of a suitable reducing substrate, either
NADH or NAD(P)H (Wong et al., 2003). Like cyclooxygenases, lipoxygenases can
produce O2-· in the presence of either NADH or NAD(P)H (Lotzer et al., 2005).
1.6.2.

Antioxidant mechanisms

Cells have developed defensive antioxidant mechanisms to eliminate excess ROS
from cell compartments and extracellularly. The antioxidant mechanisms include
superoxide dismutase (SOD), catalase, thioredoxin, glutathione peroxidases and
peroxiredoxins (Karihtala & Soini, 2007). In human cells, three different types of SODs
are expressed, including cytosolic copper-zinc SOD, mitochondrial manganese SOD and
extracellular SOD (Karihtala & Soini, 2007). All three SODs dismutate two O2-· anions
to H2O2 and O2 (Karihtala & Soini, 2007). Catalase, thioredoxin, glutathione
peroxidases, and peroxiredoxins reduce H2O2 to water and O2 (Karihtala & Soini, 2007).
When cellular production of ROS overwhelms its antioxidant capacity, a state of
oxidative stress is reached leading to serious cellular injuries and contributing to the
pathogenesis of several diseases.
1.6.3.

ROS regulation of vascular smooth muscle cell functions

When generated in optimal concentrations, ROS can act as second messengers in
regulating signal transduction pathways, leading to regulation of cellular responses in a
variety of cell types and conditions, including cytokine, growth factor and hormone
treatments, ion transport, transcription, neuromodulation, and apoptosis (Lander, 1997;
Hensley et al., 2000). Distinct properties of different species of ROS determine their
capability of stimulating diverse signaling pathways, which may then lead to convergent
or divergent consequences. O2-· and OH· are very reactive, have short half-lives and
therefore, are unlikely to mediate effects distant from where they are produced
(Paravicini & Touyz, 2006). The negative charge on O2-· prevents it from crossing
cellular membranes, except through ion channels (Paravicini & Touyz, 2006). H2O2 is
comparatively more stable, has a greater diffusion radius than O2-· and OH·, and is able
to diffuse across membranes and between cells (Paravicini & Touyz, 2006). Therefore,
different species of ROS are capable of regulating multiple signaling pathways,
depending on their reactivity and stability (Paravicini & Touyz, 2006).
In arterial smooth muscle cells, several ligands, including Ang II, ET-1, and
PDGF, mechanical stress, and hypoxia increase ROS production (Griendling et al., 1994;
Nishio & Watanabe, 1997; Xi et al., 2005; Clempus & Griendling, 2006; Paravicini &
Touyz, 2006). ROS exert their effects through interaction with and regulating the
functions of multiple cellular components, including ion channels, protein kinases and
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phosphatases, transcription factors, and cell cycle proteins (Clempus & Griendling, 2006;
Paravicini & Touyz, 2006).
In vascular smooth muscle cells, ROS regulate several processes, including
contractility, hypertrophy, hyperplasia, migration, differentiation, secretion of
inflammatory cytokines, gene expression, extracellular matrix protein deposition,
activation of matrix metalloproteinases, and inflammation (Clempus & Griendling, 2006;
Paravicini & Touyz, 2006). ROS stimulate smooth muscle cell hypertrophy and
hyperplasia by regulating the activity of redox-sensitive kinases and phosphatases, which
lead to c-Src activation (Clempus & Griendling, 2006). Several vasoactive ligands,
including PDGF, insulin-like growth factor-1, thrombin, vascular endothelial growth
factor (VEGF), and monocyte chemoattractant protein-1 (MCP-1) induce redoxdependent migration of vascular smooth muscle cells (Clempus & Griendling, 2006).
ROS mediate smooth muscle cell differentiation from a native, contractile to an invasive,
proliferative phenotype in response to arterial injury (Clempus & Griendling, 2006).
Arterial contractility is controlled by ROS by regulating functions of ion channels,
including KCa channels (Xi et al., 2005; Clempus & Griendling, 2006; Paravicini &
Touyz, 2006). In addition, ROS also influence gene expression by activating redoxsensitive transcription factors.
ROS modulate the activity of redox-sensitive transcription factors, including
activator protein (AP)-1, nuclear factor kappa B (NF-κB), cyclic AMP response elementbinding protein (CREB), hypoxia-inducible factor-1 alpha (HIF-1α), peroxisome
proliferator-activated receptors, NF-E2-related factor-2 (Nrf2), Gax, and gut-enriched
kruppel-like factor in vascular smooth muscle cells (Clempus & Griendling, 2006; Gloire
et al., 2006). ROS regulation of transcription factor activity occurs via direct and indirect
mechanisms (Kunsch & Medford, 1999). Direct mechanism involves oxidation of the
transcription factor, leading to alteration of its activity (Kunsch & Medford, 1999). ROS
can also indirectly control transcription factor function by regulating its post-translational
modifications (phosphorylation or dephosphorylation) via redox-sensitive kinases and
phosphatases (Kunsch & Medford, 1999). Both mechanisms alter several properties of
transcription factors, including cellular localization, DNA binding, and recruitment of
activators and/or repressors (Kunsch & Medford, 1999). Vasoconstrictors, including Ang
II induce expression of genes, including MCP-1 and interleukin (IL)-6 through ROSdependent NF-κB activation (Chen et al., 1998; Han et al., 1999). Therefore, ROS
regulate both physiological and pathological functions in vascular smooth muscle cells.
1.7.
1.7.1.

NF-κB in Vascular Smooth Muscle Cells

NF-κB family of proteins

NF-κB proteins comprise structurally-related eukaryotic transcription factors that
regulate gene expression and control a large number of cellular processes, including
immune and inflammatory responses, cellular growth, and apoptosis. NF-κB proteins
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regulate gene expression by binding to cis-acting κB sites in the promoter regions. In
mammals, there are five NF-κB/REL genes, NF-κB1, NF-κB2, RELA, c-REL and RELB
(Chen & Greene, 2004; Hayden & Ghosh, 2008). The NF-κB family of transcription
factors contains five members: NF-κB1 (p105/p50), NF-κB2 (p100/p52), RelA (p65),
RelB, and c-Rel (Chen & Greene, 2004; Hayden & Ghosh, 2008). NF-κB proteins are
related through the presence of a highly conserved Rel homology domain in their Nterminal region (Chen & Greene, 2004; Hayden & Ghosh, 2008). The Rel homology
domain which contains a nuclear localization sequence is involved in DNA binding,
dimerization with other NF-κB proteins, and interaction with the inhibitory I kappa B
(IκB) proteins (Chen & Greene, 2004; Hayden & Ghosh, 2008). p105 and p100 are
processed to generate the DNA binding subunits p50 and p52, respectively. p105 and
p100 proteins contain ankyrin repeats, as well as glycine-rich regions in their C-terminal
regions. The glycine-rich regions are essential for co-translational processing of p105 to
p50 and post-translational processing of p100 to p52 by the ubiquitin-proteasome
pathway (Chen & Greene, 2004; Hayden & Ghosh, 2008). In addition to the Rel
homology domain, p65, c-Rel, and RelB contain transactivation domains in their Cteminal region. Transactivation domains interact with various parts of the transcription
apparatus to regulate gene expression (Chen & Greene, 2004; Hayden & Ghosh, 2008).
p50 and p52 proteins contain the Rel homology domains but lack the transactivation
domains. NF-κB proteins are expressed in a cell- and tissue-specific manner (Chen &
Greene, 2004; Hayden & Ghosh, 2008). p50 and p65 are ubiquitously expressed,
whereas NF-κB2, Rel-B, and c-Rel are specifically expressed in lymphoid tissues
(Hayden & Ghosh, 2008).
NF-κB proteins dimerize to form homo- or hetero-dimers, which produce specific
responses to different stimuli and diverse effects on transcription. The most often
observed NF-κB complexes in cells are the p50-p65 and p52-RelB heterodimers (Sun &
Andersson, 2002). Homodimers of p50 and p52 act as transcriptional repressors (Sun &
Andersson, 2002). Presence of different NF-κB homo- and hetero-dimers determines
which dimers control transcription. Therefore, depending on the dimer, transcriptional
activity is either stimulated or inhibited (Sun & Andersson, 2002).
1.7.2.

NF-κB activation pathways

There are two modes of signaling pathways, including the “classical/canonical”
pathway and the “alternative/non-canonical” pathway, each of which lead to the
translocation of NF-κB dimers from the cytosol to the nucleus (Bonizzi & Karin, 2004).
NF-κB activated by each of these pathways regulate the transcription of distinct target
genes (Bonizzi & Karin, 2004; Chen & Greene, 2004; Hayden & Ghosh, 2008).
1.7.2.1. Classical/Canonical pathway
The prototypical NF-κB complex comprising the p50-p65 heterodimer is bound to
IκB which masks the nuclear localization signal (NLS) of p65 and causes cytosolic
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retention of NF-κB (Bonizzi & Karin, 2004). Activation occurs when signalsome
containing the IκB kinases (IKKs), including IKKα, IKKβ, and IKKγ phosphorylates IκB
on serine residues 32 and 36 (Karin, 1999). IκB phosphorylation leads to IκB
dissociation from the inactive NF-κB/IκB complex (Karin, 1999). Dissociated IκB is
ubiquitinated and degraded by the 26S proteasome complex (Karin, 1999). IκB
degradation unmasks the NLS on p65, leading to nuclear translocation of activated NFκB and DNA binding (Karin, 1999).
1.7.2.2. Alternative/Non-canonical pathway
Certain stimuli, including B-cell activating factor and CD40 activate NF-κBinducing kinase and IKKα, leading to NF-κB2 (p100) phosphorylation (Senftleben et al.,
2001). p100 phosphorylation leads to its ubiquitination, and is proteolytically processed
by the 26S proteasome to yield p52 (Lin et al., 1998). This pathway principally involves
the p52-RelB heterodimer as opposed to the p50-p65 heterodimer produced by the
canonical pathway (Senftleben et al., 2001; Chen & Greene, 2004).
Upon nuclear translocation, NF-κB regulates gene expression by recruiting
additional transcriptional activators and/or repressors, which contain κB consensus
sequences (5'-GGGRNYYYCC-3', where R is a purine, Y is a pyrimidine, and N is any
nucleic acid) (Chen & Greene, 2004). One of the target genes that is always stimulated
by NF-κB is IκBα, which is depleted during the events of NF-κB activation (Chen &
Greene, 2004). IκBα expression results in translocating the nuclear NF-κB back to the
cytosol, thereby terminating the transcriptional regulation (Chen & Greene, 2004).
1.7.3.

Mechanisms of NF-κB activation

NF-κB is activated by a range of stimuli, including various pro-inflammatory
cytokines, growth factors, DNA-damaging agents, and viral proteins. The cellular events
underlying NF-κB activation consists of IKK activation and IκBα degradation (classical
pathway) or the post-translational processing of p100 to p52 (alternative pathway) (Sun
& Andersson, 2002). With regard to vascular biology, various stimuli including TNF-α,
IL-1, advanced glycation end products, hyperglycemia, mechanical stress, ROS, and
hypoxia/reperfusion activate NF-κB (De Martin et al., 2000). ROS activates NF-κB in
vascular smooth muscle cells and other cell types (Asehnoune et al., 2004; Bubici et al.,
2006; Miller, Jr. et al., 2007). In addition, mitoROS activate NF-κB in several cell types,
including in cultured vascular smooth muscle cells, skeletal muscle myotubes, and
cultured macrophages (Li et al., 1999; Chandel et al., 2000; Lee et al., 2008). The
mechanism through which ROS activate NF-κB appears to involve the activity of IKKs,
including IKKα and IKKβ (Gloire et al., 2006).

25

1.7.4.

Regulation of vascular function by NF-κB

NF-κB is constitutively activated and inactivated in arterial smooth muscle cells
and is essential for the regulation of a variety of vascular functions, including smooth
muscle cell proliferation, angiogenesis, and induction of cytokines (Asehnoune et al.,
2004; Bubici et al., 2006; Clempus & Griendling, 2006; Miller, Jr. et al., 2007). In
arterial smooth muscle cells, NF-κB regulates expression of genes, including vascular
cell adhesion molecule-1, IL-1, and c-myc (Bourcier et al., 1997; Detmer et al., 2001).
NF-κB also induces expression of anti-apoptotic genes, leading to protection during
abnormal proliferation (De Martin et al., 2000). The physiological NF-κB-dependent
gene expression may be exaggerated in pathological situations, resulting in damage to the
vessel wall and impaired vascular cell function (De Martin et al., 2000). High levels of
NF-κB are present in arterial smooth muscle cells of arteriosclerotic intimal lesions (De
Martin et al., 2000).
Previous reports in cultured arterial smooth muscle cells have suggested that NFκB plays an important role in regulating gene expression and proliferation (Landry et al.,
1997). NF-κB is also involved in regulating gene transcription of ion channels, including
amiloride-sensitive Na+ channel, small conductance Ca2+-activated K+ channel, and
TRPC1 channel (Baines et al., 2002; Paria et al., 2006; Kye et al., 2007) in several cell
types, including cultured aortic smooth muscle cells. In pathological states, NF-κB
activation has been shown to upregulate ETB receptor expression in arterial smooth
muscle cells, leading to enhanced contraction (Xu et al., 2008). However, the
physiological functions and mechanisms of regulation of NF-B in contractile arterial
smooth muscle cells are poorly understood. In this study, we have examined the
physiological regulation of arterial contractility by NF-κB-dependent ion channel
expression.
1.8.

Transcriptional Regulation of CaV1.2 Expression

CaV1.2 channels are expressed in heart, vascular, and visceral smooth muscle
cells (Ertel et al., 2000). The α1C subunit of human CaV1.2 is encoded by the CACNA1C
gene, which is located in the distal region of chromosome 12 (Tang et al., 2004).
CACNA1C contains 55 exons, of which 15 are subjected to alternative splicing,
generating 40 reported splice variations, expressed in different tissues (Tang et al., 2004).
In smooth muscle cells, alternatively splicing has been reported in exons 1, 8, and 9 in
smooth muscle cells, and in exons 1, 8, 31, and 32 in cardiac muscle (Liao et al., 2005).
CACNA1C transcription is regulated by different promoters in cardiac muscle and
smooth muscle cells (Dai et al., 2002; Saada et al., 2003). CACNA1C transcription is
driven by promoters upstream of exon 1a and 1b in cardiac muscle and smooth muscle
cells, respectively (Dai et al., 2002; Saada et al., 2003). The promoter driving α1C
expression in cardiac muscle has binding sites for several transcription factors, including
myocyte enhancer factor-2, Nkx2.5, NFAT, and CREB (Dai et al., 2002). The promoter
region of α1C in human colonic smooth muscle cells has 2 binding sites for CREB, which
upregulates transcription, and 3 binding sites for NF-κB which represses transcription
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(Shi et al., 2005; Shi et al., 2007). The identity of the transcription factors which bind to
the promoter region of α1C in vascular smooth muscle cells are unknown. It is poorly
understood if transcription factors regulating α1C gene expression in visceral and vascular
smooth muscle cells are similar or different. In rat renal arteries, global [Ca2+]i elevation
increased CaV1.2 protein expression (Pesic et al., 2004). In coronary artery smooth
muscle cells, PKC delta (PKCδ) increased CaV1.2 protein levels (Maddali et al., 2005).
Although these studies report an increase in CaV1.2 protein levels, little is known about
the transcriptional regulation of CaV1.2 α1C gene in vascular smooth muscle cells.
1.9.

Unresolved Issues

Smooth muscle cells from small, resistance-size arteries generate multiple types
of local and global Ca2+ signals. Physiological functions of vasoconstrictor-induced Ca2+
signals, specifically Ca2+ waves in smooth muscle cells of resistance-size arteries are
poorly understood (Miriel et al., 1999; Jaggar, 2001; Mauban et al., 2001; Heppner et al.,
2002; Lamont & Wier, 2004; Jaggar, 2007). Elevation in intracellular [Ca2+]i induces
mitochondrial Ca2+ uptake (Poburko et al., 2004; Chalmers et al., 2007), but identity of
the intracellular Ca2+ signal(s) that regulate [Ca2+]mito in arterial smooth muscle cells is
unclear. Physiological functions of changes in [Ca2+]mito and mitoROS in arterial smooth
muscle cells are also poorly understood. Similarly, stimuli that cause mitochondrial
depolarization and generate mitoROS in arterial smooth muscle cells are unclear (Rizzuto
et al., 1999; Duchen, 2000b; Szado et al., 2003; Poburko et al., 2004). Also, little is
known about the mechanisms that regulate NF-κB activity in contractile arterial smooth
muscle cells. CaV1.2 channels are the major Ca2+ entry pathway for smooth muscle cells
of resistance-size arteries and are essential for myogenic tone development and blood
pressure regulation (Cheng et al., 2007). However, the transcriptional regulation of
CaV1.2 gene expression in vascular smooth muscle cells is unclear.
This study aimed to determine the Ca2+ signaling mechanisms that regulate
[Ca ]mito and to investigate the physiological functions of changes in [Ca2+]mito in smooth
muscle cells of resistance-size cerebral arteries in their native, contractile phenotype.
2+
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CHAPTER 2. HYPOTHESIS
2.1.

Goal

The unifying goal of this study was to test the hypothesis that ET-1-induced IP3Rmediated SR Ca2+ release elevates [Ca2+]mito and mitoROS generation, which activates
NF-κB, leading to transcription of CaV1.2 channels and vasoconstriction.
2.2.
2.2.1.

Specific Aims

Aim 1

To test the hypothesis that ET-1-induced IP3R-mediated SR Ca2+ release elevates
[Ca ]mito leading to mitochondrial depolarization.
2+

Regulation of local and global Ca2+ signals by ET-1 was studied. Mechanisms by
which ET-1 regulate [Ca2+]mito and ψm were examined in arterial smooth muscle cells.
ET-1 regulation of local and global Ca2+ signals was studied in intact arteries using fluo4, a Ca2+-sensitive fluorescent dye and rapid confocal imaging. [Ca2+]mito was measured
in smooth muscle cells of intact arteries using confocal imaging of 2mt8CG2, a
mitochondria-targeted, genetically-encoded Ca2+ indicator. ψm was studied by measuring
TMRM fluorescence in isolated cerebral artery smooth muscle cells.
2.2.2.

Aim 2

To investigate the hypothesis that ET-1-induced [Ca2+]mito elevation and
mitochondrial depolarization elevate mitoROS production, which activates NF-κB.
The importance of ET-1-induced [Ca2+]mito elevation and mitochondrial
depolarization in the mitoROS elevation was examined. The contributions of ET-1induced IP3R-mediated SR Ca2+ release and mitoROS elevation in mediating NF-κB
activation in arterial smooth muscle cells were also studied. MitoROS and cytosolic ROS
were measured in smooth muscle cells of intact arteries using genetically-encoded
fluorescent ROS indicators targeted to the mitochondria and cytosol, respectively. ROS
measurements obtained using genetically-encoded fluorescent ROS indicators were
confirmed using 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate,
acetyl ester (CM-H2DCFDA) and laser-scanning confocal microscopy. ET-1 regulation
of endogenous NF-κB activity was evaluated by using immunofluorescence to study
nuclear translocation of activated NF-κB in smooth muscle cells of intact arteries.
Transcriptional activity of NF-κB was measured by using luciferase reporter gene assays,
which was also used to support results obtained in immmunofluorescence experiments.

28

2.2.3.

Aim 3

To explore the hypothesis that NF-B, activated by ET-1-induced mitoROS
elevation, stimulates Cav1.2 transcription, leading to vasoconstriction.
Mechanisms by which ET-1 elevates CaV1.2 channel expression were
investigated. The importance of ET-1-induced mitoROS elevation and NF-κB activation
in regulating CaV1.2 expression in smooth muscle cells of cerebral arteries was studied.
CaV1.2 mRNA and protein levels were quantified by real-time polymerase chain reaction
(RT-PCR) and Western blotting, respectively. Pressurized artery diameter measurements
were used to assess the functional effects of the ET-1-induced elevation in CaV1.2
expression.
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CHAPTER 3. MATERIALS AND METHODS*
3.1.
3.1.1.

Vertebrate Animal Subjects

Justification of animal use

Male Sprague-Dawley rats (200–250 g body wt) (12-14 weeks of age) were
purchased from Harlan-Teklad Laboratories (Ewing, IL). Rats were chosen for this study
because diameter regulation by intravascular pressure, physiological functions of CaV1.2
channels, and vasoconstrictor-induced modulation of local and global Ca2+ signals are
best described in rats. Therefore, rats were the most appropriate species in which to
conduct this study. All experimental methodologies were carried out ex vivo on
appropriate tissues collected from rats immediately following euthanasia. The number of
animals used for a given experiment varied based on specific experimental design,
variability of the measurements of the parameter in question, and the absolute difference
among groups. For biochemical techniques such as Western blotting, it was usual for
more than one rat to be used per experimental observation since the arteries used in this
study gave smaller protein yields compared to other samples such as rat brain. For nonbiochemical techniques used herein, one rat was typically used per experimental number.
In functional studies, more than one drug was tested in a single experiment, either alone,
or in combination with other modulators, which increased the experimental observations
obtained per animal.
3.1.2.

Information on veterinary care

Research was conducted in accordance with the Guide for Care and Use of
Laboratory Animals, and the provisions of the Animal Welfare Act (USDA) and all other
applicable federal and state laws and regulations. Protocols were reviewed and approved
by IACUC. The University of Tennessee maintains an AAALAC-accredited facility that
is staffed by three full-time veterinarians, two of whom are board-certified in laboratory
animal care. The Department of Comparative Medicine (DCM) was responsible for
husbandry and veterinary care for all vertebrate animals on campus. Animals were
housed by species and health status to minimize infectious disease problems.

* Portions of this chapter adapted with permission. Narayanan D, Xi Q, Pfeffer LM, &
Jaggar JH (2010). Mitochondria control functional CaV1.2 expression in smooth muscle
cells of cerebral arteries. Circ Res 107, 631-641.
30

3.1.3.

Euthanasia

3.1.3.1. Procedure for limiting animal discomfort, distress, pain, and injury
All experiments were performed using cerebral arteries isolated from rat brain
after euthanization. Rats were rendered pliant (immobile but visibly breathing) with CO2
introduced directly into a specially designed housing chamber, prior to euthanasia by
sodium pentobarbital injection. Care was taken at all times to minimize distress to rats
during the euthanization process.
3.1.3.2. Method of euthanasia
Rats were euthanized by intraperitoneal injection of sodium pentobarbital solution
(150 mg/kg) (Vortech Pharmaceuticals, Dearborn, MI). This method induces euthanasia
smoothly and it is consistent with the recommendations of the American Veterinary
Medical Association Panel on Euthanasia (American Veterinary Medical Association
Panel on Euthanasia, 2001). Overdose of sodium pentobarbital causes rapid
unconsciousness, followed by respiratory arrest through paralysis of the diaphragm and
collapse of the lungs. The drug then suppresses cardiac activity, thus causing death. A
new syringe and small needle was used with each animal to reduce injection trauma.
Animal expiration was confirmed by cessation of spontaneous reflex movement to
toe/skin pinch, absence of respiration, heartbeat, and corneal reflex. After confirmation
of expiration, the rats were euthanized by decapitation and the brain removed, for
dissection/removal of cerebral arteries.
3.2.

Tissue Preparation

The brain was removed and placed into ice-cold (4°C) HEPES-buffered
physiological salt solution (PSS) containing (in mM): 134 NaCl, 6 KCl, 2 CaCl2, 1
MgCl2, 10 HEPES, and 10 glucose (with pH adjusted to 7.4 with NaOH). Posterior
cerebral, middle cerebral, and cerebellar arteries (~50–200 µm diameter) were removed
from the brain. The arteries were cleaned of connective tissue. Care was taken while
cleaning to avoid stretching and damage to the arteries. The cleaned arteries were placed
in a petri dish containing 4°C HEPES-buffered PSS. Intact artery segments and
enzymatically isolated smooth muscle cells were harvested on the day of
experimentation. Enzymatically isolated smooth muscle cells were used for
colocalization studies and ψm measurements. For all other experiments, intact artery
segments were used.
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3.3.

Endothelial Denudation

When appropriate, endothelial layer of the arterial wall was removed. Briefly, the
artery segments (1–2 mm in length) were cannulated at one end in a perfusion chamber
(Living Systems Instrumentation, Burlington, VT). Following cannulation at one end, an
air bubble was gently introduced into the arterial lumen for 2 minutes. After 2 minutes,
PSS was flushed through the lumen. This approach of endothelial denudation has been
shown to be effective in previous studies (Xi et al., 2005; Adebiyi et al., 2008; Zhao et
al., 2008).
3.4.
3.4.1.

Isolation of Arterial Smooth Muscle Cells

Preparation of solutions used for smooth muscle cell isolation

Isolated cerebral arteries were placed for 15 minutes in a Ca2+-free solution
containing (in mM): 55 NaCl, 80 sodium glutamate, 5.6 KCl, 2 MgCl2, 10 HEPES, and
10 glucose (with pH adjusted to 7.4 with NaOH). 3 glass vials were rinsed with KOH
and washed thoroughly with distilled water. Papain (0.7 mg/ml) and dithioerythreitol (1
mg/ml) were dissolved in enzyme solution (Ca2+-free solution containing bovine serum
albumin (BSA) (1 mg/ml)). Collagenases F and H were added to enzyme solution
supplemented with CaCl2 (100 µM) in a ratio of 2:1 (1 mg/ml total collagenase). Vials
containing papain and collagenase solutions were warmed to 37°C for 10 minutes prior to
transferring arteries into them.
3.4.2.

Dissociation of smooth muscle cells

3.4.2.1. Freshly dissociated cerebral arteries
Cerebral arteries were placed into vial containing prewarmed papain solution and
incubated for 12 minutes at 37°C. Then, the arteries were immediately transferred to a
vial containing prewarmed collagenase solution and incubated for 9 minutes at 37°C.
Arteries were subsequently washed in three petri dishes containing ice-cold Ca2+-free
solution for 10 min, to remove the enzymes from the arteries. The rinsed arteries were
transferred to a vial containing Ca2+-free solution and triturated gently using three
polished glass pasteur pipettes of progressively decreasing diameter of their opening.
The trituration process gently dissociates the smooth muscle cells from the arteries.
Smooth muscle cells were used for experimentation within 8 hours of dissociation.
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3.4.2.2. Reverse-permeabilized arteries
To deliver expression vectors into smooth muscle cells of intact arteries, reverse
permeabilization procedure (described in detail in section 3.8) was used. Reversepermeabilized arteries were then placed in Dulbecco's Modified Eagle Medium
(DMEM)/F-12 culture medium (Cellgro, Manassas, VA) supplemented with
penicillin/streptomycin (1%) (Cellgro, Manassas, VA) and placed in a 74% N2/21%
O2/5% CO2 incubator at 37°C for 4 days prior to use to allow expression of the genes of
interest. After 4 days, smooth muscle cells were isolated and used for colocalization
experiments. The protocol for dissociation of smooth muscle cells from reversepermeabilized arteries was similar to that used for dissociating smooth muscle cells from
freshly isolated arteries. The durations of papain and collagenase treatments were
reduced to 9 and 7 minutes at 37°C, respectively.
3.5.
3.5.1.

Laser-Scanning Confocal Ca2+ Imaging

Fluo-4 AM loading

Endothelium-denuded cerebral artery segments were cannulated on 10-15 mm
length borosilicate rectangular tubing (external dimensions: 220 × 40 µm) (internal
dimensions: 200 × 20 µm, wall thickness: 20 µm) (Friedrich & Dimmock Inc., Millville,
NJ). Branches were removed from cerebral artery segments to provide a flat surface for
imaging. Cannulated arteries were incubated in the dark in HEPES-buffered PSS
containing fluo-4 AM (10 µM) (Molecular Probes, Invitrogen, Eugene, OR) and 0.05%
Pluronic F-127 (Molecular Probes, Invitrogen, Eugene, OR) for 1 hour at room
temperature. To allow indicator de-esterification, the cannulated arteries were then
placed for 30 minutes at room temperature in 30 mM K+ solution containing (in mM):
110 NaCl, 30 KCl, 10 HEPES, 2 CaCl2, 1 MgCl2, and 10 glucose (with pH adjusted to
7.4 with NaOH). 30 mM K+ solution depolarizes smooth muscle cells to ~-40 mV, which
is similar to the membrane potential of cerebral arteries pressurized to 60 mmHg (Jaggar
et al., 1998; Jaggar & Nelson, 2000; Jaggar, 2001).
3.5.2.

Imaging protocol

Intracellular Ca2+ signals in cerebral artery smooth muscle cells were imaged
using a Noran Oz laser-scanning confocal microscope (Noran Instruments, Middleton,
WI) with a 60X water-immersion objective (numerical aperture=1.2) attached to a Nikon
TE300 microscope by illuminating with a krypton-argon laser at 488 nm and collecting
emitted light >500 nm. Sequential planar images (256 × 240 pixels, 56.3 × 52.8 µm) of
each region of the arterial wall containing ~8-10 smooth muscle cells were recorded
every 16.6 ms (60 Hz) for 10 seconds. In each artery, 2-3 different regions of smooth
muscle cells were scanned for each condition. The same area of artery was scanned only
once to avoid any laser-induced changes in Ca2+ signaling. Ca2+ spark frequency, Ca2+
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wave frequency and global [Ca2+]i were analyzed offline using custom software written
with IDL 5.3 (Research Systems Inc., Boulder, CO) kindly provided by Dr. M. T. Nelson
(University of Vermont, Burlington, VT). The full 10-second acquisition period of each
image stack was analyzed to measure Ca2+ sparks, Ca2+ waves, and global [Ca2+]i.
3.5.3.

Analysis of cytosolic Ca2+signals

3.5.3.1. Detection of Ca2+ sparks and Ca2+ waves
Ca2+ sparks were detected by dividing fluorescence (F) in an area 1.54 µm × 1.54
µm (7 × 7 pixels, 2.37 µm2) in individual smooth muscle cells in each image by a
baseline fluorescence (F0) that was determined by averaging 10 images without Ca2+
spark activity. The entire area of each image was analysed to detect Ca2+ sparks. A Ca2+
spark was defined as a localized rapid increase in F/F0>1.2 (Jaggar et al., 2000).
Ca2+ waves were detected by placing 2.2 × 2.2 µm (10 × 10 pixel, 4.84 µm2)
boxes in individual smooth muscle cells, and refer to an elevation in F/F0>1.3 that was
monitored for >200 milliseconds and propagated for more than 20 µm.
3.5.3.2. Calculation of Ca2+ spark and wave frequency, and global [Ca2+]i
Changes in Ca2+ spark frequency, Ca2+ wave frequency, and global [Ca2+]i in
response to pharmacological manipulation were determined in paired arteries. For each
condition, Ca2+ spark and wave frequency for a region was calculated by dividing the
number of Ca2+ sparks or waves detected in that region by the time of acquisition. Ca2+
spark and wave frequency per cell was calculated by dividing the frequency for each
region by the number of smooth muscle cells in that region. Ca2+ spark and Ca2+ wave
frequency, and global [Ca2+]i that were obtained from smooth muscle cells of multiple
regions of the same artery were averaged, giving data under each condition. Global F/F0
for a given condition was calculated as the mean pixel value of 100 different images
acquired over 10 seconds. Global [Ca2+]i was calculated using the following equation:
[Ca2+]i = KR/{K/([Ca2+]rest + 1 – R)}, where K is the apparent affinity of fluo-4 AM for
Ca2+ (770 nM) (Cheranov & Jaggar, 2004), R is the fractional fluorescence increase
(F/F0), and [Ca2+]rest is [Ca2+]i at F0 (193 nM) (Cheranov & Jaggar, 2004). Changes in
global [Ca2+]i were calculated from a control value previously determined using fura-2
(Cheranov & Jaggar, 2004). Arterial Ca2+ signal values were then averaged generating
mean data. In results, n (experimental number) refers to the number of arteries from
which data were obtained under each condition.
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3.6.
3.6.1.

Genetically-Encoded Fluorescent Indicators

2mt8CG2

pMITO-2mt8CG2 vector encoding 2mt8CG2, a genetically-encoded,
mitochondria-targeted, fluorescent Ca2+ indicator (Griesbeck et al., 2001; Filippin et al.,
2005) was a kind gift from Dr. Tullio Pozzan (University of Padua, Italy). pMITO2mt8CG2 was constructed as follows: firstly, CaM, the Ca2+ probe was inserted into the
backbone of yellow fluorescent protein (YFP) in place of Tyr145 (Griesbeck et al., 2001).
YFP-tagged CaM was then inserted in-frame with two copies of the first 36 amino acids
of subunit VIII of human cytochrome c oxidase (ETC complex IV), a mitochondrial
specific protein (Filippin et al., 2005). 2mt8CG2 targets to mitochondria via cytochrome
c oxidase subunit expression (Filippin et al., 2005). Upon mitochondrial localization,
Ca2+ in the mitochondrial matrix binds to CaM and causes a conformational change in
YFP, leading to a change in fluorescence (Filippin et al., 2005). 2mt8CG2 has a Kd for
Ca2+ of ~5.3 µM (Griesbeck et al., 2001). Therefore, 2mt8CG2 is not capable of
detecting changes in global [Ca2+]i, which is usually in the nanomolar range (Rizzuto &
Pozzan, 2006).
3.6.2.

mt-cpYFP

pShuttle-CMV vector encoding mt-cpYFP, a genetically-encoded, mitochondriatargeted, fluorescent O2-· indicator was a kind gift from Dr. Heping Cheng (Peking
University, China). mt-cpYFP comprises a circularly permuted YFP (cpYFP) that
selectively detects O2-·, the major ROS generated by the mitochondrial ETC (Wang et al.,
2008a). mt-cpYFP localizes to mitochondria using subunit IV of cytochrome C oxidase
targeting sequence (Wang et al., 2008a). In vitro experiments have suggested that
fluorescence changes of cpYFP are highly selective to O2-· levels since its fluorescence is
unchanged by H2O2 and ONOO·, and is decreased by OH· and NO (Wang et al., 2008a).
3.6.3.

HyPer-CYTO

pHyPer-Cyto vector encoding HyPer-CYTO, a genetically-encoded cytosolic
fluorescent H2O2 indicator was purchased from Axxora, Evrogen (San Diego, CA).
HyPer comprises a cpYFP inserted into the regulatory domain of Escherichia Coli OxyR,
a prokaryotic H2O2-sensing protein (Belousov et al., 2006). Upon exposure to H2O2, the
regulatory domain of OxyR undergoes a dramatic conformational change leading to an
increase in cpYFP fluorescence (Belousov et al., 2006). HyPer demonstrates affinity to
H2O2 but is insensitive to other oxidants including O2-·, reactive nitrogen species, NO,
and ONOO· (Belousov et al., 2006).
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3.7.
3.7.1.

Transformation of Bacteria

Introduction of expression vectors

Ultracompetent GC10 bacterial cells (Sigma-Aldrich, St.Louis, MO)
(transformation efficiency is ~1 × 109 colony-forming units/μg of plasmid DNA) were
used for transformation. Vector (~10 ng) was added to GC10 cells (50 µl) and incubated
at 4ºC for 30 minutes. Cells were then heat shocked in a water bath at 42ºC for 45
seconds. This heat shock step permeabilizes the membrane of the competent cells so that
the expression vector can enter the cells. Following heat shock, GC10 cells were added
to LB Broth (950 µl) and incubated for 60 minutes at 37ºC. Incubation allows the cell
membranes to recover from heat shock and permits cell replication to begin.
Transformed bacteria were then plated onto LB agar plates. Ampicillin (100 µg/ml)resistant plates were used for pMITO-2mt8CG2 vector. Kanamycin (50 µg/ml)-resistant
plates were used for pShuttle-CMV and pHyPer-Cyto vectors, respectively. Agar plates
were then incubated at 37°C for 16 to 20 hours. Following incubation, bacterial colonies
which have taken up the expression vector and therefore resistant to the antibiotic added
to the agar plate, appear on agar plates.
3.7.2.

DNA Maxiprep

LB Broth (3 ml) was supplemented with ampicillin (100 µg/ml) (for pMITO2mt8CG2) or kanamycin (50 µg/ml) (for pShuttle-CMV and pHyPer-Cyto). LB Broth
supplemented with antibodies was inoculated with a single bacterial colony and
incubated at 37°C at 200 RPM for 6 to 8 hours. This “starter culture” was then added to
a large volume of LB Broth (150 ml) supplemented with antibodies and incubated at
37°C for 16 to 20 hours or until the solution turns turbid. Incubation allows amplification
of the bacteria which have taken up the expression vector. Plasmid cDNA was purified
from the bacterial culture using Qiagen Maxiprep HiSpeed Plasmid Purification kit
(Qiagen, Valencia, CA).
3.7.3.

Quantification of DNA

Maxipreped DNA (1:80 dilution) was quantified by measuring the absorbance of
UV light at 230 nm (A230), 260 nm (A260), and 280 nm (A280 nm) using a UV
spectrophotometer. DNA concentration was calculated using the equation:
DNA concentration (µg/ml) = (A260 – A230) × dilution factor × 50 µg/ml
Nucleic acid purity was estimated from A260/A280 and A260/A230 ratios.
Ratios between 1.8 and 2.0 generally represent high-quality nucleic acid sample.
Reduction of A260/A280 and A260/A230 ratios indicate contamination with protein and
organic compounds, respectively.
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3.8.
3.8.1.

Reverse Permeabilization

Composition of solutions used

To deliver expression vectors into smooth muscle cells of intact arteries, reverse
permeabilization was used (Lesh et al., 1995; Welsh et al., 2002). Compositions of the
solutions used for reverse permeabilization are as follows. Solution 1 (in mM): 10
EGTA, 120 KCl, 5 ATP, 2 MgCl2, 20 TES (pH 6.8 at 4°C); solution 2 (in mM): 120 KCl,
5 ATP, 2 MgCl2, 20 TES (pH 6.8 at 4°C); solution 3 (in mM): 120 KCl, 5 ATP, 10
MgCl2, 20 TES (pH 6.8 at 4°C); solution 4 (in mM): 140 NaCl, 5 KCl, 10 MgCl2, 5.6
glucose, 2 MOPS (pH 7.1 at 22°C).
3.8.2.

Procedure

Freshly isolated and cleaned arteries were placed into the following solutions:
solution 1 for 20 minutes at 4°C, solution 2 containing expression vector (10 µg/ml) for
90 minutes at 4°C, solution 3 containing expression vector (10 µg/ml) for 30 minutes at
4°C, and solution 4 containing expression vector (10 µg/ml) for 30 minutes at room
temperature. Ca2+ concentration in solution 4 was then increased incrementally to (in
mM): 0.01, 0.1 and 1.8 at 15-minute intervals. Arteries were then placed in DMEM/F-12
culture medium supplemented with penicillin/streptomycin (1%) and placed in a 74%
N2/21% O2/5% CO2 incubator at 37°C for 4 days prior to use. Fig. 3-1 illustrates HyPerCYTO expression in smooth muscle cells of intact arteries.
3.8.3.

Principle

The mechanism of reversible permeabilization has been suggested to involve
binding of ATP4- to cell surface receptors and the removal of membrane-associated
divalent cations when the arteries are in solutions 1, 2, and 3 (Lesh et al., 1995). The
resulting increase in membrane permeability is responsible for the delivery of the
expression vectors into the smooth muscle cells. The increase in membrane permeability
is reversed in solution 4 by removal of extracellular ATP and addition of high [Mg2+]
followed by graded restoration of the physiological concentrations of extracellular Ca2+.
Arteries are then placed in DMEM/F-12 culture medium supplemented with
penicillin/streptomycin (1%) for 4 days to allow expression of the genes of interest.
Culture of arteries in serum-supplemented DMEM has been suggested to change the
phenotype of smooth muscle cell from a contractile to an invasive proliferative one
(Absher et al., 1989; Campbell et al., 1989; Eguchi et al., 1994). To prevent the
phenotypic change of smooth muscle cells, the arteries are incubated in serum-free
DMEM. Studies suggest that reverse permeabilization does not alter the ultrastructural
features and contractile properties of smooth muscle cells (Lesh et al., 1995).
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Figure 3-1. Reverse permeabilization of HyPer-CYTO in smooth muscle cells of
intact arteries
Notes: Images comparing fluorescence in smooth muscle cells of intact arteries reverse
permeabilized with either no vector or vectors encoding HyPer-CYTO. Rectangular
glass cannula inserted intralumenally to provide a flat surface for imaging can be seen
within each artery. Scale bar=20 µm.
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3.9.
3.9.1.

Confocal Imaging of Genetically-Encoded Fluorescent Indicators

Introduction of indicators into arterial smooth muscle cells

pMITO-2mt8CG2, pShuttle-CMV, or pHyPer-Cyto vectors were inserted into
smooth muscle cells of intact cerebral arteries using reverse permeabilization to express
2mt8CG2, mt-cpYFP, or HyPer-CYTO, respectively. Following incubation for 4 days in
serum-free DMEM, cerebral artery segments were cannulated on borosilicate rectangular
tubing for confocal imaging.
3.9.2.

Imaging protocol

Cannulated artery segment was placed in a No. 0 glass coverslip bottom petri dish
(MatTek Corporation, Ashland, MA). 2mt8CG2, mt-cpYFP, or HyPer-CYTO were
excited with 488 nm light and emitted light >510 nm captured using a Zeiss LSM5 Pascal
laser-scanning confocal microscope. In experiments where indicated, fluorescence was
measured in smooth muscle cells of intact arteries. 2mt8CG2 fluorescence was measured
using a z-resolution of ~4.5 µm, and mt-cpYFP and HyPer-CYTO fluorescence were
measured using a z-resolution of ~2.5 µm. Adjusting the z-plane, the field for image
acquisition was chosen in a region containing exclusively of smooth muscle cells. Laser
intensity was kept at a minimum while choosing the field to prevent laser-induced
bleaching of the indicator fluorescence. Once the imaging field was chosen, the laser
intensity was restored to original values. At the end of each experiment, smooth muscle
cell viability was confirmed by application of CCCP, which uncouples the ETC and
disrupts ψm, leading to decrease in 2mt8CG2 and mt-cpYFP fluorescence. For
experiments performed using HyPer-CYTO, cell viability at the end of each experiment
was confirmed by an elevation in fluorescence to H2O2 application.
3.9.3.

Analysis of confocal images

Mean intensity of smooth muscle cells in the imaging field was used as a measure
of fluorescence. Cerebral arteries reverse permeabilized with no vector were used as
controls. Background (autofluorescence) was measured from smooth muscle cells in
these arteries with the same imaging parameters (laser intensity, detector gain, and zresolution) used to image smooth muscle cells of intact arteries expressing 2mt8CG2, mtcpYFP, or HyPer-CYTO. Autofluorescence was then subtracted from all fluorescence
measurements obtained from arteries expressing the fluorescent indicators. Following
autofluorescence subtraction, changes in indicator fluorescence induced by
pharmacological agents were calculated as a % of the initial pre-exposure fluorescence.
Time control measurements were also obtained in arteries expressing the fluorescent
indicators. Percentage changes in 2mt8CG2, mt-cpYFP, or HyPer-CYTO were corrected
for indicator bleaching using time control measurements.
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3.10.

Localization of Mitochondria-Targeted Indicators

3.10.1. Loading smooth muscle cells with MitoTracker
To confirm targeting of 2mt8CG2 and mt-cpYFP to the mitochondria,
colocalization experiments were performed with MitoTracker Orange CMTMRos
(Molecular Probes, Invitrogen, Eugene, OR), an organic mitochondria-selective dye.
MitoTracker Orange CMTMRos is a cell permeant dye which upon entering the cells is
sequestered to the mitochondria because of its mildly thiol-reactive chloromethyl moiety
(Poot et al., 1996) (Molecular Probes, Invitrogen, Eugene, OR). Smooth muscle cells
expressing 2mt8CG2 or mt-cpYFP were isolated from intact arteries. Dissociated smooth
muscle cells were allowed to adhere to glass coverslips for 15 minutes and then incubated
with prewarmed (37°C) DMEM/F-12 culture medium supplemented with
penicillin/streptomycin (1%) containing MitoTracker Orange CMTMRos (100 nM) for
30 minutes at 37°C in a 74% N2/21% O2/5% CO2 incubator. Following wash with
DMEM/F-12 culture medium for 10 minutes at 37°C, cells were fixed with 4%
paraformaldehyde in phosphate-buffered saline (PBS) for 15 minutes at room
temperature and imaged using a Zeiss LSM5 Pascal laser-scanning confocal microscope.
3.10.2. Imaging protocol
MitoTracker and 2mt8CG2 or mt-cpYFP were imaged using an interleaved image
acquisition protocol. Interleaved image acquisition requires sequential collection of
fluorescence images from the same field for one channel followed immediately for
another channel. MitoTracker was excited with 545 nm light and emitted light >560 nm
was captured. 2mt8CG2 or mt-cpYFP was excited with 488 nm light and emitted light
505-530 nm captured. Bandpass emission filter of 505-530 nm collects fluorescence
emitted within that range, and a long pass emission filter of >510 nm collects all
fluorescence emitted above 510 nm. Bandpass emission filter of 505-530 nm was used to
collect 2mt8CG2 or mt-cpYFP fluorescence to prevent bleedthrough of MitoTracker
fluorescence (which emits at wavelength >560 nm) into 2mt8CG2 or mt-cpYFP
emission. Isolated smooth muscle cells were imaged using a z-resolution of ~1 µm to
visualize organelle distribution in the cytosol.
3.10.3. Analysis of confocal images
Data was analyzed using the Zeiss LSM5 Pascal colocalization module, which
permits interactive analysis of fluorescence from two channels of an image. In a smooth
muscle cell, colocalization would occur when fluorescence of 2mt8CG2 or mt-cpYFP,
and MitoTracker, a mitochondria-selective indicator are present in the same pixel.
Therefore, weighted colocalization between 2mt8CG2 or mt-cpYFP and MitoTracker
was used to quantify mitochondrial targeting of the fluorescent indicator. Weighted
colocalization is determined as the sum of intensities of colocalizing pixels in 2mt8CG2
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or mt-cpYFP channel compared to sum of intensities of all 2mt8CG2 or mt-cpYFP pixels
above threshold (background). The values for weighted colocalization range from 0 to
100%, where 0 indicates no colocalization, and 100 indicates colocalization of all pixels.
Threshold value was taken from a region in the imaging field where no cells are present.
3.11.

Imaging 2mt8CG2 in HEK293 Cells

3.11.1. Transfection of HEK293 cells with 2mt8CG2
Human Embryonic Kidney 293 (HEK293) cells (ATCC, Manassas, VA) were
maintained in DMEM culture medium supplemented with 10% fetal bovine serum (FBS)
(Cellgro, Manassas, VA) and penicillin-streptomycin (1%) under standard tissue culture
conditions (74% N2/21% O2/5% CO2; 37°C). HEK293 cells were grown on sterile glass
coverslips placed in 35 mm petri dishes to achieve 20-50% confluency and transfected
using the Ca2+ phosphate method. Briefly, a reaction mixture containing 0.5 µg of
pMITO-2mt8CG2 and 0.125 M CaCl2 in N,N-bis(2-hydroxyethyl)-2aminoethanesulfonic acid (BES)-buffered solution was added dropwise to HEK293 cells
and placed at 37°C for 16 to 18 hours in a 74% N2/21% O2/5% CO2 incubator.
Following aspiration of media, cells were washed with sterile PBS and incubated in
DMEM for 24 hours at 37°C in a 74% N2/21% O2/5% CO2 incubator.
3.11.2. Imaging protocol
2mt8CG2 was excited with 488 nm light and emitted light >510 nm captured
using a Zeiss LSM5 Pascal laser-scanning confocal microscope using a z-resolution of
~1 µm.
3.12.

Tetramethylrhodamine, Methyl Ester Imaging for ψm Measurements

3.12.1. Principle
ψm was studied using tetramethylrhodamine, methyl ester (TMRM) (Molecular
Probes, Invitrogen, Eugene, OR), a membrane-permeant fluorescent potentiometric
indicator (Scaduto, Jr. & Grotyohann, 1999; Cheranov & Jaggar, 2004; Xi et al., 2005).
Following cell permeation, TMRM is cleaved by intracellular esterases to yield a cationic
fluorescent probe. The mitochondrial matrix is negatively charged compared to the
cytosol, thus enabling the uptake of the cationic TMRM into the mitochondrial matrix
(Scaduto, Jr. & Grotyohann, 1999). Mitochondrial depolarization makes the
mitochondria more positively charged, thereby leading to extrusion of TMRM from the
mitochondria into the cytosol, and eventually from the cell, leading to a decrease in
TMRM fluorescence.
41

3.12.2. Procedure
A small volume (100 µl) of Ca2+-free solution containing freshly isolated arterial
smooth muscle cells was placed on a No. 0 glass coverslip bottom petri dish. Cells were
allowed to adhere to the coverslip for 15 minutes. Cells were subsequently incubated in
HEPES-buffered PSS containing TMRM (100 nM) for 20 minutes, followed by a 15minute wash in HEPES-buffered PSS. Solutions were perfused through the petri dish at
room temperature. Perfusing solutions containing TMRM (1 nM) in addition to the
stimulus were used to maintain a steady extracellular TMRM concentration. This was
found to facilitate TMRM reuptake into the mitochondria when the depolarizing stimulus
was washed off and when ψm returned to its resting negative value. At the end of each
experiment, cell viability was confirmed by application of CCCP, which uncouples the
ETC and disrupts ψm, leading to a decrease in TMRM fluorescence.
3.12.3. Imaging
In a region, every TMRM-loaded smooth muscle cell was chosen as a separate
zone and fluorescence from every zone was collected. To measure temporal changes in
TMRM intensity, smooth muscle cells were excited with 535 nm light, and background
corrected fluorescence collected every 1 second at 610 nm using a Dage MTI iCCD
camera and Ionwizard software (Ionoptix, Milton, MA). Background fluorescence was
collected from a zone where no smooth muscle cells were present.
3.12.4. Analysis
Background-corrected TMRM fluorescence measurements for 2 minutes prior to
addition of a stimulus were averaged to obtain the control fluorescence. TMRM
fluorescence changes in response to stimuli were normalized to the pre-exposure control
fluorescence.
3.13.

Dichlorofluorescein Imaging for ROS Measurements

3.13.1. Principle
ROS measurements in isolated intact cerebral artery segments (1–2 mm) were
performed using CM-H2DCFDA (Molecular Probes, Invitrogen, Eugene, OR), a cellpermeant ROS indicator. CM-H2DCFDA , which is an acetylated form of 2′,7′dichlorofluorescein (DCF) is hydrolyzed by intracellular esterases to remove the acetate
groups yielding the nonfluorescent derivative dichlorodihydrofluorescein (H2DCF)
(Jakubowski & Bartosz, 2000). ROS oxidize the nonfluorescent H2DCF to fluorescent
DCF (Jakubowski & Bartosz, 2000; Cheranov & Jaggar, 2006). Amount of DCF
fluorescence is proportional to the amount of ROS present. DCF fluorescence changes
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can therefore be used to measure changes in ROS levels in arterial smooth muscle cells.
The thiol-reactive chloromethyl group forms covalent bonds with intracellular
components, permitting retention within the cell (Jakubowski & Bartosz, 2000).
3.13.2. Procedure
Cerebral artery segments were cannulated on borosilicate rectangular tubing and
incubated for 60 minutes at room temperature in HEPES-buffered PSS containing CMH2DCFDA (10 µM). The DCF-loaded arteries were washed with HEPES-buffered PSS
for 15 minutes at room temperature. Following wash, the cannulated arteries were placed
on a No. 0 glass coverslip bottom petri dish and imaged using a confocal microscope.
3.13.3. Imaging
DCF was excited with 488 nm light, and emitted light >510 nm was collected
using a Zeiss LSM5 Pascal laser-scanning confocal microscope using a z-resolution of
~4.5 µm. Because the dye is susceptible to photo-oxidation, DCF fluorescence can
increase spontaneously upon exposure to excitation light (Afzal et al., 2003; Cheranov &
Jaggar, 2006). To reduce the laser-induced photo-oxidation, each arterial region was
scanned only once, and the laser intensity was set to minimize excitation.
3.13.4. Analysis
Mean intensity of DCF fluorescence from smooth muscle cells in the imaging
field was subtracted from background (autofluorescence) to obtain the corrected
fluorescence in a field. Autofluorescence was measured in control arteries that were not
loaded with DCF but underwent the same imaging protocol (laser intensity, detector gain,
and z-resolution). Following autofluorescence subtraction, changes in DCF fluorescence
induced by pharmacological agents were calculated as a % of the initial pre-exposure
fluorescence. % changes in DCF fluorescence were then corrected for time-dependent
photo-oxidation-induced elevation in DCF fluorescence. Time control measurements
were obtained in smooth muscle cells of intact DCF-loaded arteries that underwent the
same imaging protocol, but were not exposed to stimuli.
3.14.

NAD(P)H Oxidase Inhibitors

gp91phox docking sequence represents the binding site of p47phox subunit of
NAD(P)H oxidase (Rey et al., 2001). p47phox translocation to the smooth muscle cell
membrane and anchoring with gp91phox is required for NAD(P)H oxidase activation (Rey
et al., 2001). Therefore, to prevent association of NAD(P)H oxidase subunits and
activation of NAD(P)H oxidase, peptides were used.
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gp91ds-tat peptide contains the gp91phox docking sequence (NH2-LQRRIRTSCCOOH) (Rey et al., 2001) conjugated to the N-terminus of a specific amino acid peptide
(NH2-RRRQRRKKR-COOH) of HIV viral coats (HIV-tat), which is known to be
internalized by all cells (Fawell et al., 1994). gp91scrm-tat contains a scrambled gp91
peptide (NH2-RSQRTIRLC-COOH) conjugated to N-terminus of HIV-tat (Rey et al.,
2001). gp91ds-tat and gp91scrm-tat peptides were synthesized by Tufts University Core
Facility (Boston, MA).
3.15.

NF-κB Immunofluorescence

3.15.1. Principle
NF-κB immunofluorescence was performed to study NF-κB p50 localization in
the smooth muscle cells of intact arteries. Following treatment, arteries were incubated
with anti-p50 antibody and the corresponding fluorophore-conjugated secondary
antibody. Nucleus was labeled using a dimeric cyanine nucleic acid stain. Upon nuclear
translocation of p50, colocalization of fluorophore (attached to the secondary antibody)
and nucleic acid stain was anticipated.
3.15.2. Procedure
Intact arteries were exposed to pharmacological agents in DMEM/F-12 culture
medium supplemented with penicillin/streptomycin (1%) and incubated in a 74% N2/21%
O2/5% CO2 incubator at 37ºC. Following treatment, arteries were fixed with 4%
paraformaldehyde in PBS for 1 hour at room temperature, and washed three times for 5
minutes each with PBS. Permeabilization of cell membrane to facilitate passage of
antibodies into cells to bind the protein(s) of interest was done using 0.5% TritonX-100
dissolved in PBS for 15 minutes at room temperature. After three washes with PBS,
arteries were incubated in 5% BSA in PBS for 1 hour at room temperature. Arteries were
then incubated with mouse monoclonal anti-NF-κB p50 antibody (1:100 dilution; Santa
Cruz Biotechnology Inc., Santa Cruz, CA) overnight at 4°C. The epitope recognized by
the anti-NF-κB p50 antibody is located in the N-terminus (amino acids 120-239) of NFκB p50 of human origin. After five washes with PBS at room temperature, arteries were
incubated with Cy3-conjugated goat anti-mouse IgG (1:100 dilution; Jackson
ImmunoResearch, West Grove, PA) for 1 hour at 37°C. After ten washes with PBS at
room temperature, YOYO-1 iodide (1:10,000 dilution; Molecular Probes, Invitrogen,
Eugene, OR), a fluorescent nucleic acid indicator and Ribonuclease A (RNase A) (250
µg/ml; Sigma-Aldrich, St.Louis, MO) were added for 30 minutes at 37ºC to counterstain
smooth muscle cell nuclei. RNase A was added to destroy cellular RNA and thereby
prevent YOYO-1 binding to RNA. A borosilicate rectangular tubing was then placed in
the lumen of each fixed artery to provide a flat surface for imaging. The artery was then
mounted on a glass slide and used for imaging.
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3.15.3. Imaging
NF-κB localization in smooth muscle cells of intact arteries was examined using a
Zeiss LSM 5 Pascal laser-scanning confocal microscope using a z-resolution of ~0.8 µm.
Cy3 was excited with 545 nm light, and emitted light >560 nm was collected. YOYO-1
was excited with 488 nm light, and emitted light 505-530 nm was collected. YOYO-1
fluorescence was collected using bandpass emission filter (505-530 nm) instead of long
pass emission filter (>510 nm) to prevent collection of Cy3 fluorescence into the YOYO1 channel.
3.15.4. Analysis
Data was analyzed using the Zeiss LSM5 Pascal colocalization module.
Colocalization of p50 and YOYO-1 was determined using weighted colocalization, as
previously described in section 3.10.3. Weighted colocalization of p50 pixels with
YOYO-1 pixels in the field was used to quantify p50 nuclear translocation. Threshold
value for each channel was taken from a region in the imaging field outside the artery.
3.16.

NF-κB-Dependent Luciferase Reporter Gene Activity

3.16.1. Vectors encoding luciferase
NF-κB-p-Luc vector contains a luciferase reporter gene under the control of an
NF-κB promoter (κB sites in the promoter region of the immunoglobulin gene). Three
κB sites in the promoter regions are as follows: GGAAATTCCCC (-63 to -53),
AGGACTTTCC (-225 to -216), and GGGAAACCCC (-319 to -310) (Le Bail et al.,
1993; Arsura et al., 2003; Kaur et al., 2005). pGL3 Basic control vector (Promega
Corporation, Madison, WI) which contains the luciferase reporter gene but no promoter
was used as a control.
3.16.2. Principle
NF-κB-dependent transcriptional activity was studied using NF-κB-dependent
luciferase reporter gene assay. NF-κB binds to promoter of NF-κB-p-Luc, leading to
transcription of luciferase reporter gene, resulting in luciferase protein expression and
fluorescence. Stimuli which activate NF-κB increase the number of NF-κB proteins
binding to the κB sites in the promoter. Transcription of luciferase reporter gene is
elevated, leading to an increase in luciferase protein expression and fluorescence.
Therefore, fluorescence obtained from NF-κB-p-Luc is proportional to NF-κB activity.
pGL3 Basic vector contains a luciferase reporter gene but no promoter. Changes
in NF-κB activity would therefore not alter the luciferase expression and fluorescence.
45

3.16.3. Procedure
NF-κB-p-Luc or pGL3 Basic vectors were inserted into smooth muscle cells of
intact arteries using reverse permeabilization. The arteries were then placed for 3 days at
37ºC in DMEM/F-12 culture medium supplemented with penicillin/streptomycin (1%) in
a 74% N2/21% O2/5% CO2 incubator. After 3 days, the arteries were exposed to stimuli
for an additional 24 hours at 37ºC. Arterial protein lysates were then isolated and
quantified (described in detail in section 3.19). Luciferase activity was determined using
the Luciferase Assay System (Promega Corporation, Madison, WI).
3.16.4. Measuring luciferase activity
Protein lysate (50 µg) was added to Luciferase Assay Reagent (100 µl) and
luciferase luminescence was measured using a TD-20/20 luminometer (Turner Designs,
Sunnyvale, CA). As suggested by the vendor (Promega), the luminometer was
programmed to perform a 2-second measurement delay followed by a 10-second
measurement read for luciferase activity. Luminescence measurements were corrected
for background luciferase luminescence, which was recorded from lysates of arteries that
underwent the same reverse permeabilization, culture, and luminescence measurement
protocol, but were not exposed to NF-κB-p-Luc or pGL3 Basic vectors during the reverse
permeabilization procedure.
3.17.

Real-Time PCR

3.17.1. RNA isolation
Intact cerebral arteries were either untreated or treated with ET-1 (10 nM) in
DMEM/F-12 culture medium supplemented with penicillin/streptomycin (1%) in a 74%
N2/21% O2/5% CO2 incubator for 6 hours at 37ºC. Following treatment, Trizol
(Invitrogen, Eugene, OR) was added to arteries, homogenized, and incubated for 5
minutes at room temperature to completely dissociate cellular nucleoprotein complexes.
Chloroform was added and centrifuged at 12000  g for 15 minutes at 4°C to separate the
samples into a DNA-containing phenol, a DNA/protein-containing interphase, and an
RNA-containing aqueous phase. RNA in the aqueous phase was precipitated by adding
isopropyl alcohol and centrifuged at 12000  g for 10 minutes at 4°C. RNA precipitate
which forms a gel-like pellet at the bottom of the tube was washed with 75% ethanol and
reconstituted in RNase-free water.
3.17.2. Quantification of RNA
RNA concentration was quantified measuring the absorbance of UV light at 230
nm (A230), 260 nm (A260), and 280 nm (A280 nm) using a UV spectrophotometer.
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RNA concentration was calculated from the equation:
RNA concentration (µg/ml) = (A260 – A230) × dilution factor × 40 µg/ml
Nucleic acid purity was estimated from A260/A280 and A260/A230 ratios.
Ratios between 1.8 and 2.0 generally represent high-quality nucleic acid sample.
3.17.3. Reverse transcription
RNA (~250 ng) from arteries for each condition was used in reverse transcription
to obtain cDNA. The remaining RNA from each condition was used as template in
negative control reactions for RT-PCR. cDNA was reverse transcribed from RNA using
AffinityScript Multiple Temperature Reverse Transcriptase (Stratagene, Cedar Creek,
TX). Briefly, RNA, random primers, and RNase-free water were added to a nucleasefree centrifuge tube and incubated at 65°C for 5 minutes. The mixture was slowly cooled
to room temperature for 10 minutes, to allow annealing of primers to RNA. DTT (100
mM), dNTP (100 mM), buffer, and reverse transcriptase were added and the reaction
incubated at 50°C for 1 hour. The reaction was stopped by heat inactivating the enzymes
at 70°C for 15 minutes. Following reverse transcription, cDNA was used as template for
RT-PCR.
3.17.4. Principle
TaqMan probes are designed to anneal to the DNA region which is amplified by a
pair of primers. Probes consist of a fluorophore which is in close proximity to a
quencher, which inhibits fluorescence from the fluorophore (Holland et al., 1991). Using
the DNA template, Taq DNA polymerase synthesizes the nascent strand from the 3’ end
of the primer. TaqMan probe that is annealed to the DNA is degraded by the 5' to 3'
exonuclease activity of the polymerase. Degradation of the probe releases the
fluorophore from it, thereby preventing it from being in close proximity to the quencher,
resulting in elevation of fluorescence. Presence of more DNA templates causes probe
binding to more DNA, leading to elevated fluorescence. Therefore, fluorescence detected
is directly proportional to the amount of DNA template present in the PCR. Since the
DNA template used is reverse-transcribed from mRNA, the fluorescence detected is an
indication of the cellular mRNA levels and hence, is used to quantify changes in gene
expression.
3.17.5. Primers and probes
RT-PCR assays, hydrolysis probes, and gene specific primers that span long
introns were designed to distinguish cDNA from genomic DNA using primer design
online software Universal Probe Library available at
http://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp. Primers were ordered
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from Integrated DNA Techonologies (Coralville, IA). Hydrolysis probes were ordered
from Molecular Resource Center, University of Tennessee Health Science Center
(Memphis, TN). Primers and probes used for RT-PCR are listed in Table 3-1. Melting
temperature of all the primers was between 59 and 60°C.
3.17.6. PCR conditions
Quantitative TaqMan PCR reactions were performed using an LC480 light cycler
(Roche Applied Science, Indianapolis, IN). Each PCR mixture (10 µl) contained 5 µl of
Taqman LC480 Master Mix, 0.1 µl of forward primer, 0.1 µl of reverse primer, 0.1 µl of
hydrolysis probe, 2.7 µl of RNase-free water, and 2 µl of cDNA or mRNA template.
Reaction was activated at 95ºC for 5 minutes. Following activation, amplification was
performed with 40 cycles of denaturation for 10 seconds at 95ºC, and annealing of
primers for 30 seconds at 60ºC, and 1 cycle of extension for 10 seconds at 72ºC.
Reaction was cooled to 40°C for 5 minutes. A negative control using RNA instead of
cDNA was carried out in each experiment. Standard curves using four 10-fold dilution
steps of cDNA samples were run for all probe and primer pairs to determine PCR
efficiency. PCR efficiency, determined by the slope of standard curves for all primer and
probe pairs were between ~1.7 and 2.3.
3.17.7. Analysis
CaV1.2 mRNA expression under each condition was calculated from the
difference between CT values (ΔCT) of CaV1.2 and ribosomal protein subunit 5 (Rps5),
reference gene. ΔΔCT was calculated from the difference between the ΔCT values for
control and ET-1 treatment. ET-1-induced elevation in CaV1.2 mRNA levels was
calculated using the formula 100  (2-ΔΔCT) (Livak & Schmittgen, 2001). All PCR
reactions including standard curves were performed in triplicate.
3.18.

Agarose Gel Electrophoresis

Products of RT-PCR were mixed with Green GoTaq Flexi Buffer (Promega
Corporation, Madison, WI) and separated by electrophoresis using 2% agarose gel
containing 0.01% ethidium bromide. Images of fluorescence from ethidium bromide
bound to DNA within the gel were collected using the Kodak In-Vivo Imaging System
(Carestream Health Inc., Woodbridge, CT) and the Kodak Molecular Imaging Software
v4.5.1 (Carestream Health Inc., Woodbridge, CT).
3.19.

Protein Quantification and Estimation

Cerebral arteries were homogenized in Laemmli sample buffer (2.5% SDS, 10%
glycerol, 0.01% bromophenol blue, 5% β-mercaptoethanol, and 100 mM Tris-HCl, pH
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Table 3-1.

Primers and probes used in RT-PCR

Gene
(Accession number)

Forward primer (5’sequence3’)
(Position)

Reverse primer (5’sequence3’)
(Position)

Hydrolysis probe
(Position)

CaV1.2
(DQ538522.1)

GAGAGCTTTCCGTGTGCTTC
(727-746)

GTTCAGGACCACCTGGAGAC
(777-796)

CTGGAGTC
(765-772)

Rps5
(NM_001105722.1)

GACTGAGAAGCCCGGTTTG
(70-88)

CTTGATGTCCGGGGTCTCT
(134-152)

CAGCCACA
(115-122)

HGPRT
(ENSRNOT00000045153.2)

TCAACGGGGGACATAAAAGT
(394-413)

AGTGTCAATTATATCCAAACCCAAT
(462-486)

TGGTGGAG
(417-424)

Cyclophilin B
(ENSRNOT00000022828.4)

ACGTGGTTTTCGGCAAAGT
(524-542)

CTTGGTGTTCTCCACCTTCC
(566-585)

TGGAAGGC
(545-552)

β tubulin
(ENSRNOT00000023452.4)

CAGAGCCATTCTGGTGGAC
(239-257)

GCCAGCACCACTCTGACC
(333-350)

GAGCCTGG
(261-268)

β actin
(ENSRNOT00000042459.1)

CCCGCGAGTACAACCTTCT
(17-35)

CGTCATCCATGGCGAACT
(71-88)

CAGCTCCT
(38-45)
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6.8). Tissue debris and nuclear fragments were removed by centrifugation at 6000  g
for 10 minutes at 4°C. The whole cell lysate, obtained as a supernatant was transferred to
a fresh tube and used for protein quantification and Western blotting. A 5 µl aliquot of
supernatant was placed on a nitrocellulose membrane, and following amido black
staining, protein concentration was measured by spectrophotometric quantification at 630
nm.
3.20.

Western Blotting

Protein extracts were heated for 3 minutes at 100°C. Proteins (30 µg per lane)
were separated by size on 7.5% SDS-PAGE Tris-glycine gels. Prestained molecular
weight markers (Bio-Rad, Hercules, CA) were used to monitor progress on the gel. Gel
was run in MOPS-SDS Running Buffer (containing SDS and Tris-Glycine) at 200 V until
the 37 kDa marker reached the bottom of the gel. Following this, the gel was placed onto
a PVDF membrane treated with methanol and placed between two sheets of filter paper
between two sponges, all soaked in Transfer Buffer (Tris base, glycine, and methanol),
into a binding cassette. Proteins were transferred for 2 hours at 100 V using a Mini Trans
Blot Cell (Bio-Rad, Hercules, CA). The apparatus was placed on ice to manage heat
exchange during the transfer.
Membranes were blocked in 5% nonfat dry milk in Tris-buffered solution (TBS)
with 0.1% Tween-20 (TBS-T) for 1 hour at room temperature. Membranes were then
incubated with rabbit monoclonal anti-p105/p50 antibody (1:1000 dilution; Abcam Inc.,
Cambridge, MA), mouse monoclonal anti-CaV1.2 antibody (1:200 dilution; UC
Davis/NINDS/NIMH NeuroMab Facility), or mouse monoclonal anti-actin antibody
(1:50,000 dilution; Millipore, Billerica, MA) overnight at 4ºC in TBS-T and 5% nonfat
dry milk. Anti-CaV1.2 antibody was produced against intracellular C-terminus (amino
acids 1507-1733) of rabbit CaV1.2. Epitope recognized by the anti-actin antibody is
located in the N-terminus (amino acids 50-70) of actin. Following overnight incubation
with primary antibodies, membranes were washed three times with TBS-T for 5 minutes
each, and incubated for 1-2 hours at room temperature with HRP-conjugated secondary
antibody in TBS-T and 5% nonfat dry milk. Membranes were then washed three times
with TBS-T for 5 minutes each, and incubated with enhanced chemiluminiscence
substrate (Amersham, Arlington heights, IL) for the HRP enzyme conjugated in the
secondary antibody.
HRP-induced chemiluminescence from bound secondary antibodies was detected
using a Kodak In-Vivo Imaging System and visualized using the Kodak Molecular
Imaging Software v4.5.1. Membranes were developed multiple times using different
exposure times, to optimize band intensity for densitometric analysis.
The PVDF membranes can be reprobed for other proteins after probing them for
one. To achieve this, the membrane was stripped using a Stripping Buffer (Thermo
Scientific, Rockford, IL) for 15 minutes at room temperature, washed with TBS-T,
reblocked, and reprobed as explained above.
50

3.21.

Densitometric Analysis of Western Blots

Band intensity was quantified using digital densitometry using Quantity One
software v4.6.9 (Bio-Rad, Hercules, CA). Briefly, background-subtracted band density
was calculated by placing rectangular boxes of the same size around bands in each lane.
Average band density was calculated from all images of the same blot acquired using
different exposure times. Averaged band density for a protein was then normalized to the
band density of actin for the corresponding sample. Actin was used to normalize data
because pharmacological treatments used in this study did not alter its expression.
3.22.

NF-κB p105 Knockdown

3.22.1. Principle
siRNA are long double-stranded RNA molecules that have a characteristic two
nucleotide 3' overhang that allows them to be recognized by the enzymatic machinery of
RNA interference. siRNA are separated into single strands which homology-dependently
bind to target mRNA. siRNA-mRNA complex is eventually destroyed by the RNAinduced silencing complex, leading to target mRNA degradation. siRNA-mediated
reduction in mRNA levels translate to a decrease in target protein levels.
3.22.2. Procedure
Two siRNAs directed against NF-κB p105 subunit (p105siRNA1 and
p105siRNA2) (10 µg/ml each) (Qiagen, Valencia, CA) were used to inhibit p105
expression. p105siRNA1 and p105siRNA2 were directed against target sequences in
regions 458-478 and 939-959, respectively of p105 sequence (XM_001075876).
Scrambled siRNA (p105scrm) (20 µg/ml) (Qiagen, Valencia, CA) was used as a control.
siRNAs were introduced into smooth muscle cells of intact cerebral arteries using reverse
permeabilization (Lesh et al., 1995; Welsh et al., 2002). After 3 days in DMEM/F-12
culture medium supplemented with penicillin/streptomycin (1%) in a 74% N2/21%
O2/5% CO2 incubator at 37ºC, arteries were exposed to stimuli for an additional 24 hours
at 37°C. Artery segments were then either used for pressurized artery diameter
measurements or protein lysates were isolated, quantified, and used for Western blotting.
3.23.

Pressurized Artery Diameter Measurements

3.23.1. Procedure
Experiments were performed using PSS containing (in mM): 112 NaCl, 4.8 KCl,
26 NaHCO3, 1.8 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, and 10 glucose (with pH adjusted to
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7.4 with NaOH). Prior to use, PSS was oxygenated by bubbling with 74% N2/21%
O2/5% CO2. Endothelium-denuded artery segments 1–2 mm in length were cannulated at
each end in a temperature-controlled perfusion chamber (Living Systems
Instrumentation, Burlington, VT) containing PSS. Care was taken to cannulate artery
segments that did not have a branch or tear in their wall. The chamber containing the
cannulated artery was placed on the stage of a Nikon TS100-F microscope. Intravascular
pressure was altered using a water-filled reservoir and monitored using a pressure
transducer. Arterial wall diameter was measured at 1 Hz using a CCD camera attached to
the Nikon TS100-F microscope and diameter changes measured in real time using the
automatic edge-detection function of IonWizard software. Luminal flow was absent
during experiments. Vessels were constantly superfused with PSS alone or containing
pharmacological agent(s).
At the beginning of each experiment, the artery was allowed to equilibrate for 10
minutes at an intravascular pressure of ~10 mm Hg. The artery dilated during this
equilibration process because of its exposure to warm PSS. After the arterial diameter at
10 mm Hg became stable for a period of 5 minutes, the intravascular pressure was
elevated to ~60 mm Hg. Elevation of intravascular pressure to 60 mm Hg resulted in
arterial dilation. The artery was allowed to sense the elevated intravascular pressure and
develop pressure-induced vasoconstriction (myogenic tone). Pharmacological stimuli
were perfused only after myogenic tone remained steady for a period of 15 minutes.
After perfusion of the stimulus in PSS, stable diameter achieved for a period of 5 minutes
was considered as active diameter. After a stimulus was washed off, time was given for
the arterial diameter to return to its myogenic tone before addition of the next stimulus.
Arterial diameter after perfusion of Ca2+-free solution containing EGTA (10 mM) and
nimodipine (1 µM) was considered as passive diameter. Endothelial denudation was
confirmed by the lack of response to carbachol (1 µM), an endothelial-dependent
vasodilator.
3.23.2. Analysis
Experimental traces were analyzed using IonWizard software. Measurements
were obtained when the diameter remained stable. Myogenic tone (%) was calculated as
100  (1-active diameter/passive diameter).
3.24. Reagents and Chemicals
XeC and 17-octadecynoic acid (17-ODYA) were purchased from Cayman
Chemical Company (Ann Arbor, MI). Manganese (III) tetrakis (1-methyl-4-pyridyl)
porphyrin (MnTMPyP) was purchased from AG Scientific Inc.(San Diego, CA).
Apocynin and Ru360 were purchased from EMD Chemicals (Gibbstown, NJ).
Recombinant rat TNF-α was purchased from BD Pharmingen (BD Biosciences, San Jose,
CA). All other reagents and chemicals were purchased either from Sigma-Aldrich
Company (St.Louis, MO) or Fisher Scientific (Pittsburgh, PA), unless specified.
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3.25. Statistical Analysis
OriginLab and GraphPad InStat software were used for statistical analyses.
Values are expressed as mean±SEM. Student’s t-test with two-tail p value was used for
comparing paired and unpaired data from two populations. Ordinary one-way ANOVA
followed by Student-Newman-Keuls post-hoc test were used for all multiple data
comparisons. For ANOVA, the values were assumed to be sampled from a Gaussian
distribution. Repeated measures ANOVA could not be performed since all the conditions
to be compared were not paired and the sample numbers were not identical. Adjustments
for multiple comparisons were made when necessary. P<0.05 was considered
statistically significant.
Power analysis was carried out where P>0.05 to verify that sample size was
sufficient to give a power value of >0.8. Power value, which is directly proportional to
the sample size, is the probability of correctly rejecting the null hypothesis that there is no
significant difference between the groups. The Type I error probability that the null
hypothesis was falsely rejected was set to 0.05. Power analysis was performed using PS
Power and Sample Size Calculations software (Dupont & Plummer, Jr., 1990).
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CHAPTER 4. RESULTS*
4.1.

ET-1 Modifies Local and Global Ca2+ Signals in Cerebral Artery Smooth
Muscle Cells

The regulation of local and global Ca2+ signals by ET-1, a PLC-coupled receptor
agonist and vasoconstrictor, was studied in smooth muscle cells of endothelium-denuded
cerebral artery segments using Noran Oz high-speed laser-scanning confocal imaging and
fluo-4 AM. ET-1 elevated mean Ca2+ wave frequency from ~0.34 to 1.42 Hz (~135% of
control), reduced mean Ca2+ spark frequency from ~1.06 to 0.4 Hz (~32% of control),
and increased mean global [Ca2+]i from ~193 to 253 nM (~127% of control) (Fig. 4-1).
Pretreatment with XeC, an IP3R inhibitor (Gafni et al., 1997) did not alter ET-1-induced
Ca2+ spark inhibition but blocked ET-1-induced Ca2+ wave activation (Fig. 4-1D). In the
presence of XeC, ET-1 elevated global [Ca2+]i from ~193 to 225 nM (~113% of control)
(Fig. 4-1D). Data indicate that ET-1-induced IP3R activation increases Ca2+ wave
frequency and contributes to global [Ca2+]i elevation but does not regulate ET-1-induced
Ca2+ spark inhibition.
4.2.

ET-1-Induced IP3R-Mediated SR Ca2+ Release Elevates [Ca2+]mito in Cerebral
Artery Smooth Muscle Cells

To study [Ca2+]mito in arterial smooth muscle cells, complex loading procedures
have previously been used to enhance mitochondrial loading of synthetic, inorganic Ca2+
indicators such as Rhod-2 (Monteith & Blaustein, 1999). Since inorganic Ca2+ indicators
cannot be targeted to specific subcellular localizations, non-specific measurements of
[Ca2+]mito were inevitably obtained (Hajnoczky et al., 1995; Monteith & Blaustein, 1999;
Kaftan et al., 2000; Trollinger et al., 2000; Collins et al., 2001; Gerasimenko & Tepikin,
2005). To specifically measure [Ca2+]mito, genetically-encoded, targetable Ca2+ indicators
have been developed (Griesbeck et al., 2001; Filippin et al., 2005). Regulation of
[Ca2+]mito by ET-1-induced Ca2+ signals was measured in smooth muscle cells of intact
arteries using 2mt8CG2, a genetically-encoded, mitochondria-targeted, fluorescent Ca2+
indicator (Griesbeck et al., 2001; Filippin et al., 2005).

* Portions of this chapter adapted with permission. Narayanan D, Xi Q, Pfeffer LM, &
Jaggar JH (2010). Mitochondria control functional CaV1.2 expression in smooth muscle
cells of cerebral arteries. Circ Res 107, 631-641.
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Figure 4-1.
cells

ET-1 regulates local and global Ca2+ signals in arterial smooth muscle

Notes: A, Confocal images illustrating average fluo-4 fluorescence in smooth muscle
cells in the same artery in control and after ET-1 (10 nM). White boxes illustrate
locations where Ca2+ sparks occurred during 10 seconds of imaging. Colored boxes
illustrate locations from where normalized fluorescence (F/F0) over time traces shown in
C were obtained. B, Two representative Ca2+ sparks that occurred at locations labeled in
A for each condition. C, F/F0 over time traces illustrate that ET-1 elevates Ca2+ wave
frequency. D, Mean data (n=7 for each condition). Values are expressed as mean±SEM.
* indicates P<0.05 compared to control. # indicates P<0.05 compared to ET-1.
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4.2.1.

Mitochondrial localization of 2mt8CG2

4.2.1.1. HEK293 cells
2mt8CG2 expression in HeLa cells produces punctuate fluorescence when
localized to mitochondria (Filippin et al., 2005). Here, transfection of HEK293 cells with
the pMITO-2mt8CG2 vector by using Ca2+ phosphate, reproduced the punctuate
fluorescence pattern when visualized using a Zeiss LSM 5 Pascal laser-scanning confocal
microscope, suggesting mitochondrial localization of 2mt8CG2 (Fig. 4-2A).
4.2.1.2. Cerebral artery smooth muscle cells
pMITO-2mt8CG2 vector was inserted into smooth muscle cells of intact cerebral
arteries using reverse permeabilization (Lesh et al., 1995; Welsh et al., 2002). Confocal
imaging revealed punctate staining in smooth muscle cells, indicating mitochondrial
localization of 2mt8CG2 (Fig. 4-2B). To confirm mitochondrial targeting of 2mt8CG2,
colocalization studies were performed using MitoTracker Orange. 2mt8CG2
fluorescence exhibited ~95% pixel colocalization with MitoTracker Orange, confirming
mitochondrial localization (Fig. 4-2C).
4.2.2.

[Ca2+]mito measurements using 2mt8CG2

In smooth muscle cells of intact arteries, ET-1 increased mean 2mt8CG2
fluorescence to ~140% of control, and this elevation was blocked by thapsigargin and
XeC (Fig. 4-3A,B), suggesting that ET-1 elevates [Ca2+]mito due to IP3R-mediated SR
Ca2+ release. Thapsigargin was applied 15 minutes prior to ET-1, a time course sufficient
to deplete SR Ca2+ load (Xi et al., 2008). Ionomycin, a Ca2+ ionophore (Liu & Hermann,
1978), elevated mean 2mt8CG2 fluorescence to ~137% of control in smooth muscle cells
of intact arteries (Fig. 4-3B), consistent with the fluorescence range of this indicator
(Filippin et al., 2003; Filippin et al., 2005). Ru360, a MCU blocker (Matlib et al., 1998),
also blocked the ET-1-induced elevation in 2mt8CG2 fluorescence (Fig. 4-3B),
indicating that ET-1-induced mitochondrial Ca2+ uptake occurs through the MCU.
Thapsigargin, XeC, or Ru360 alone did not alter 2mt8CG2 fluorescence (Fig. 4-3B).
Membrane depolarization (60 mM K+), which elevates global [Ca2+]i, did not alter
2mt8CG2 fluorescence (Fig. 4-3B), suggesting that [Ca2+]mito elevation occurs due to
local Ca2+ signals and not due to global [Ca2+]i elevation. CCCP, a protonophore that
disrupts ψm by permeabilizing the inner mitochondrial membrane to H+ (Goldsby &
Heytler, 1963; Heytler, 1963) and abolishes the driving force for mitochondrial Ca2+
uptake (McCarron & Muir, 1999), reduced 2mt8CG2 fluorescence to ~63% of control
(Fig. 4-3B). Results with Ru360 and CCCP confirm the mitochondrial localization of
2mt8CG2. These data indicate that ET-1-induced IP3R-mediated SR Ca2+ release
elevates [Ca2+]mito in arterial smooth muscle cells.
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Figure 4-2. Mitochondrial localization of 2mt8CG2 in HEK293 cells and cerebral
artery smooth muscle cells
Notes: A, Confocal image illustrates punctate fluorescence of 2mt8CG2 in HEK293
cells. B, Confocal image of smooth muscle cells dissociated from arteries reverse
permeabilized with pMITO-2mt8CG2. Punctate pattern of fluorescence suggests
mitochondrial targeting of 2mt8CG2. C, Colocalization of punctate 2mt8CG2
fluorescence with MitoTracker Orange in a smooth muscle cell. Colocalization
quantified using weighted colocalization was 94.8±0.8% (n=10, p<0.001). Scale bar=10
µm.
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Figure 4-3. ET-1-induced IP3R-mediated SR Ca2+ release elevates [Ca2+]mito in arterial
smooth muscle cells
Notes: A, Confocal images of 2mt8CG2 fluorescence in smooth muscle cells in the same
area of a cerebral artery in control and ET-1. Scale bar=10 µm. B, Average changes in
2mt8CG2 fluorescence for ionomycin (10 µM, n=7), ET-1 (n=8), thapsigargin (100 nM,
n=5), ET-1+thapsigargin (n=6), XeC (20 µM, n=5), ET-1+XeC (n=6), Ru360 (10 µM,
n=4), ET-1+Ru360 (n=4), CCCP (10 µM, n=4), and 60 mM K+ (n=6). ET-1
concentration was 100 nM in all experiments. Values are expressed as mean±SEM.
* indicates P<0.05 compared to control. # indicates P<0.05 compared to ET-1.
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4.3.

ET-1-Induced IP3R-Mediated SR Ca2+ Release Depolarizes Mitochondria in
Cerebral Artery Smooth Muscle Cells

Regulation of mitochondria potential ET-1 was studied in isolated smooth muscle
cells using TMRM. ET-1 (30 nM) reversibly reduced TMRM fluorescence intensity to
~67% of control (Fig. 4-4A-C). A second application of ET-1 (30 nM) produced a
similar amplitude change in TMRM fluorescence (~69% of control), indicating that the
first ET-1 application did not desensitize the ET-1 receptors (Fig. 4-4A,B). ET-1 caused
concentration-dependent reduction in TMRM fluorescence with an EC50 of 29 nM (Fig.
4-4B). Thapsigargin and XeC abolished the ET-1-induced reduction in TMRM
fluorescence, but did not alter TMRM fluorescence when applied alone (Fig. 4-4C).
CCCP reduced TMRM fluorescence intensity to ~34% of control, whereas 60 mM K+ did
not alter TMRM fluorescence (Fig. 4-4C). These data indicate that ET-1-induced IP3Rmediated SR Ca2+ release depolarizes mitochondria in arterial smooth muscle cells. In
contrast, a global [Ca2+]i elevation does not alter ψm.
4.4.

4.4.1.

ET-1-Induced IP3R-Mediated SR Ca2+ Release and [Ca2+]mito Elevation
Stimulates MitoROS Generation
MitoROS measurements using mt-cpYFP

To examine physiological functions of [Ca2+]mito, we tested the hypothesis that an
elevation in [Ca2+]mito may alter mitoROS generation. MitoROS was measured using mtcpYFP, a genetically-encoded mitochondria-targeted fluorescent O2-· indicator (Wang et
al., 2008a).
4.4.1.1. Mitochondrial localization of mt-cpYFP
Mitochondrial targeting of mt-cpYFP was studied by performing colocalization
studies using MitoTracker Orange. mt-cpYFP fluorescence exhibited ~95% pixel
colocalization with MitoTracker Orange, indicating mitochondrial localization (Fig. 4-5).
4.4.1.2. ET-1 elevates mitoROS production
In smooth muscle cells of intact arteries, ET-1 elevated mt-cpYFP fluorescence to
~199% of control, and this was blocked by XeC, Ru360, rotenone, a mitochondrial ETC
complex I inhibitor (Fukami et al., 1967), and micromolar CCCP (Fig. 4-6A,B). When
applied alone, rotenone and micromolar CCCP reduced mt-cpYFP fluorescence to ~54
and 64% of control, respectively (Fig. 4-6B). In contrast, Ru360, XeC, and 60 mM K+
did not alter mt-cpYFP fluorescence (Fig. 4-6B). In cerebral artery smooth muscle cells,
1 nM CCCP reduced TMRM fluorescence to ~87% of control, and elevated DCF
fluorescence to ~140% of control, suggesting that a low concentration of CCCP induces a
59

Figure 4-4. ET-1-induced IP3R-mediated SR Ca2+ release depolarizes mitochondria in
arterial smooth muscle cells
Notes: A, ET-1 caused reproducible mitochondrial depolarization in cerebral artery
smooth muscle cells. ET-1-induced mitochondrial depolarization was blocked by
pretreatment with XeC (20 µM). B, Concentration-dependent mitochondrial
depolarization by ET-1 (n=4-7). C, Average changes in TMRM fluorescence for ET-1
(n=37), second ET-1 application (n=12), thapsigargin (100 nM, n=18), ET1+thapsigargin (n=18), XeC (20 µM, n=12), ET-1+XeC (n=12), 60 mM K+ (n=10), and
CCCP (10 µM, n=65). ET-1 concentration was 30 nM in all experiments. Values are
expressed as mean±SEM. * indicates P<0.05 compared to control. # indicates P<0.05
compared to ET-1.
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Figure 4-5.
cells

Mitochondrial localization of mt-cpYFP in cerebral artery smooth muscle

Notes: Confocal images illustrate colocalization of punctate mt-cpYFP fluorescence with
MitoTracker Orange in a smooth muscle cell. Colocalization quantified using weighted
colocalization was 94.7±1.2% (n=10, p<0.001). Scale bar=10 µm.
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Figure 4-6. ET-1-induced IP3R-mediated SR Ca2+ release and mitochondrial Ca2+
uptake elevates mitoROS generation in arterial smooth muscle cells
Notes: A, Original images illustrating ET-1-induced elevation in mt-cpYFP fluorescence
in smooth muscle cells of an intact artery. Scale bar=20 µm. B, Average mt-cpYFP
fluorescence changes in smooth muscle cells of intact arteries. ET-1, XeC (20 µM), ET1+XeC, Ru360 (10 µM), ET-1+Ru360, rotenone (10 µM), ET-1+rotenone, CCCP (10
µM), ET-1+CCCP, CCCP (1 nM), and 60 mM K+. ET-1 concentration was 100 nM in
all experiments. n=5 for each condition. Values are expressed as mean±SEM.
* indicates P<0.05 compared to control. # indicates P<0.05 compared to ET-1.
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small mitochondrial depolarization and increases mitoROS generation (Xi et al., 2005).
Similarly, here 1 nM CCCP elevated mt-cpYFP fluorescence to ~124% of control (Fig.
4-6B). These data indicate that mitochondria generate ROS in the absence of ET-1, and
that ET-1-induced IP3R-mediated SR Ca2+ release and [Ca2+]mito elevation stimulate
mitoROS generation. Results with Ru360, rotenone, and micromolar CCCP confirm the
mitochondrial localization of mt-cpYFP.
4.4.2.

ET-1-induced mitoROS generation elevates cytosolic ROS levels

Cytosolic ROS was measured using HyPer-CYTO, a genetically-encoded
fluorescent cytosolic H2O2 indicator (Fig. 3-1) (Belousov et al., 2006). Exogenous H2O2
elevated HyPer-CYTO fluorescence to ~234% of control (Fig. 4-7A). ET-1 similarly
increased HyPer-CYTO fluorescence in smooth muscle cells of endothelium-intact and denuded arteries to ~158 and 168% of control, respectively (Fig. 4-7B,C). When applied
alone, rotenone and MnTMPyP, a SOD and catalase mimetic (Faulkner et al., 1994),
reduced HyPer-CYTO fluorescence ~75 and 80% of control, respectively (Fig. 4-7C).
Rotenone and MnTMPyP blocked the ET-1-induced elevations in HyPer-CYTO
fluorescence (Fig. 4-7C). These data indicate that mitoROS production contributes to
cytosolic ROS levels in the absence of ET-1 and that ET-1-induced mitoROS elevation
leads to an increase in cytosolic ROS in cerebral artery smooth muscle cells.
4.4.3.

ROS measurements using DCF

4.4.3.1. ET-1 stimulates ROS generation
To confirm measurements obtained using mt-cpYFP and HyPer-CYTO, ROS
levels were studied in smooth muscle cells of cerebral arteries using CM-H2DCFDA, an
inorganic fluorescent ROS indicator. ET-1 increased mean DCF fluorescence in smooth
muscle cells of endothelium-intact and -denuded arteries to ~154 and 151% of control,
respectively (Fig. 4-8A,B). Exogenous H2O2 application elevated mean DCF
fluorescence intensity to ~219% of control (Fig. 4-8B). ET-1-induced DCF fluorescence
elevations were blocked by thapsigargin, XeC, and MnTMPyP (Fig. 4-8B). When
applied alone, thapsigargin and XeC did not alter, but MnTMPyP reduced DCF
fluorescence to ~74% of control (Fig. 4-8B). 60 mM K+, which leads to global [Ca2+]i
elevation did not alter DCF fluorescence (Fig. 4-8B). These data confirm the finding that
ET-1-induced IP3R-mediated SR Ca2+ release stimulates ROS generation.
4.4.3.2. Source of ET-1-induced ROS elevation is mitochondria
ET-1-induced DCF fluorescence elevations were blocked by CCCP and rotenone
(Fig. 4-9A). In the presence of oxypurinol, a xanthine oxidase inhibitor (Elion et al.,
1968) and 17-ODYA, a cytochrome P450 blocker (Zou et al., 1994), ET-1 elevated DCF
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Figure 4-7. ET-1-induced IP3R-mediated SR Ca2+ release elevates cytosolic ROS in
arterial smooth muscle cells
Notes: A,B, Confocal images illustrating that exogenous H2O2 (A) and ET-1 (B)
elevates HyPer-CYTO fluorescence in arterial smooth muscle cells. C, Average changes
in HyPer-CYTO fluorescence for H2O2 (100 µM), ET-1 (endothelium-intact), ET-1
(endothelium-denuded), rotenone (10 µM), ET-1+rotenone, MnTMPyP (10 µM), and
ET-1+MnTMPyP. ET-1 concentration was 100 nM in all experiments. n=5 for each
condition. Values are expressed as mean±SEM. * indicates P<0.05 compared to control.
# indicates P<0.05 compared to ET-1.
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Figure 4-8. ET-1-induced IP3R-mediated SR Ca2+ release elevates DCF fluorescence
in arterial smooth muscle cells
Notes: A, Confocal images of DCF fluorescence in smooth muscle cells of the same
cerebral artery in control and ET-1. Scale bar=20 µm. B, Mean DCF fluorescence
changes in arterial smooth muscle cells. H2O2 (100 µM, n=6), ET-1 (endothelium-intact,
n=10), ET-1 (endothelium-denuded, n=6), thapsigargin (100 nM, n=5), ET1+thapsigargin (n=10), XeC (20 µM, n=5), ET-1+XeC (n=6), MnTMPyP (10 µM, n=5),
ET-1+MnTMPyP (n=6), and 60 mM K+ (n=6). Values are expressed as mean±SEM.
* indicates P<0.05 compared to control. # indicates P<0.05 compared to ET-1.
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Figure 4-9. ET-1-induced mitoROS generation elevates DCF fluorescence in arterial
smooth muscle cells
Notes: A, Mean DCF fluorescence change for ET-1 (endothelium-intact, n=10), rotenone
(10 µM, n=5), ET-1+rotenone (n=10), CCCP (10 µM, n=5), ET-1+CCCP (n=10),
gp91ds-tat (50 µM, n=5), ET-1+gp91ds-tat (n=5), oxypurinol (10 µM, n=5), ET1+oxypurinol (n=6), 17-octadecynoic acid (10 µM, n=5), and ET-1+17-octadecynoic acid
(n=6). B, Mean DCF fluorescence change for TNF-α (100 ng/ml, n=5), ET-1
(endothelium-intact, n=10), gp91scrm-tat (50 µM, n=5), TNF-α+gp91scrm-tat (n=5), ET1+gp91scrm-tat (n=5), gp91ds-tat (50 µM, n=5), TNF-α+gp91ds-tat (n=5), and ET1+gp91ds-tat (n=5). ET-1 concentration was 100 nM in all experiments. * indicates
P<0.05 compared to control. Values are expressed as mean±SEM. # indicates P<0.05
compared to ET-1. § indicates P<0.05 compared to TNF-α.
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fluorescence to ~153 and 146% of control, respectively (Fig. 4-9A). Oxypurinol and 17ODYA did not alter baseline DCF fluorescence, whereas CCCP and rotenone alone
decreased baseline DCF fluorescence to ~62 and 72% of control, respectively (Fig.
4-9A).
TNF-α, which stimulates NAD(P)H oxidase-derived ROS in cerebral artery
smooth muscle cells (Cheranov & Jaggar, 2006), elevated DCF fluorescence to ~190% of
control (Fig. 4-9B). gp91ds-tat did not alter baseline DCF fluorescence, whereas blocked
DCF fluorescence elevations induced by TNF-α, suggesting that gp91ds-tat inhibits
NAD(P)H oxidase (Fig. 4-9B). In the presence of gp91ds-tat, ET-1 increased DCF
fluorescence to ~143% of control (Fig. 4-9B). Scrambled gp91-tat did not alter baseline
DCF fluorescence, or ET-1- or TNF-α-induced DCF fluorescence elevations (Fig. 4-9B).
Data obtained using DCF confirm ROS measurements obtained using mt-cpYFP
and HyPer-CYTO, that mitochondria generate ROS in the absence of ET-1, and that ET1-induced IP3R-mediated SR Ca2+ release and [Ca2+]mito elevation stimulate mitoROS
generation, leading to an increase in cytosolic ROS in cerebral artery smooth muscle
cells.
4.5.
4.5.1.

ET-1-Induced IP3R-Mediated MitoROS Elevation Stimulates NF-κB
ET-1 stimulates nuclear translocation of NF-κB p50

To examine physiological functions of an IP3R-mediated mitoROS elevation, we
tested the hypothesis that mitochondria regulate the expression of genes that modulate
smooth muscle cell contractility. Therefore, immunofluorescence was performed to
study cellular localization of the p50 subunit of NF-κB, a ROS-sensitive transcription
factor (Lee et al., 2008), in arterial smooth muscle cells. ET-1 increased mean pixel
colocalization of p50 with YOYO-1 from ~12 to 22% (Fig. 4-10A-C), suggesting that
ET-1 stimulates nuclear translocation of p50.
4.5.2.

ET-1 elevates NF-κB-dependent transcriptional activity

To investigate the regulation of NF-κB-dependent transcriptional activity, assays
were performed using vectors that express firefly luciferase under the control of an NFκB promoter. As a control, regulation of luciferase activity by TNF-α, which activates
NF-κB (Li et al., 1999) was measured. TNF-α increased mean luciferase activity to
~547% of control (Fig. 4-11). ET-1 increased luciferase activity to ~372% of control,
and this was blocked by thapsigargin and XeC (Fig. 4-11). Rotenone and MnTMPyP
reduced the ET-1-induced elevation in luciferase activity to ~152 and 109% of control,
respectively (Fig. 4-11). Exogenous H2O2 elevated luciferase activity to ~252% of
control, and this effect was not altered by rotenone, indicating that rotenone did not cause
general inhibition of luciferase expression (Fig. 4-11). When applied alone, thapsigargin,
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Figure 4-10. ET-1 stimulates p50 nuclear translocation in arterial smooth muscle cells
Notes: A, Immunofluorescence images of smooth muscle cells in arteries illustrating
YOYO-1 (nuclear stain, green), p50 (red), overlay, and DIC (lumenally-inserted
rectangular glass cannula can be seen). B, Enlarged images indicated by boxes in A
illustrate ET-1-induced elevation in p50 and YOYO-1 pixel colocalization (purple).
Scale bars=20 µm. C, Mean data for weighted pixel colocalization (n=10 for each).
Values are expressed as mean±SEM. * indicates P<0.05 compared to control.
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Figure 4-11. ET-1 stimulates NF-κB-dependent transcription through IP3R-mediated
SR Ca2+ release and mitoROS elevation in arterial smooth muscle cells
Notes: Average NF-κB-p-Luc luciferase activity with TNF-α (100 ng/ml, n=4), ET-1
(n=5), thapsigargin (100 nM, n=5), ET-1+thapsigargin (n=5), XeC (20 µM, n=5), ET1+XeC (n=5), rotenone (1 µM, n=5), ET-1+rotenone (n=5), MnTMPyP (10 µM, n=4),
ET-1+MnTMPyP (n=4), H2O2 (100 µM, n=4), and H2O2+rotenone (n=4). ET-1
concentration was 100 nM in all experiments. Values are expressed as mean±SEM.
* indicates P<0.05 compared to control. # indicates P<0.05 compared to ET-1.
§ indicates P<0.05 compared to rotenone or MnTMPyP.
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XeC, rotenone, and MnTMPyP reduced luciferase activity to ~84, 78, 77, and 80% of
control, respectively (Fig. 4-11). TNF-α, ET-1, thapsigargin, XeC, rotenone, MnTMPyP,
and H2O2 did not alter luciferase activity in arteries in which a promoter-deficient control
vector was inserted (Fig. 4-12). These data indicate that IP3R-mediated SR Ca2+ release
stimulates NF-κB primarily by elevating mitoROS generation, but also via a secondary
mitochondria- and ROS-independent pathway in arterial smooth muscle cells.
4.5.3.

ROS measurements corresponding to transcriptional studies

For transcriptional studies performed using luciferase reporter assays, arteries
were exposed to stimuli for 24 hours. To determine if the inhibitors used, blocked the
ET-1-induced ROS elevations which corresponded to the time points used in the above
transcriptional studies, ROS levels were measured using DCF. After a 24-hour
incubation in control, ET-1 elevated DCF fluorescence to ~145% of control (Fig. 4-13).
ET-1-induced DCF fluorescence elevations were blocked by 24-hour incubation in
thapsigargin, XeC, or rotenone (Fig. 4-13). These data indicate that the inhibitors used
for a period of time in transcriptional studies blocked the ET-1-induced ROS elevations.
4.6.

ET-1-Induced IP3R-Mediated SR Ca2+ Release Stimulates CaV1.2 Expression
by MitoROS Elevation and NF-κB Activation

We sought to examine the functional significance of IP3R-mediated,
mitochondrial-dependent NF-κB activation. CaV1.2 channels are the principal Ca2+
influx pathway in smooth muscle cells of resistance-size arteries and are essential for
contractility regulation by a wide variety of stimuli, including intravascular pressure and
membrane potential (Cheng et al., 2007). However, mechanisms that regulate
CACNA1C transcription in arterial smooth muscle cells are unclear. Three NF-κB
binding motifs are located immediately upstream of the human Cav1.2 promoter (Shi et
al., 2005). Therefore, we tested the hypothesis that ET-1-induced IP3R-mediated,
mitoROS-dependent NF-κB activation regulates CaV1.2 expression in cerebral arteries.
4.6.1.

ET-1 stimulates CaV1.2 gene transcription

To study ET-1 regulation of gene expression we performed RT-PCR. We sought
to identify a reference gene whose transcription is not affected by ET-1 (6 hours). RTPCR reactions were performed for five genes, namely beta (β) actin, beta (β) tubulin,
cyclophilin B, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), and Rps5.
CT values for the reference genes in control and ET-1 are shown in Table 4-1. Rps5
which had the least difference in average CT values between control and ET-1 treatment
groups was chosen as the reference gene.
RT-PCR data indicated that in cerebral arteries, ET-1 increased CaV1.2 channel
mRNA expression to ~244% of control, after normalization to Rps5 (Fig. 4-14D).
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Figure 4-12. Mean changes in promoter-deficient (pGL3 Basic) luciferase activity
Notes: Mean data. TNF-α (100 ng/ml, n=4), ET-1 (n=5), thapsigargin (100 nM, n=4),
ET-1+thapsigargin (n=4), XeC (20 µM, n=3), ET-1+XeC (n=3), rotenone (1 µM, n=4),
ET-1+rotenone (n=4), MnTMPyP (10 µM, n=3), ET-1+MnTMPyP (n=3), H2O2 (100
µM, n=3), and H2O2+rotenone (n=3). ET-1 concentration was 100 nM in all
experiments. Values are expressed as mean±SEM.
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Figure 4-13. ROS measurements at time points used for transcriptional studies
Notes: Average change in DCF fluorescence with ET-1 (100 nM, n=5) after a 24 hour
incubation in control, in the presence of thapsigargin (100 nM, n=3), XeC (20 µM, n=3),
or rotenone (1 µM, n=5). Values are expressed as mean±SEM. * indicates P<0.05
compared to control. # indicates P<0.05 compared to ET-1.
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Table 4-1.

Identification of reference gene for RT-PCR

Gene

CTcontrol

CTET-1

CTcontrol - CTET-1

Rps5

25.43

24.83

0.60

HGPRT

31.90

31.21

0.69

Cyclophilin B

27.39

26.71

0.68

β tubulin

32.81

32.12

0.69

β actin

22.5

21.53

0.97

76

Figure 4-14. ET-1 stimulates CaV1.2 gene transcription in cerebral arteries
Notes: A,B, Representative amplification curves generated with probes and RT-PCR
primers specific for CaV1.2 (A) and Rps5 (B) genes in control (blue) and ET-1(10 nM)treated (red) arteries. The data points for the amplification curves shown were obtained
by calculating the average of data points from triplicates for each condition. C,
Application of ET-1 (10 nM) for 6 hours elevated mean CaV1.2 mRNA in cerebral
arteries compared to control arteries (n=7 for each condition). Values are expressed as
mean±SEM. * indicates P<0.05 compared to control. D, Agarose gel illustrating
transcripts amplified using RT-PCR primers for CaV1.2 (70 bp) and Rps5 (83 bp) from
cerebral arteries in control and ET-1 (10 nM). NC, negative control using cerebral artery
mRNA.
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4.6.2. ET-1-induced IP3R activation and mitoROS elevation stimulate CaV1.2
expression
Western blotting indicated that ET-1 (24 hrs) increased CaV1.2 channel (190 and
240 kD bands) protein to ~141% of control (Fig. 4-15A,B). XeC, rotenone, and
MnTMPyP alone reduced basal CaV1.2 expression to ~87, 89, and 80% of control,
respectively (Fig. 4-15A,B). XeC blocked the ET-1-induced elevation in CaV1.2
expression (Fig. 4-15A,B). Rotenone and MnTMPyP reduced the ET-1-induced
elevation in CaV1.2 expression to ~113 and 90% of control, respectively (Fig. 4-15B).
Exogenous H2O2 increased CaV1.2 expression to ~128% of control, and this elevation
was not altered by rotenone, indicating that rotenone did not induce non-specific
inhibition of CaV1.2 expression (Fig. 4-15B). These data indicate that ET-1-induced
IP3R-mediated SR Ca2+ release and mitoROS elevation stimulate CaV1.2 expression in
cerebral arteries.
4.6.3.

ET-1-induced NF-κB activation elevates CaV1.2 expression

Two different siRNAs were used to knockdown expression of p105, the p50
precursor (Baeuerle & Baltimore, 1996). p105siRNA1, p105siRNA2, and a combination
of both siRNAs (p105siRNAs) reduced mean p105 protein to ~73, 80, and 57%,
respectively, of that in arteries treated with scrambled siRNA (p105scrm) (Fig. 4-16A,B).
p105siRNAs reduced CaV1.2 expression to ~64% of p105scrm (Fig. 4-17A,B),
indicating that NF-κB controls basal CaV1.2 expression. In p105scrm-treated arteries,
ET-1 increased CaV1.2 protein to ~136% of p105scrm (Fig. 4-17A,B). In p105siRNAstreated arteries, ET-1 increased CaV1.2 protein from ~64 to 74% of p105scrm (~117% of
p105siRNAs) (Fig. 4-17A,B). These data indicate that IP3R-mediated SR Ca2+ release
stimulates CaV1.2 expression via mitochondria-dependent NF-κB activation.
4.7.

ET-1-Induced IP3R-Mediated SR Ca2+ Release Also Stimulates p105
Expression

The p105 gene promoter contains an NF-κB-binding sequence, and p50 activation
can elevate p105 expression (Ten et al., 1992). Therefore, mechanisms that regulate NFκB subunit expression in cerebral arteries were investigated. Inhibiting IP3R-mediated
SR Ca2+ release using XeC reduced basal p105 and p50 expression to ~87 and 90% of
control, respectively (Fig. 4-18A,B). Inhibiting mitoROS production using rotenone or
dismutating cellular ROS using MnTMPyP, did not alter basal p105 or p50 expression
(Fig. 4-18B). ET-1 elevated p105 and p50 expression to ~127 and 119% of control,
respectively and XeC blocked this effect (Fig. 4-18B). In contrast, rotenone or
MnTMPyP had no effect on the ET-1-induced elevation in p105 and p50 subunit
expression (Fig. 4-18B). Exogenous H2O2 applied alone or in the presence of rotenone
did not change p105 and p50 expression (Fig. 4-18B).
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Figure 4-15. ET-1-induced IP3R-mediated SR Ca2+ release and mitoROS elevation
stimulate CaV1.2 protein expression in cerebral arteries
Notes: A, Western blot indicating that ET-1(10 nM) application for 24 hours elevated
CaV1.2 protein expression and XeC (20 µM) blocked the ET-1-induced elevation in
CaV1.2 expression. B, Mean data for ET-1 (n=12), XeC (20 µM, n=7), ET-1+XeC (n=7),
rotenone (1 µM, n=6), ET-1+rotenone (n=6), MnTMPyP (10 µM, n=5), ET1+MnTMPyP (n=5), H2O2 (100 µM, n=5), and H2O2+rotenone (n=5). ET-1
concentration was 10 nM in all experiments. Values are expressed as mean±SEM.
* indicates P<0.05 compared to control. # indicates P<0.05 compared to ET-1.
§ indicates P<0.05 compared to rotenone or MnTMPyP.
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Figure 4-16. p105 knockdown in cerebral arteries
Notes: A, Western blot illustrating that p105siRNA1, p105siRNA2, and p105siRNA1+2
reduce p105 expression in cerebral arteries. B, Mean data. n=5 for each. Values are
expressed as mean±SEM. * indicates P<0.05 compared to arteries reverse permeabilized
with p105scrm.
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Figure 4-17. NF-κB controls basal and ET-1-induced elevation in functional CaV1.2
expression in cerebral arteries
Notes: A, Western blot illustrating effects of p105siRNAs (10 µg/ml each) on basal and
ET-1-induced CaV1.2 expression. B, Mean data. n=5 for each. Values are expressed as
mean±SEM. * indicates P<0.05 compared to arteries reverse permeabilized with
p105scrm. # indicates P<0.05 compared to arteries reverse permeabilized with
p105siRNAs.
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Figure 4-18. ET-1-induced IP3R-mediated SR Ca2+ release elevates p105/p50
expression via a mitochondria-, and ROS-independent mechanism in cerebral arteries
Notes: A, Western blots indicating that XeC (20 µM) blocked an ET-1-induced elevation
in p105 and p50 expression. B, Mean data for p105 (black) and p50 (red). p105 and p50
data were measured in the same blots, and thus experimental number is identical for each
protein. ET-1 (n=8), XeC (20 µM, n=6), ET-1+XeC (n=6), rotenone (1 µM, n=5), ET1+rotenone (n=5), MnTMPyP (10 µM, n=5), ET-1+MnTMPyP (n=5), H2O2 (100 µM,
n=6), and H2O2+rotenone (n=6). Values are expressed as mean±SEM. * indicates
P<0.05 compared to control. # indicates P<0.05 compared to ET-1. § indicates P<0.05
compared to rotenone or MnTMPyP.
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4.8.

ET-1-Induced NF-κB Activation Does Not Stimulate p105 Expression

p105siRNAs reduced p105 and p50 expression to ~57 and 53% of p105scrm (Fig.
4-19A,B). ET-1 increased p105 expression in p105scrm-treated arteries to ~123% of
p105scrm, and in p105siRNAs-treated arteries from ~57 to 67% of p105scrm (~121% of
p105siRNAs) (Fig. 4-19A,B). Similarly, ET-1 increased p50 expression in p105scrmtreated arteries to ~118% of p105scrm, and in p105siRNAs-treated arteries from ~53 to
65% of p105scrm (~124% of p105siRNAs) (Fig. 4-19A,B). These data indicate that
p105siRNAs did not alter the ET-1-induced relative increase in p105 and p50 expression
(Fig. 4-19A,B).
Collectively, these data indicate that IP3R-mediated SR Ca2+ release activates
p105/p50 expression via a mitochondria-, ROS-, and NF-κB-independent pathway. Data
also indicate that rotenone, MnTMPyP, and p105siRNAs do not cause general inhibition
of gene transcription.
4.9.

NF-κB Stimulates Functional CaV1.2 Expression in Cerebral Artery Smooth
Muscle Cells

To investigate NF-κB regulation of functional CaV1.2 expression, diameter
regulation of pressurized (60 mmHg) endothelium-denuded arteries was studied.
4.9.1.

Myogenic tone development in arteries

In resistance-size cerebral arteries, an elevation of intravascular pressure from 10
to 60 mmHg stretches the smooth muscle cells of the arterial wall, leading to activation of
mechanosensitive ion channels (Hill et al., 2001). Stimulation of stretch-activated cation
channels induces a graded membrane depolarization of smooth muscle cells from ~-60 to
-40 mV (Jaggar, 2001), which increases the steady-state open probability of CaV1.2
channels on smooth muscle cells (Knot & Nelson, 1998). This leads to increased Ca2+
influx through CaV1.2 channels to elevate steady-state arterial wall [Ca2+]i. Increased
arterial wall [Ca2+]i activates myosin light chain kinase, which leads to maintained
constriction (‘myogenic tone’) (Fig. 4-20).
4.9.2.

ET-1-stimulates functional CaV1.2 expression via NF-κB activation

Arteries were treated with either p105scrm or p105siRNAs and then exposed to
either no further treatment or to ET-1 for 24 hours. At 60 mm Hg, control arteries
(p105scrm) developed ~21% myogenic tone and membrane depolarization with 60 mM
K+ elevated tone to ~45%. p105 knockdown (p105siRNAs) reduced myogenic tone and
depolarization-induced vasoconstriction to ~14 and 31%, respectively (Fig. 4-21A,B). A
24-hour exposure to ET-1 elevated mean myogenic tone and depolarization-induced tone
in control arteries to ~32 and 55%, respectively (Fig. 4-21A,B). p105siRNAs attenuated
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Figure 4-19. ET-1 elevates p105/p50 expression via an NF-κB-independent pathway in
cerebral arteries
Notes: A, Western blot illustrating effects of p105siRNAs (10 µg/ml each) on p105 and
p50 expression and regulation by ET-1. B, Mean data for p105 (black) (n=5 for each)
and p50 (red) expression (n=4 for each). ET-1 concentration was 10 nM in all
experiments. Values are expressed as mean±SEM. * indicates P<0.05 compared to
arteries reverse permeabilized with p105scrm. # indicates P<0.05 compared to arteries
reverse permeabilized with p105siRNAs.
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Figure 4-20. Myogenic tone development in cerebral arteries
Notes: Respresentative trace illustrating that an elevation of intravascular pressure from
10 to 60 mm Hg induces nimodipine-sensitive myogenic tone in a cerebral artery.
Addition of 60 mM K+ causes massive depolarization leading to further vasoconstriction.
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Figure 4-21. p105 knockdown reduces myogenic tone and attenuates ET-1-induced
elevation in myogenic tone in cerebral arteries
Notes: A, Representative traces illustrating diameter in arteries pressurized to 60 mm Hg
(6 mM K+). Nimodipine (1 µM) fully dilated p105scrm- and p105siRNAs-treated
arteries. B, Mean myogenic tone at 60 mm Hg (p105scrm, n=5, p105scrm + ET-1, n=6,
p105siRNAs, n=6, p105siRNAs + ET-1, n=6), in 60 mM K+ at 60 mm Hg (p105scrm,
n=5, p105scrm + ET-1, n=5, p105siRNAs, n=5, p105siRNAs + ET-1, n=5), or
nimodipine (1 µM) at 60 mm Hg (p105scrm, n=5, p105scrm + ET-1, n=6, p105siRNAs,
n=5, p105siRNAs + ET-1, n=5). Values are expressed as mean±SEM. * indicates
P<0.05 compared to arteries reverse permeabilized with p105scrm. # indicates P<0.05
compared to arteries reverse permeabilized with p105siRNAs.
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the ET-1-induced elevation in myogenic tone and depolarization-induced
vasoconstriction to ~17 and 39%, respectively (Fig. 4-21A,B). Nimodipine fully dilated
arteries regardless of treatment, indicating that vasoconstriction occurred due to CaV1.2
channel activation (Fig. 4-21A,B). These data indicate that NF-κB is essential for
functional basal CaV1.2 expression in cerebral artery smooth muscle cells and that ET-1induced NF-κB activation elevates CaV1.2 expression and vasoconstriction.
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CHAPTER 5. DISCUSSION*
5.1.

Summary of Findings

Here, we investigated physiological signaling mechanisms that regulate [Ca2+]mito,
functional consequences of changes in [Ca2+]mito, and mitochondrial regulation of ion
channel gene expression in arterial smooth muscle cells. This study was performed using
small, resistance-size cerebral arteries that regulate blood pressure and regional blood
flow to the brain. In this study, we have used state-of-art techniques, including
genetically-encoded fluorescent indicators and laser-scanning confocal microscopy to
measure [Ca2+]mito and ROS, fluorescence imaging and luciferase reporter gene assays to
examine NF-κB activity, molecular biology and biochemical techniques to examine
CaV1.2 expression, and pressurized artery diameter measurements to study the functional
significance of elevated CaV1.2 channel expression.
A schematic diagram summarizing major findings of this study is provided in
Figs. 5-1 and 5-2. Under resting conditions, basal levels of IP3 activate IP3R, leading to
SR Ca2+ release. IP3R-mediated SR Ca2+ release and constitutively produced mitoROS
activate NF-κB. NF-κB controls basal CaV1.2 expression in cerebral artery smooth
muscle cells and NF-κB knockdown leads to vasodilation.
ET-1-induced IP3R-mediated SR Ca2+ release generates Ca2+ waves, elevates
[Ca ]mito, and depolarizes mitochondria, leading to an increase in mitoROS generation.
ET-1-induced IP3R-mediated mitoROS elevate cytosolic ROS that increase NF-κB
nuclear translocation and transcriptional activity. ET-1-induced NF-κB activation
stimulates CaV1.2 expression, leading to an elevation in CaV1.2-dependent pressure- and
depolarization-induced vasoconstriction. ET-1-induced IP3R-mediated SR Ca2+ release
also elevates NF-κB p105/p50 subunit expression via a mitochondria-, ROS-, and NFκB-independent pathway. Collectively, these data indicate that IP3R-mediated SR Ca2+
release elevates [Ca2+]mito, stimulating mitoROS which activate NF-κB-dependent CaV1.2
channel expression. Thus, mitochondria sense IP3R-mediated SR Ca2+ release to control
functional CaV1.2 channel transcription in arterial smooth muscle cells, thereby
regulating arterial contractility.
2+

5.2.

Ca2+ Signaling in Vascular Smooth Muscle Cells by PLC-Coupled Agonists

Several vasoconstrictors, including UTP, Ang II, and ET-1 activate PLC
(Rosendorff, 1997; Ralevic & Burnstock, 1998; Touyz & Schiffrin, 2000; Zhang et al.,
2003), leading to PIP2 hydrolysis and the generation of IP3 and DAG. IP3 stimulates
* Portions of this chapter adapted with permission. Narayanan D, Xi Q, Pfeffer LM, &
Jaggar JH (2010). Mitochondria control functional CaV1.2 expression in smooth muscle
cells of cerebral arteries. Circ Res 107, 631-641.
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Figure 5-1.

Proposed signaling pathways that control basal CaV1.2 expression in smooth muscle cells of cerebral arteries

Notes: Basal levels of IP3R-mediated SR Ca2+ release and constitutively produced mitoROS activate NF-κB leading to CaV1.2
expression. IP3 indicates inositol 1,4,5-trisphosphate, ETC indicates mitochondrial electron transport chain, and ψm indicates
mitochondrial membrane potential.
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Figure 5-2.

Proposed signaling pathways that control ET-1-induced CaV1.2 expression in smooth muscle cells of cerebral arteries

Notes: ET-1-induced IP3R-mediated SR Ca2+ release activates NF-κB: (a) primarily by stimulating a mitochondrial ROS elevation
and (b) via a secondary mitochondria-independent pathway, leading to CaV1.2 expression. IP3 indicates inositol 1,4,5-trisphosphate,
ETC indicates mitochondrial electron transport chain, and ψm indicates mitochondrial membrane potential.
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IP3Rs, and DAG activates PKC. Activation of IP3R1, the major isoform expressed in
smooth muscle cells of resistance-size cerebral arteries stimulates SR Ca2+ release in the
form of Ca2+ waves, which contribute to global [Ca2+]i elevation (Jaggar & Nelson, 2000;
Zhao et al., 2008). IP3R1 activation also induces physical coupling of the N-terminus of
IP3R1 and the C-terminus of plasma membrane TRPC3 channel, leading to ICat activation.
IP3R-dependent ICat activation produces membrane depolarization, CaV1.2 channel
activation, a global [Ca2+]i elevation, and vasoconstriction (Xi et al., 2008; Zhao et al.,
2008; Adebiyi et al., 2010). Therefore, vasoconstrictor-induced IP3R activation elevates
[Ca2+]i in cerebral artery smooth muscle cells via SR Ca2+ release-dependent and independent mechanisms. In contrast, vasoconstrictor-activated PKC inhibits Ca2+
sparks, which leads to membrane depolarization, CaV1.2 channel activation, and a global
[Ca2+]i elevation (Jaggar & Nelson, 2000).
5.3.

Regulation of [Ca2+]mito by Cytosolic Ca2+ Signals

The regulation of arterial smooth muscle cell [Ca2+]mito by vasoconstrictorinduced intracellular Ca2+ signals is unclear. Electron microscopy studies indicate that
mitochondria can be located in close proximity (~20 nm) to the SR membrane in many
cell types, including cultured arterial smooth muscle cells (Rizzuto et al., 1999; Duchen,
2000b; Szado et al., 2003; Pacher et al., 2008). Such localization should place
mitochondria within the vicinity of SR Ca2+ release channels that generate micromolar
cytosolic Ca2+ elevations. Given that the MCU is sensitive to Ca2+ only within the
micromolar concentration range (Gunter & Pfeiffer, 1990), such structural orientation
allows local signaling between SR Ca2+ release channels and mitochondria. In cultured
vascular smooth muscle cells, SR Ca2+ release elicited a [Ca2+]mito elevation (Pacher et
al., 2008) and a delayed [Ca2+]mito elevation occurred when [Ca2+]i increased >1 µM, but
not when the [Ca2+]i elevation was <500 nM (Monteith & Blaustein, 1999). Ca2+ influx
via the plasma membrane Na+/Ca2+ exchanger also elevated [Ca2+]mito in cultured
vascular smooth muscle cells (Poburko et al., 2009). In non-cultured, voltage-clamped
colonic smooth muscle cells, uncaging IP3 leads to mitochondrial Ca2+ uptake that feeds
back to regulate IP3R activity (Olson et al., 2010).
Previous studies have used inorganic Ca2+ indicators to measure [Ca2+]mito in
cultured arterial smooth muscle cells (Monteith & Blaustein, 1999; Pacher et al., 2008;
Poburko et al., 2009). These fluorophores are not designed to target to specific cellular
locations, which inevitably leads to non-specific Ca2+ measurements. To our knowledge,
our study is the first to use a genetically-encoded, mitochondria-targeted, fluorescent
indicator to measure [Ca2+]mito in contractile arterial smooth muscle cells. Furthermore,
we studied cerebral artery smooth muscle cells in their native, contractile phenotype,
while previous studies primarily used cultured, proliferating vascular smooth muscle
cells. In vitro cultivation of vascular smooth muscle cells results in phenotypic
alterations, characterized by changes in cell morphology, receptor expression, and
contractile-cytoskeletal protein profiles, and switches arterial smooth muscle cell
phenotype from a contractile state to an invasive, proliferative state (Absher et al., 1989;
Campbell et al., 1989; Eguchi et al., 1994). Therefore, it is highly likely that
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physiological functions of mitochondria differ in these different cell phenotypes,
particularly since spatial proximity to Ca2+ channels and transporters are critical for
mitochondrial Ca2+ uptake.
Our data indicate that in contractile cerebral artery smooth muscle cells,
thapsigargin, XeC, and Ru360 did not alter resting [Ca2+]mito, ψm, or mitoROS. In
contrast, mitochondrial inhibitors reduced basal [Ca2+]mito, depolarized mitochondria, and
reduced mitoROS levels. These data indicate that in resting arterial smooth muscle cells,
mitochondria contain Ca2+ and generate low levels of ROS through mechanisms that are
independent of IP3R-mediated SR Ca2+ release. Therefore, basal mitochondrial Ca2+
levels appear to be maintained by Ca2+ uptake through transporters other than the MCU,
which is sensitive to micromolar Ca2+ as that produced by SR Ca2+ release (Gunter &
Pfeiffer, 1990). Apart from the MCU, several mitochondrial pumps and exchangers,
including RaM (Gunter et al., 2000) and reversal mode of mNCX (Griffiths et al., 1998)
have been speculated to be responsible for mitochondrial Ca2+ uptake and the
maintenance of resting [Ca2+]mito levels (Gunter et al., 2000).
ET-1-induced IP3R-mediated SR Ca2+ release stimulated Ca2+ waves and elevated
[Ca ]mito, leading to mitochondrial depolarization and mitoROS generation. Here,
thapsigargin and XeC blocked the ET-1-induced [Ca2+]mito elevation, mitochondrial
depolarization, and mitoROS generation. In contrast, membrane depolarization, which
elevates global [Ca2+]i, did not alter [Ca2+]mito, ψm, or mitoROS generation. These data
are consistent with the hypothesis that IP3R-mediated SR Ca2+ release stimulates
mitochondrial Ca2+ uptake, leading to a [Ca2+]mito elevation, mitochondrial depolarization,
and mitoROS generation.
2+

5.4.

Ca2+ Waves May Be the Cytosolic Ca2+ Signal Regulating Mitochondrial
Events

Consistent with imaging data indicating that vasoconstrictor-induced Ca2+ waves
occur due to IP3R activation in smooth muscle cells (Zhao et al., 2008), our data suggest
that Ca2+ waves specifically regulate [Ca2+]mito and mitoROS generation in arterial
smooth muscle cells. Given that Ca2+ waves are propagating Ca2+ signals, [Ca2+]mito and
mitoROS may also oscillate. Here, [Ca2+]mito and mitoROS was measured within
multiple smooth muscle cells in the arterial wall. [Ca2+]mito and mitoROS within
individual mitochondria may oscillate. In our experiments, 2mt8CG2 and mt-cpYFP
fluorescence in each field was measured from mitochondria within ~25 smooth muscle
cells within the arterial wall. Therefore, any asynchronous [Ca2+]mito or mitoROS
oscillations within individual mitochondria would have been averaged out by the imaging
protocol. This protocol was necessary to measure sufficient 2mt8CG2 or mt-cpYFP
fluorescence and to reduce the effects of indicator bleaching on measurements in cerebral
artery smooth muscle cells. It would be interesting to study spatial and temporal
relationships between ET-1-induced Ca2+ waves and [Ca2+]mito or mitoROS changes
within individual mitochondria in arterial smooth muscle cells. However, such an
examination of millisecond changes in [Ca2+]mito or mitoROS is more suitable for a future
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investigation, and may require the use of a different mitochondria-targeted Ca2+ or ROS
indicator that better suits the type of experiment. Future studies should be designed to
examine spatial and temporal relationships between Ca2+ waves and [Ca2+]mito or
mitoROS signals within individual mitochondria in arterial smooth muscle cells.
5.5.

Regulation of MitoROS Generation by [Ca2+]mito and Mitochondrial
Potential

ET-1-induced mitoROS elevation was blocked by XeC, Ru360, rotenone, and
CCCP, indicating that IP3R-mediated SR Ca2+ release, mitochondrial Ca2+ uptake, and
mitochondrial depolarization stimulate mitoROS generation. The mechanism by which
mitochondrial Ca2+ uptake induces mitochondrial depolarization and elevates ETCgenerated mitoROS was not determined. A [Ca2+]mito elevation may stimulate mitoROS
generation at complexes I, III, and via QH· generation through multiple mechanisms
(Brookes et al., 2004): 1) stimulation of the tricarboxylic acid cycle enhancing electron
flow through the ETC complexes; 2) inhibition of complex I; 3) dissociation and release
cytochrome c from inner mitochondrial membrane; and 4) mPTP opening (Brookes et al.,
2004).
Mitochondrial depolarization has been demonstrated to increase or decrease ROS
in a variety of different cell types, including smooth muscle cells of anatomically diverse
blood vessels (Brookes et al., 2004; Xi et al., 2005; Belousov et al., 2006; Wang et al.,
2008a). ψm is another important regulator of mPTP opening. Mitochondrial
depolarization can induce mPTP opening by shifting the threshold potential to higher
levels (Petronilli et al., 1993; Bernardi, 1999). mPTP opening can in turn depolarize the
mitochondria further, thereby enhancing the mitochondrial Ca2+ uptake-induced
depolarization (Brookes et al., 2004; Wang et al., 2008a). Therefore, as suggested by a
previous study, mitochondrial Ca2+ uptake may depolarize mitochondria due to (a) flow
of Ca2+ ions into the mitochondrial matrix, and (b) mPTP opening (Duchen, 2004).
mPTP opening also elevates mitoROS generation via several pathways, including
dissipation of chemical gradients across the mitochondrial membrane, and by changing
the fluidity and rigidity of the inner mitochondrial membrane, leading to diversion of
electrons in the ETC to mitoROS generation (Wang et al., 2008a). Therefore, a [Ca2+]mito
elevation and mitochondrial depolarization may stimulate mitoROS generation by
opening the mPTP.
In the present study, a small mitochondrial depolarization increased mitoROS
generation, whereas a large mitochondrial depolarization inhibited mitoROS production,
consistent with an earlier report in cerebral artery smooth muscle cells (Xi et al., 2005).
A small mitochondrial depolarization induced by nanomolar CCCP may increase
mitoROS generation by shifting the mPTP threshold potential to higher levels (Petronilli
et al., 1993; Bernardi, 1999). Micromolar CCCP, which causes massive uncoupling of
ETC, and disrupts the regulation of ψm, may severely affect electron transfer through the
ETC complexes, resulting in a reduction in mitoROS generation. ETC uncoupling has
93

been shown to decrease mitoROS generation in many cell types, including vascular
smooth muscle cells (Okuda et al., 1992; Negre-Salvayre et al., 1997; Xi et al., 2005).
MitoROS production is also regulated by additional factors, including redox
status of respiratory substrates, permeability of the inner mitochondrial membrane, and
proton pumping by ETC complexes (Starkov & Fiskum, 2003). Future investigations
should examine the mechanisms by which a vasoconstrictor-induced [Ca2+]mito elevation
and mitochondrial depolarization stimulate mitoROS generation.
5.6.

Characterization of ET-1-Induced ROS Elevation

Endothelial denudation did not alter the ET-1-induced HyPer-CYTO and DCF
fluorescence elevations, indicating that ROS were generated within smooth muscle cells
and not by endothelial cells. This is in agreement with a previous study in pulmonary
arteries suggesting that ET-1 elevates ROS in the arterial smooth muscle cells and not
endothelial cells (Wedgwood et al., 2001). Our data with mt-cpYFP suggest that ET-1
elevates mitochondrial O2-· production in arterial smooth muscle cells. Rotenone blocked
the ET-1-induced elevations in mt-cpYFP and HyPer-CYTO fluorescence suggesting that
ET-1-induced mitoROS elevation leads to an increase in cytosolic H2O2 levels.
Dismutation of O2-· to H2O2 may occur both in the mitochondrial matrix and in the
intermembrane space by mitochondrial SOD (Turrens, 2003; Li et al., 2005; Archer et
al., 2010). Therefore, ET-1 elevates generation of mitochondrial O2-· and cytosolic
H2O2. However, ET-1-induced elevations in O2-· and H2O2 may also result in generation
of OH·, NO, and ONOO· through various pathways, including Fenton reaction (Turrens,
2003). ROS regulation of cellular signaling depends on the reactivity, and stability of the
species. H2O2 which is more stable than O2-·, can diffuse for a longer distance allowing it
to serve as a signaling molecule (Archer et al., 2010). H2O2 modulates the activity of
several ROS-sensitive transcription factors such as HIF-1α (Huang et al., 1996) and NFκB (Takada et al., 2003; Oliveira-Marques et al., 2009).
5.7.

ROS–Dependent and –Independent Pathways Which Activate NF-κB

Physiological functions and mechanisms of regulation of NF-κB in contractile
arterial smooth muscle cells are poorly understood. Our data indicate that thapsigargin,
XeC, rotenone, and MnTMPyP reduced basal NF-κB-dependent luciferase activity.
Therefore, under basal conditions, NF-κB activation is regulated by both IP3R-mediated
SR Ca2+ release and constitutively produced mitoROS. This is consistent with studies in
neurons, indicating that Ca2+ influx through VDCCs and IP3R-mediated Ca2+ release are
responsible for the basal NF-κB activity (Lilienbaum & Israel, 2003).
ET-1-induced NF-κB activation was blocked by XeC, and inhibited by rotenone
and MnTMPyP. This indicates that ET-1-induced NF-κB activation occurs primarily via
IP3R-mediated mitoROS generation in cerebral artery smooth muscle cells. MitoROS
activate NF-κB in several cell types, including in cultured vascular smooth muscle cells
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(Lee et al., 2008). However, alternate ROS-mediated mechanisms have also been
demonstrated to activate NF-κB in arterial smooth muscle cells. For example, following
arterial balloon injury, ROS derived from NO and NAD(P)H oxidase are primarily
responsible for the elevated NF-κB activity in arterial smooth muscle cells (Souza et al.,
2000; Ialenti et al., 2001). The mechanisms by which ROS activate NF-κB are unclear,
with reports suggesting that ROS stimulate IKK, leading to serine phosphorylation and
proteasomal degradation of IκB (Gloire et al., 2006). Studies also indicate that ROS
activate other kinases, such as tyrosine kinase to cause IκB tyrosine phosphorylation
rather than the classical serine phosphorylation (Takada et al., 2003; Brzoska & Szumiel,
2009). Additional studies will be necessary to identify the specific mechanisms by which
ROS activate NF-κB in contractile arterial smooth muscle cells.
Rotenone and MnTMPyP abolished the ET-1-induced mitoROS elevation, but did
not completely block ET-1-induced NF-κB activation. Therefore, ET-1-induced IP3Rmediated SR Ca2+ release may activate NF-κB via a secondary mitoROS-independent
pathway. Ca2+-dependent, redox-independent NF-κB activation mechanisms may be
mediated by calcineurin, PI3K/Akt, and/or PKC, as demonstrated in neurons (Lilienbaum
& Israel, 2003). Calcineurin activation occurs due to Ca2+ binding to CaM, leading to the
dissociation of the two proteins, allowing the catalytic site of calcineurin to become
accessible (Lilienbaum & Israel, 2003). In addition to CaM, Ca2+ activate NF-κB via
Ca2+-sensitive PKC isoforms, including PKCα and PKCβ1, and PI3K/Akt (Lilienbaum &
Israel, 2003). Supporting bi-modal activation, ER Ca2+ release activates NF-κB through
both calcineurin- and redox-dependent mechanisms in U937 cells (Shatrov et al., 1997).
In addition to ET-1, Ang II, another PLC-coupled receptor agonist activates transcription
factors, including NF-κB through ROS-dependent and -independent mechanisms
(Iadecola & Gorelick, 2004). Binding of Ang II to AT1 receptors leads to PLC
activation, [Ca2+]i elevation, and PKC activation (Iadecola & Gorelick, 2004). PKCmediated phosphorylation of p47phox stimulates ROS generation via NAD(P)H oxidase
(Iadecola & Gorelick, 2004). Activated PKC could also stimulate cellular effectors in a
ROS-independent manner (Iadecola & Gorelick, 2004).
In whole artery immunofluorescence experiments to study NF-κB localization, it
is interesting to note that p50 nuclear translocation occurred in nuclei of some smooth
muscle cells but not others. These experiments were performed on fixed arteries after 1
hour of ET-1 treatment, therefore, representing a snapshot of the cellular events occurring
in the arterial smooth muscle cells at that time point. NF-κB activation and nuclear
translocation may not occur at the same time in all smooth muscle cells of the artery due
to a variety of reasons. The time taken for ET-1 to reach individual smooth muscle cells
and stimulate its receptors will depend upon the location of the smooth muscle cell in the
arterial wall. ET-1 will stimulate receptors of smooth muscle cells located on the
periphery of the arterial wall prior to activating those cells in deeper layers. In some
cells, ET-1 may have stimulated SR Ca2+ release but there may not be mitochondria in
close proximity to the SR to stimulate mitoROS elevation and NF-κB activation. It is
also possible that NF-κB nuclear translocation and activation of transcription may have
already taken place and NF-κB may have recycled back to the cytosol within 1 hour.
Nevertheless, our data suggests that ET-1 increases p50 nuclear translocation, thereby
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activating NF-κB in cerebral artery smooth muscle cells. Transcriptional studies
performed using NF-κB-dependent luciferase constructs confirm the finding that ET-1
activates NF-κB.
5.8.

Regulation of Basal and ET-1-Induced Elevation in CaV1.2 Expression

CaV1.2 channels are the principal functional Ca2+ influx pathway in smooth
muscle cells of resistance-size arteries (Jaggar et al., 2000; Jaggar, 2001; Cheng et al.,
2007). CaV1.2 channels regulate multiple physiological functions in arterial smooth
muscle cells, including contractility and gene expression, but signaling mechanisms and
transcription factors that regulate their expression in these cells are unclear.
Our data indicate that IP3R-mediated NF-κB activity controls basal CaV1.2
expression through both mitoROS generation and via a mitochondria-independent
pathway. XeC, rotenone, and MnTMPyP slightly reduced basal CaV1.2 expression. In
the absence of PLC-coupled receptor ligands, [IP3]i and thus, IP3R activity should be low.
However, in the intact artery preparation studied here, basal release of receptor ligands,
including ET-1, by endothelial cells may generate low levels of [IP3]i in smooth muscle
cells. Even though this basal IP3R-mediated SR Ca2+ release was insufficient to elevate
[Ca2+]mito, depolarize mitochondria, or stimulate mitoROS and cytosolic ROS, it was
sufficient to activate NF-κB and stimulate CaV1.2 expression. IP3R-independent basal
mitoROS generation also activates NF-κB, leading to stimulation of basal CaV1.2
expression. Thus, IP3Rs contribute to basal CaV1.2 expression through mitochondriadependent and -independent NF-κB activation. In our experiments, the degree of p105
knockdown and the reduction in basal CaV1.2 expression were similar, indicating that
NF-κB is a major transcriptional factor regulating CaV1.2 gene expression in arterial
smooth muscle cells.
Data indicate that ET-1-induced IP3R-mediated Ca2+ release stimulates CaV1.2
expression by causing a [Ca2+]mito elevation, leading to mitoROS generation that activate
NF-κB. Consistent with effects on NF-κB transcriptional activity, rotenone and
MnTMPyP did not fully block the ET-1-induced elevation in CaV1.2 expression. Thus,
IP3R activation may also stimulate CaV1.2 expression via a secondary mitochondria- and
ROS-independent pathway that also involves NF-κB. Therefore, ET-1-induced IP3R
activation stimulates NF-κB-dependent elevation in CaV1.2 expression primarily via a
mitoROS-dependent pathway and through a secondary mitochondria- and ROSindependent pathway. Consistent with our finding that NF-κB controls CaV1.2
expression, TNF-α-induced NF-κB activation elevated L-type Ca2+ current in cultured rat
hippocampal neurons (Furukawa & Mattson, 1998). In contrast, in human colonic
smooth muscle cells NF-κB p50 and p65 subunit activation reduced CaV1.2 channel
expression (Shi et al., 2005). Opposing regulation of CaV1.2 transcription by NF-κB in
these different smooth muscle cell types may occur through interaction with different κB
binding motifs, of which there are several upstream of the CaV1.2 gene (Shi et al., 2005).
Furthermore, the presence or absence of additional transcriptional activators and/or
repressors may explain differential regulation of CaV1.2 expression by NF-κB.
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Ang II, a vasoconstrictor caused an endothelium-dependent increase in CaV1.2
expression in primary culture of rat mesenteric artery smooth muscle cells although it is
unclear if depolarization of the smooth muscle cells is involved in this upregulation
(Wang et al., 2008b). Ang II has been shown to stimulate endothelial cells and induces
ET-1 gene expression and secretion (Dohi et al., 1992; Morey et al., 1998). Therefore,
the Ang II-induced ET-1 elevation may stimulate the pathway described here, resulting in
an elevation in CaV1.2 expression in mesenteric artery smooth muscle cells. In cultured
ventricular myocytes, global [Ca2+]i elevation stimulated transcription of CaV1.2 α1
subunit (Davidoff et al., 1997). In rat renal arteries, membrane depolarization which
elevates global [Ca2+]i, increased CaV1.2 protein (Pesic et al., 2004). Here, IP3Rmediated SR Ca2+ release stimulated CaV1.2 expression. Data from these studies raise
several possibilities, including that local and global Ca2+ signals regulate CaV1.2
expression by different mechanisms in cerebral and renal artery smooth muscle cells and
ventricular myocytes. Conceivably, this could occur at many levels in the pathway
described here, including that global [Ca2+]i may elevate [Ca2+]mito in renal artery smooth
muscle cells and ventricular myocytes, leading to mitoROS generation and NF-κB
activation.
5.9.

Regulation of p105/p50 Expression by IP3R-Mediated SR Ca2+ Release

Factors that regulate p105 gene expression in arterial smooth muscle cells are
poorly understood. Our data indicate that XeC reduced the basal p105/p50 expression
and blocked the ET-1-induced elevation in p105/p50 expression. However, rotenone and
MnTMPyP did not affect the basal and ET-1-induced elevation in p105/p50 expression.
In addition, p105 knockdown did not alter the ET-1-induced relative increase in p105/p50
expression. These data indicate that ET-1-induced IP3R-mediated SR Ca2+ release
stimulated p105/p50 subunit expression via a mitochondria-, ROS-, and p105/p50independent pathway. This is in contrast to the mitoROS- and p105/p50-dependence of
CaV1.2 expression. Thus, ET-1-induced IP3R-mediated SR Ca2+ release regulates CaV1.2
and NF-κB subunit expression through mitoROS- and p105/p50-dependent and independent pathways, respectively.
The p105 promoter has binding sites for several transcription factors, including
NF-κB, Sp1, Egr-1, and PEA3 (Cogswell et al., 1993). In our study, using siRNA we
specifically suppressed expression of only one NF-κB protein, namely p105, and its
product p50. Expression of other NF-κB proteins, including p100/p52, p65, RelB, and cRel were not studied. Our data indicate that IP3R-mediated SR Ca2+ release regulates
p105 expression through a p105/p50-independent pathway. p105 gene transcription
could be regulated by other members of the NF-κB family, as previously shown
(Cogswell et al., 1993). In addition, other Ca2+-activated transcription factors, including
Sp1 (Santini et al., 2001) and Egr-1 (Thiel et al., 2010) may also regulate p105
expression in the cerebral artery smooth muscle cells.
ET-1-induced IP3R-mediated SR Ca2+ release activates NF-κB and also elevates
NF-κB subunit expression. It is interesting to determine the relative contribution of each
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of these signaling events in the ET-1-induced NF-κB-dependent elevation in CaV1.2
expression. Our data indicate that rotenone and MnTMPyP reduced the ET-1-induced
elevation in NF-κB-dependent luciferase activity and CaV1.2 expression but did not affect
the ET-1-induced elevation in p105/p50 expression. This suggests that ET-1 regulation
of CaV1.2 expression is dependent on NF-κB activation and not an elevation in p105
expression. However, the ET-1-induced elevation in NF-κB subunit expression may
amplify the elevation in NF-κB-dependent CaV1.2 transcription.
5.10.

ET-1 and Vascular Function

ET-1 belongs to the endothelin (ET) peptide family, which have three more
isoforms (Masaki, 2004). ET synthesis begins with production of preproET, which is
cleaved by peptidases to yield big-ET, a biologically inactive intermediate (Masaki,
2004). Big-ET undergoes further cleavage by ET converting enzymes to produce ET
(Masaki, 2004). Endothelial cell is the major source of ET-1 produced. In addition to
endothelial cells, ET-1 is also produced by airway epithelial cells, macrophages,
fibroblasts, cardiomyocytes, and neurons (Kedzierski & Yanagisawa, 2001). ET-1
released from the endothelial cells acts in a paracrine and autocrine manner by interacting
with receptors on vascular smooth muscle cells and endothelial cells, respectively, and
thereby modifying vascular contractility, growth, and proliferation (Kedzierski &
Yanagisawa, 2001). Arterial smooth muscle cells express ETA and ETB2 receptors
(Masaki, 2004; Dammanahalli & Sun, 2008a), and endothelial cells express ETB1
receptors (Dammanahalli & Sun, 2008a). Stimulation of ETA and ETB2 receptor
activation stimulates Ca2+ waves, increases global [Ca2+]i, and vasoconstriction. ETB1
receptor activation leads to endothelial release of NO and prostaglandins, resulting in
arterial vasodilation (Dammanahalli & Sun, 2008b).
ET-1 was used in this study to elicit local and global Ca2+ signals in cerebral
artery smooth muscle cells. ET-1 plasma levels in rats and normal human subjects is ~20
pg/ml (8 pM) and 3.6 pg/ml (1.44 pM), respectively (Loffler et al., 1993; Parlapiano et
al., 1999). Circulating levels of ET-1 in the plasma represent merely the "spillover" by
endothelial cells (Zhu et al., 1994; Maeda et al., 1998). Vascular smooth muscle cells are
exposed to ET-1 concentrations which are much higher than its plasma level (Zhu et al.,
1994; Maeda et al., 1998). In this study, concentrations of ET-1 used for different
experiments ranged from 10-100 nM based on the experimental preparations and
conditions. Experiments designed to study mRNA and protein levels, required exposure
of arteries to ET-1 over a long period of time. In these experiments, smooth muscle cell
ET-1 receptors were intact and using higher concentrations over a long period of time
could have desensitized the receptors. Therefore, a low concentration of ET-1 (10 nM)
was used. ψm measurements were performed using isolated smooth muscle cells. The
enzymes and trituration procedure used during the dissociation process could also result
in damaging a few ET-1 receptors on the surface of arterial smooth muscle cells,
resulting in a reduction of healthy ET-1 receptors. Therefore, a moderately high
concentration of ET-1 (30 nM) was used. [Ca2+]mito, mitoROS, and cytosolic ROS
measurements were obtained using moderately expressed amounts of genetically-encoded
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fluorescent indicators. Therefore, a higher concentration of ET-1 (100 nM) was used for
these experiments to elicit fluorescence changes from these indicators. ψm measurements
using TMRM suggested that the different concentrations of ET-1 (10, 30, and 100 nM)
used are within the slope of the sigmoidal curve. This indicates that the ET-1
concentrations used in this study neither understimulated nor saturated the receptors.
5.11.

Regulation of Gene Expression by Ca2+ Signals

Vasoconstrictors, including purinergic and adrenergic receptor agonists modulate
local and global Ca2+ signals similarly to ET-1 in smooth muscle cells of cerebral and
systemic resistance-size arteries (Jaggar & Nelson, 2000; Mauban et al., 2001).
Therefore, IP3R regulation of Ca2+ waves, [Ca2+]mito, and mitoROS generation may be a
common mechanism by which vasoconstrictors regulate smooth muscle cell NF-κB
activity, and thus control functional CaV1.2 expression and arterial contractility.
Identification of this transcriptional pathway expands knowledge of Ca2+ signaling
mechanisms regulating ion channel expression in vascular smooth muscle cells. Local
and global Ca2+ signals have been shown to activate transcription factors and regulate ion
channel gene expression in arterial smooth muscle cells. IP3R-mediated SR Ca2+ release
and local Ca2+ influx through CaV1.2 channels also stimulates calcineurin-dependent
nuclear translocation of NFATc3 in cerebral artery smooth muscle cells (Gomez et al.,
2002; Nieves-Cintron et al., 2008). However, Ca2+ sparks suppress calcineurindependent NFATc3 activation (Gomez et al., 2002). NFATc3 activation downregulates
expression of the KCa channel β1 subunit and Kv2.1, leading to hypertension (Amberg et
al., 2004; Nieves-Cintron et al., 2007). In arterial smooth muscle cells, voltagedependent Ca2+ influx and Ca2+ spark inhibition activate CREB leading to an increase in
c-fos expression (Cartin et al., 2000). Our data not only demonstrate that mitochondria
are essential for mediating Ca2+-dependent gene expression in arterial smooth muscle
cells, but indicate that these organelles do so by sensing IP3R-mediated Ca2+ release.
5.12.

Conclusion

In native cerebral artery smooth muscle cells, SR Ca2+ release through IP3R-gated
Ca channels elevates [Ca2+]mito, leading to mitochondrial depolarization and mitoROS
generation. An IP3R-mediated elevation in mitoROS generation activates NF-κB, leading
to an elevation in CaV1.2 expression and vasoconstriction. In summary, this study
indicates that mitochondria sense IP3R-mediated SR Ca2+ release to control NF-κB
activity, and thereby, functional CaV1.2 expression in cerebral artery smooth muscle
cells.
2+

A previous study has shown that mitochondria are involved in acute regulation of
arterial contractility by activating Ca2+ sparks (Xi et al., 2005). This study identifies
another physiological function for mitochondria in arterial smooth muscle cells and
shows that mitochondria can control ion channel gene expression and regulate arterial
contractility on a more long-term basis. This study also highlights an important signaling
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cascade wherein intracellular local Ca2+ signals modulate functional expression of plasma
membrane Ca2+ channels and thereby regulate Ca2+ influx and arterial contractility.
5.13.

Restoration of Homeostasis – Possible Negative Feedback Mechanisms

The pathway studied here begins with ET-1 binding to its receptors on arterial
smooth muscle cells, and eventually results in elevated CaV1.2 expression and enhanced
arterial contractility. Under normal conditions, various negative feedback mechanisms
could regulate individual signaling events in the pathway described here leading to
restoration of homeostasis. 1) ET-1 binding to endothelial ETB receptors decreases the
circulating ET-1 available to bind smooth muscle cell receptors thereby buffering the
circulating ET-1 levels (Sanchez et al., 2002), preventing overstimulation of smooth
muscle cell receptors. 2) Increased ET-1 secretion can exert a negative feedback on ET-1
gene transcription in endothelial cells, through activation of ETB receptors and
internalization of the ET-1/ETB receptor complex, as previously demonstrated in cultured
porcine aortic endothelial cells (Sanchez et al., 2002). Inhibition of ET-1 gene
transcription would result in decreased ET-1 synthesis and therefore, result in a reduction
in ET-1 secretion. 3) ET-1-induced [IP3]i elevation stimulates IP3R-mediated SR Ca2+
release. IP3 and Ca2+ have been suggested to inhibit IP3R (Hajnoczky & Thomas, 1994),
thereby maintaining cytosolic IP3R-mediated Ca2+ elevations. 4) Mitochondrial
depolarization which occurs due to [Ca2+]mito elevation, reduces the driving force for
further mitochondrial Ca2+ uptake (Gunter et al., 2000) and therefore could limit
[Ca2+]mito and mitoROS elevation. 5) NF-κB activation leads to nuclear translocation and
stimulation of gene transcription. One of the mechanisms by which NF-κB autoregulates
its activity is by stimulating transcription of IκBα, which causes cytosolic retention of
NF-κB and reduces its activation (Chen & Greene, 2004). 6) As previously reported in
cultured neurons, an elevation in [Ca2+]i, can internalize CaV1.2 channels reducing Ca2+
influx and [Ca2+]i elevation.
Presence of these negative feedback loops may be essential for normal vascular
physiology. Deregulation of these regulatory mechanisms could contribute to the
development and maintenance of cardiovascular diseases.
5.14.

Clinical Significance

Functional integrity of the endothelium is responsible for Ca2+ channel
availability in vascular smooth muscle cells (Simard & Li, 2000). Dysfunctional
endothelium is associated with a variety of diseases including hypertension and
atherosclerosis (Ogita & Liao, 2004; Ray & Shah, 2005). Cardiovascular diseases,
including systemic (Shichiri et al., 1990) and pulmonary hypertension (Stewart et al.,
1991b) are associated with an elevation in circulating vasoconstrictors, including ET-1
(Ishikawa et al., 1995; Abdel-Sayed et al., 2003). Hypertension is also associated with
an increase in vascular ROS, NF-κB activity, CaV1.2 protein, and Ca2+ currents (Wang et
al., 2006; Sawada et al., 2007; Touyz & Schiffrin, 2008). These disease-associated
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alterations may occur through activation of the IP3R/mitoROS/NF-κB/CaV1.2 pathway.
Apart from hypertension, circulating plasma levels of ET-1 are elevated in other
cardiovascular diseases, including cardiogenic shock (Cernacek & Stewart, 1989),
myocardial infarction (Stewart et al., 1991a), atherosclerosis (Luscher & Barton, 2000),
and ischemic stroke (Estrada et al., 1994). In addition, TNF-α, interferon-γ, Ang II, and
thrombin increase ET-1 release from endothelial cells (Delerive et al., 1999). Elevated
levels of ET-1 receptors on arterial smooth muscle cells are observed in cardiovascular
diseases, including pulmonary hypertension (Masaki, 2004), ischemic heart disease
(Wackenfors et al., 2004), and atherosclerosis (Pernow et al., 2000). Enhancement of the
ET-1-induced signaling pathways in arterial smooth muscle cells may occur due to
endothelial injury resulting in increased ET-1 secretion, elevated ET-1 plasma levels,
and/or enhanced ET-1 receptor expression levels. Pathological changes related to
increased activation of ET-1 receptors may occur due to triggering of the
IP3R/mitoROS/NF-κB activation pathway. Therefore, targeting this pathway may
provide a better understanding of the disease-related pathological changes and could be
beneficial in developing therapeutic strategies to treat cardiovascular diseases.
5.15.

Future Directions

This study shows that mitochondria control functional ion channel expression in
native contractile cerebral artery smooth muscle cells. Future studies could be performed
in several parts of the proposed signaling cascade to better characterize the individual
events in the pathway. Potential investigations could be designed to explore:
1. The spatial and temporal relationships between Ca2+ waves and [Ca2+]mito or mitoROS
signals within individual mitochondria in arterial smooth muscle cells to determine if
[Ca2+]mito and mitoROS oscillate within individual mitochondria. It would also be
interesting to examine whether propagation of Ca2+ waves induces waves of [Ca2+]mito
and mitoROS originating from mitochondria located along the path of propagation of
the Ca2+ wave.
2. The precise mechanisms by which a [Ca2+]mito elevation and mitochondrial
depolarization stimulate mitoROS generation.
3. The pathways by which mitoROS and IP3R-mediated SR Ca2+ release activate NF-κB
in arterial smooth muscle cells.
4. The involvement of other members of the NF-κB family, including p52, p65, c-Rel,
and RelB in regulating CaV1.2 expression.
5. The role(s) played by additional ROS-sensitive transcription factors, including AP-1,
CREB, and Kruppel-like factor transcription factor(s) in the regulation of CaV1.2
gene expression.

101

6. If the proposed pathway is common to most Gq-protein coupled receptor agonists,
including UTP and Ang II.
7. The regulation of expression of α2δ, β, and γ subunits of CaV1.2, and other NF-κB
proteins, including p52, p65, c-Rel, and RelB by IP3R-mediated SR Ca2+ release,
mitoROS, and NF-κB.
8. The importance and relevance of this pathway in the maintenance of hypertension by
administration of pharmacological inhibitors of NF-κB and smooth muscle cell ET-1
receptors to hypertensive rodent models, followed by monitoring the blood pressure.
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